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1. History
In July and August 1976, an explosive outbreak of pneumonia of unknown etiology occurred 
among American Legion members attending a convention in Philadelphia. A total of 221 cases 
were documented, the death rate in this outbreak was 16% [1]. It was six month later that a 
Gram negative bacterium, presumed to be the etiological agent was isolated and characterized 
[2]. Because of the historical association with the American Legion convention, the pneumonia 
is called Legionnaires’ disease (LD), and the etiologic agents belong to the family Legionellaceae, 
with Legionella pneumophila being the species responsible for this outbreak. The availability of 
various detection methods for the disease showed that several prior unsolved outbreaks of pneu-
monia had been Legionnaires’ disease [3]. Legionella has been retrospectively identified as the 
cause of outbreaks of Legionnaires’ disease since 1947 [4, 5]. Since then, Legionnaires’ disease 
is identified as a cause of pneumonia all over the world. 
2. Microbiology
2.1. Taxonomy
The Legionellaceae are small obligatory aerobic Gram-negative bacilli with fastidious growth re-
quirements. Proteins rather than carbohydrates are used as an energy source, the bacteria grows 
at temperatures ranging from 20° to 42°C. The Legionella bacteria are in the taxonomic order 
Legionellales, which includes the families Coxiellaceae and Legionellaceae. The Legionellaceae and 
C. burnetti, the cause of Q-fever, have similar intracellular lifestyles, and may have common 
genes associated with the infection processes in their hosts [6, 7]. Three different genera have 
been proposed for the Legionellaceae: Legionella, Fluoribacter, and Tatlockia;  however, the latter 
two generic names have never been widely used or accepted, and the single genus Legionella is 
almost universally used to describe all species [8].  
At least 58 different Legionella species have been described. In 25 of these species some 
strains have been reported to infect humans [9-11]. L. pneumophila contains at least 15 different 
 serogroups; ten other species can be subtyped into at least two serogroups, with the remaining 
species containing only one serogroup each [10, 12]. L. pneumophila serogroup 1 caused the 
1976 Philadelphia outbreak and is the cause of 70 % to 90 % of all cases of Legionnaires’ disease 
for which there has been a bacterial isolate. Like L. pneumophila, other Legionella species are 
widely distributed in aquatic habitats and soil. Recovery of these species is generally less frequent 
and technically more demanding than is recovery of L. pneumophila. 
Twenty-five Legionella species have been documented to cause human infection (see Table. 1) 
based on isolation from clinical material [11]. Isolates of the other species are limited to water 
and soil, although several have been implicated in human infection based on seroconversion in 
the absence of isolation.
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Table 1: Legionella species causing human disease
L. anisa L. feeleii L. lytica L. sainthelensi
L. birminghamensis L. gormanii L. maceachernii L. steelei
L. bozemanii L. hackeliae L. micdadei L. tusconensis
L. cardiaca L. jordanis L. nagasakiensis L. wadsworthii
L. cincinnatiensis L. lansingensis L. oakridgensis
L. dumoffii L. londiniensis L. parisiensis
L. erythra L. longbeachae L. pneumophila
In addition L. waltersii has been detected with PCR from a clinical sample.
2.2. Habitats of Legionella
Water is the major natural reservoir for Legionella spp., and the organism can been found world-
wide in many different natural and artificial aquatic environments, such as cooling towers, 
water systems in hotels, homes, ships and factories, fountains, misting devices, and spa pools. 
Legionella spp. is part of the natural aquatic environment and the bacterium is capable of sur-
viving an extreme range of environmental conditions [13]. For example, L. pneumophila is able 
to withstand temperatures of 50°C and can withstand exposure to pH 2.0 for a short period of 
time [14]. Therefore, the recommended temperature for storage and distribution of cold water 
is below 25°C and the distribution of hot water is > 60°C. The presence of amoebae is impor-
tant for survival and growth of Legionella in aquatic and moist soil environments (e.g. potting 
soil). Protozoa not only provide nutrients for the intracellular growth of L. pneumophila, but 
also form a shelter when environmental conditions became unfavorable [15]. A large number 
of free-living protozoa have been identified as hosts for L. pneumophila by using in  vitro studies 
[16-19]. These studies describe Legionella’s ability to survive and to multiply in about 30 species 
of amoeba, especially Acanthamoeba, Naegleria and Hartmanella. The free-living protozoa multi-
ply on biofilms, and there grazing behavior is influenced by the composition of the biofilm [20]. 
The understanding of the factors that effect Legionella survival and growth in the environment is 
important in controlling the bacteria in artificial water systems and potting soil.
2.3. Transmission
Despite Legionella spp. being ubiquitous in the (aqueous) environment, transmission is rare un-
less certain conditions are simultaneously present, e.g., appropriate environmental conditions, 
human pathogenic strains and aerosol formation. Inhalation of airborne droplets or droplets 
nuclei containing Legionella is generally accepted to be the mode of transmission. Some authors 
believe that aspiration could be the major mode of transmission [21]. 
12
Chapter 1
Adherence followed by entry of the bacterium into the host cell is a crucial step in the 
infection cycle. Together with the flagellum and the pili, certain bacterial surface proteins are 
involved in the adherence and entry of Legionella into alveolar macrophages and protozoa. These 
proteins include the major outer membrane protein (MOMP), the heat shock protein (Hsp60) 
and, the major infectivity potentiator protein (MIP) [22, 23]. 
 
2.4 Epidemiology
Legionnaires’ disease is the severe and sometimes fatal form of an infection with Legionella spp. 
It is classically described as a severe pneumonia that may be accompanied by different systemic 
symptoms. L. pneumophila is the etiological agent of approximately 90% of all cases. In Eu-
rope the surveillance of Legionnaires’ disease is carried out by the European Centre for Disease 
Control (ECDC) in Stockholm, Sweden. All cases reported in 2009 and 2010 and meeting the 
European case definition were electronically transmitted to The European Surveillance system 
(TESSy) database [24]. A total of 5.551 and 6.305 cases were reported by 29 European countries 
in 2009 and 2010, respectively (see table). 
2009 2010
Case (n) ASR* Case (n) ASR
Europe 5551 1.07 6305 1.20
The Netherlands 251 1.53 466 2.79
ASR* = Age standardized rates per 100.000 inhabitants 
Although outbreaks of Legionnaires’ disease have received a lot of attention, the majority of 
Legionnaires’ disease cases are sporadic. Apparently sporadic cases that appear over time are in 
fact clustered around the same source of infection [25-27]. The longest time span covering such 
a cluster is 17 years [26, 27]. Source identification and elimination would prevent new cases 
of Legionnaires’ disease [26]. Hot water systems in hotels, homes and hospitals are often these 
sources. Cooling towers are more often related to large outbreaks, while whirlpools, saunas and 
wellness centers are related to sporadic cases and smaller outbreaks [28]. Legionnaires’ disease 
is recognized as a major form of travel-associated pneumonia.
3. Clinical Manifestations 
After transmission from the environment to humans by inhalation of an infectious aerosol or by 
aspiration, Legionella spp. can cause pneumonia with severe multisystem disease  (Legionnaires’ 
disease). It is an atypical pneumoniae, non –productive cough and with no clinical  differences as 
compared to other pneumonias. Apart from pneumonia, Legionella is associated with a  self-limited 
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influenza-like respiratory infection (Pontiac Fever) [21, 36, 37]. Some L.  pneumophila strains are 
more virulent than others, although the precise factors causing virulence remain unclear [33]. 
Legionella produces a number of exotoxins, including a hemolysin, cytotoxin, deoxyribonuclease, 
ribonuclease, and various proteases [29, 30]. Legionellaceae also produce a weak lipopolysaccha-
ride endotoxin capable of activating the complement pathway [31, 32].
 Some individuals may be more susceptible to Legionnaires’ disease if conditions that hinder 
mucociliary clearance, e.g., smoking or underlying disease are present [34, 35]. Surgery and 
organ transplantation are major risk factors for acquisisting nosocomial Legionella infection. 
Chronic obstructive pulmonary disease (COPD) and immunnosuppression have also consist-
ently been implicated as risk factors for acquisition of Legionnaires’ disease [34, 40]. The key to 
diagnosis is performing appropriate microbiological testing.
3.1 Legionnaires’ Disease
Legionnaires’ disease lacks characteristic symptoms or signs, there is no typical syndrome, and 
not everyone exposed to the organism will develop symptoms of the disease [35, 38-42]. A large 
epidemiological study of a major outbreak of Legionnaires’ disease associated with a flower show 
in the Netherlands found that 16% of cases had incubation times longer than 10 days, with the 
average being 7 days [55].
Legionnaires’ disease generally starts with fever, headache, fatigue, muscle aches and cough, 
initially characterized by anorexia, malaise and lethargy [43]. Legionnaires’ disease patients may 
develop a mild and unproductive cough. Before full-blown pneumonia is present, chest pain, 
diarrhoea, confusion, shaking chills and shortness of breath may be seen. Fewer than one half 
of the patients with Legionnaires’ disease produce purulent sputum, and about one third devel-
ops blood-streaked sputum or cough up blood (haemoptysis). Chest pain, either pleuritic (i.e. 
involving infection of the lung lining) or non-pleuritic, is prominent in about 30% of patients, 
and may be mistaken for blood clots in the lungs when associated with haemoptysis. Gastro-
intestinal symptoms are prominent, with up to half of patients having watery diarrhoea, and 
10–30% suffering nausea, vomiting and abdominal pains [44, 45]. If untreated, Legionnaires’ 
disease usually worsens during the first week and can be fatal. The most frequent complications 
are respiratory failure, shock and acute renal and multi-organ failure.
According to the source of infection, Legionnaires’ disease is commonly classified as com-
munity-acquired (CAP), nosocomial, or travel associated. Legionella is an important pathogen in 
health-care acquired (nosocomial) pneumonia, particularly in immunocompromised patients. 
Legionella spp. can also cause community-acquired pneumonia (CAP), the more severe cases of 
pneumonia required hospitalization or admission into intensive care [46, 47]. 
On the basis of diagnostic criteria there are standardized case definitions (ECDC-ELDSNet-
EU case definition) [48]. A confirmed case of Legionnaires’ disease is a patient presenting  clinical 
and radiological signs of pneumonia with at least one of the following laboratory criteria:
1.  isolation of Legionella spp. from respiratory secretions or any normally sterile site,
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2. detection of L. pneumophila antigen in urine, or
3. L. pneumophila serogroup 1 specific antibody response.
A probable case of Legionnaires’ disease is defined as a patient presenting clinical and/or radio-
logical signs of pneumonia with at least one of the following laboratory criteria:
1. detection of L. pneumophila antigen in respiratory secretions or lung tissue e.g. by 
 direct fluorescent antibody staining,
2. detection of Legionella spp. nucleic acid in a clinical specimen,
3. L. pneumophila non-serogroup 1 or other Legionella spp. specific antibody response,
4. a single high titer in specific antibody response for L. pneumophila serogroup 1, other  
 serogroups or other Legionella spp.
After experiencing Legionnaires’ disease, almost half of patients suffer from disorders related 
to the nervous system, such as confusion, delirium, depression, disorientation and hallucina-
tions [43, 49, 50]. These disorders may also occur in the first week of the disease. Other neuro-
logical deficits that can arise after a severe infection include residual cerebellar dysfunction [51, 
52]. Minor problems may include persistent pulmonary scars and restrictive pulmonary disease 
in some patients who experience severe respiratory failure, retrograde amnesia, and neurological 
symptoms [53, 54]. Appropriate treatment usually results in full recovery; however, long-term 
pathological conditions resulting from the disease may occur [43, 55].  
The mortality rate among patients with Legionnaires’ disease caused by L. pneumophila varies 
from 0% to 26 %, depending on the clinical setting, severity of disease, patient population and 
timely antimicrobial treatment [59, 60]. Early recognition, through correct diagnostic methods, 
enables appropriate antimicrobial treatment which is potentially life-saving [59, 62].
Legionella spp. are facultative intracellular bacteria that can survive and multiply in human 
macrophages. The intracellular location of this pathogen is thought to be relevant for the effica-
cy of the antimicrobial agent in the treatment of the disease. Antimicrobials that achieve intra-
cellular concentrations higher than the minimal inhibitory concentration (MIC) are regarded as 
more effective than antibiotics with poor intracellular penetration [9]. The antimicrobial agents 
most commonly used for treatment are fluoroquinolones, macrolides and rifampicin [56-58].
3.2 Pontiac fever
Pontiac fever, or non-pneumonic Legionellosis, is a milder form of infection associated with 
 Legionella spp.. It is an acute, self-limiting, influenza-like illness without pneumonia. Pontiac 
 fever occurs after exposure to aerosols of water colonized with Legionella spp. Unlike  Legionnaires’ 
disease, Pontiac fever has a high attack rate, often in the range 50% to 80%, affecting 95% or 
more of exposed individuals [44]. The influenza-like syndromes are fever, chills, headache, and 
muscle pain, with or without nausea. This type of Legionellosis is a mild, self-limited illness of 
short duration, the incubation period is 1-3 days, and does not require antimicrobial treatment 
[63].
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4 Laboratory diagnosis
The methods currently used for the laboratory diagnosis of Legionellosis are: isolation of the 
organism on culture media, detection of antigens in urine, microscopic examination, detection 
of bacterial deoxyribonucleic acid (DNA), and using paired serology. Urine antigen tests and 
cultures of sputum or bronchoalveolar lavage are the most suitable clinical tests for Legionella. 
Tests for Legionnaires’ disease, including culturing, should also be performed for patients who 
might have been exposed to Legionella during an outbreak [64, 65].
4.1 Culture 
Culture of Legionella is often the most designated detection method, and has high specificity, 
although the sensitivity of cultures varies from 50 to 80%. Cultivation followed by identifica-
tion of Legionella spp. is the definitive method for the diagnosis of Legionnaires’ disease, and is 
therefore the “gold standard” [66, 67]. Isolation of the infecting strain allows phenotypic and 
genotypic sub-typing providing valuable epidemiological data for the control and prevention of 
further cases.
The Legionella spp. will not grow on ordinary laboratory media commonly used for respira-
tory specimens which has not supplemented with iron and L-cysteine. Iron, L-cysteine, α-keto-
glutarate, and charcoal-containing yeast extract agar buffered with an organic buffer (BCYEα) 
is the preferred growth medium for isolation [68]. Supplements, with antibiotics, may be added 
to BCYEα-media avoid overgrowth by other bacteria to increase the selectivity of the media [69].
Clinically important Legionella spp. grow best, usually in 2 to 5 days after inoculation, at  
35 °C in humidified air on BCYEα- medium. When grown on yeast extract agar, Legionella spp. 
produces a water-soluble, extracellular compound that fluoresces yellow-green on exposure to 
long-wave ultraviolet light. Several species exhibit blue-white or red auto fluorescence under 
ultraviolet light (366nm).
Differentiation of the common species is most conveniently made in the laboratory by direct 
fluorescent antibody staining of the isolates or performing biochemical tests. All species of the 
genus Legionella show a weak catalase and peroxidase activity, and most produce a soluble brown 
pigment from tyrosine [66]. Newer methods, such as Matrix-Assisted Laser-Desorption-Ioniza-
tion Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) and molecular techniques are avail-
able [70-74]. Identification of L. pneumophila serogroups other than serogroup 1, and other 
Legionella spp., is often much more difficult and is best left to specialized reference laboratories. 
Determination on species level by using molecular techniques is the definitive method, especial-
ly for the less common strains.
4.2 Non culture based diagnosis
Detection of Legionella spp. directly in clinical specimens offers the most rapid procedure for the 
diagnosis of Legionnaires’ disease. However great care is required to avoid false-positive results. 
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Staining
Legionellaceae are Gram-negative bacteria with a thin cell wall, but stain poorly in the Gram pro-
cedure if neutral red or safranin is used as the counter stain, counterstaining with basic fuchsine 
gives a better result. The Gimenez staining is more sensitive. On its own, Gram- and Giminez 
staining directly in specimens is inconclusive, more sensitive and specific methods of identifying 
Legionella spp. can be used.
DFA-testing
Direct examination using a direct fluorescent antibody (DFA) procedure has been successfully 
used for rapid detection of Legionella spp. from the respiratory tract [75]. DFAs using antibody 
conjugated with a fluorochrome require 2-3 hours to complete the staining procedure. The DFA-
test requires close attention to detail and precautions to ensure that all steps are performed 
properly, and have to be done by an experienced microbiologist [76]. There are several spe-
cies-specific polyvalent and monoclonal reagents available with different specificity and sensi-
tivity (25-75%), cross reactions have been reported [77, 35]. In conclusion, DFA is not useful 
for routine diagnosis of Legionella.
Nucleic acid amplification-based tests.
Amplification of DNA by polymerase chain reaction (PCR) is able to detect low quantities of 
Legionella in respiratory material. PCR is also the diagnostic test with the potential to detect 
infections caused by any of the known species of Legionella [35, 78]. Identification of  Legionella 
spp. can be achieved by DNA sequencing of the macrophage infectivity  potentiator (mip) gene 
provides results within one day and is therefore useful in the early  diagnosis of  infection with 
Legionella spp. [79-83]. The use of a multilocus sequence typing with  nonselective  housekeeping 
genes enables the rapid generation of sequence data and provides valuable typing data. The 
described sequence-based typing (SBT) scheme for epidemiological typing of  L. pneumophila 
 serogroup 1 offers advantages over other molecular methods [82, 83]. With the SBT method 
typing data can be obtained direct from clinical respiratory samples without the need for culture 
and isolate the organism. By combining L. pneumophila PCR and direct SBT typing data can be 
obtained in less then 24 hours [84].
4.3 Urine antigen tests
Patients with pneumonia caused by L. pneumophila excrete a polysaccharide (antigen) in their 
urine that can be detected with immunologic procedures. Legionella antigenuria can be detect-
ed as early as one day after onset and can persist for weeks, the longest duration of excretion 
was 326 days [85]. The first urine antigen tests were described in 1979, since then numerous 
immunochromatographic (ICT) tests and enzyme-immuno-assay (EIA) tests have followed and 
have been evaluated. Those studies confirmed the value, given the rapidity of the test and the 
performance, of urine antigen detection for the diagnosis of Legionnaires’ disease [86-90]. The 
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reported sensitivities of both enzyme immunoassay (EIA) and immunochromatographic test 
(ICT) vary from 50 to 90% [88, 89, 91]. The differences between the test sensitivities were not 
significant, more important is the severity of the disease. When Legionnaires’ disease patients 
were divided in three groups according to their CAP category the sensitivity increased from 42% 
for patients in the moderate CAP category to 93% for those in the severe CAP category [92]. 
Indicating that there is an association between the test sensitivity and the clinical severity.
Until now the majority of the urine antigen tests are limited to L. pneumophila serogroup 1, 
the most frequent cause of Legionnaires’ disease. Concentration of urine improves the sensi-
tivity of both the ICT and EIA tests, without decreasing their specificity [89, 92]. Important for 
these urine antigen tests is the high specificity (>99%), which is a requirement when testing a 
relatively rare disease [9].
Compared with other non culture based diagnostic methods, the advantages of urinary an-
tigen detection are striking. Specimens are easily obtained, the antigen is detectable very early in 
the course of disease, and the test is rapid and specific, and does not require additional labora-
tory equipment [90].
4.4 Serology
After the explosive outbreak in Philadelphia in the summer of 1976, a number of serologic 
assays were developed and evaluated to detect antibodies to Legionella spp. [93-97]. Of the var-
ious antibody detection methods that are available, indirect immunofluorescence assay (IFA) 
and enzyme-linked immunosorbent assays (EIA) are the most used ones. For sero-diagnosis of 
the disease it is recommended that an acute-phase serum sample be collected early and a fol-
low-up serum specimen be collected within 2-6 weeks. A fourfold rise in antibody titer between 
an acute-phase serum specimen and a convalescent-phase specimen is considered suggestive 
of infection with Legionella spp. [94, 96]. In most cases unfortunately, the development of a 
diagnostic fourfold rise in antibody titer can be slow and may occur in no more than 75% to 
80% of patients who ultimately are shown to have Legionnaires’ disease [98, 42]. Antibodies 
in patients with culture-confirmed Legionnaires’ disease are not detectable within 3 weeks and 
immunosuppressed patients may not produce detectable antibodies [99, 100]. Single elevated 
titers may be suggestive of Legionella infection, a high titer does not necessarily indicate recent 
infection because high titers can still be detected 48 month after disease onset [101]. In the 
normal population elevated anti-Legionella titers have been found to vary from 1 to 36% [35, 
102, 103]. Also high antibody titer can persist in healthy persons with no current clinical evi-
dence of Legionnaires’ disease. It is also known that using antigens for antibody testing has the 
potential for cross-reacting with serum from patients with other kinds of infections [104-106]. 
A disadvantage of serological testing is the inability to detect accurately all Legionella species and 
serogroups. Seroconversion (fourfold increase of antibody titer) may take several weeks and 
therefore not useful as a diagnostic tool. The use of serologic methods remains important for 
epidemiological studies of outbreaks, prevalence studies etc. [107]. 
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5. Identification of isolates
The use of biochemical test for routinely identification and differentiating Legionella species is 
limited. Legionellaceae are positive for catalase and the oxidase reaction gives variable results and 
is therefore not very useful. Most Legionella spp. produce beta-lactamase, lipase, phosphatase 
and gelatinase [109]. Newer methods, such as Matrix-Assisted Laser-Desorption-Ionization 
Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) has been explored and proved to be cost 
effective for identification of Legionella species [70-74].
Isolates of L. pneumophila serogroup 1 can also be rapidly sub typed by using monoclonal 
antibodies [116].
5.1 Serotyping
Commercial latex agglutination tests can be performed for rapidly identification and serogroup-
ing for the isolated strains of L. pneumophila. Latex particles are coated with rabbit antibodies 
raised against L. pneumophila serogroup 1 and serogroup 2-14. For L. pneumophila with the 
existing 15 different serogroups the serotyping can also be performed with monoclonal antisera 
against those different 15 serogroups.
5.2 Molecular typing
Ratcliff et al., developed in 1998 for Legionella spp. a sequence-based classification scheme that 
targets the mip gene that can discriminate the Legionella spp. [110, 111]. A number of molecular 
methods have been employed for epidemiological purposes. These include ribotyping, pulsed-
field gel electrophoreses (PFGE), restriction fragment length polymorphism (RFLP) analysis, 
amplified fragment length polymorphism (AFLP) [112, 113].
The need for rapid and reproducible molecular characterization method that can be con-
ducted in real time by the different laboratories has led to the development of sequence-based 
typing (SBT) technique [82, 83]. Based on “housekeeping” and virulent genes the sequences of 
seven genes, flaA, pilE, Asd, mip, mompS, proA and neuA are analyzed. Based on the sequences 
obtained for those genes, the results is assigned to a Sequence Type (ST) or allele profile, which 
can be compared to known STs provided in the EWGLI SBT database for L. pneumophila (www.
ewgli.org). This SBT method has been adopted as an international standard and has been widely 
used by members of the ESCMID studygroup European Study Group for Legionella Infections 
(ESGLI) [114].
5.3 Monoclonal antibody typing
Isolates of L. pneumophila serogroup 1 can be rapidly sub typed using monoclonal antibody 
(MAb) sub grouping with panels based on the international MAb sub grouping panel [115, 116]. 
Helbig et al. suggested that differences in the virulence of Legionella species or serogroups are 
associated with different epitopes within the bacterial cell wall (epitopes are parts of a foreign 
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organism or its proteins that are recognized by the immune system and targeted by antibodies, 
cytotoxic T cells or both) [117].
Tests using monoclonal sub-typing show that the strains of L. pneumophila serogroup 1 most 
commonly associated with disease in humans share a common epitope [118-120].  Depending 
on the typing scheme used, these strains may be referred to as Pontiac [118]; monoclonal 
 antibody (MAb) 2-reactive [121] or MAb 3/1 -positive [116]. Globally, the primary Legionellae 
associated with outbreaks of disease from these systems appear to be L. pneumophila serogroup 
1 MAb 3/1 reactive strains.
6. Antimicrobial susceptibility 
Since the first described outbreak of Legionnaires’ disease, erythromycin has been the  antibiotic 
of first choice [122]. The intracellular location of the pathogen is relevant for the efficacy of the 
antimicrobial agent [9]. Antimicrobial agents that achieve intracellular concentrations high-
er than the minimal inhibitory concentration (MIC) are more effective than antibiotics with 
poor intracellular penetration [123]. The new macrolide antibiotics, such as clarithromycin 
and azithromycin, show more effective in-vitro activity and a better intracellular and tissue 
penetration than erythromycin, as do the quinolones. The antimicrobial agents most commonly 
used for the treatment of Legionnaires’ disease are fluoroquinolones, macrolides, and rifampicin 
[56-58].
Clinical efficacy studies in humans are limited to case reports and small retrospective studies, 
only a few studies have evaluated the efficacy of macrolides (erythromycin, clarithromycin and 
azithromycin) versus levofloxacin [57, 58, 124]. In summary, the findings suggest that levoflox-
acin appears to be more effective than clarithromycin in treating severe cases of Legionnaires’ 
disease.
Where a rapid diagnostic test for Legionnaires’ disease is not in use, people presenting with 
Legionnaires’ disease are simply treated with macrolides plus beta-lactam antibiotics, because a 
delay in the application of appropriate therapy for Legionella pneumonia significantly increases 
mortality [125]. In the Netherlands the choice of empiric antimicrobial therapy for CAP is based 
on the intention of providing optimal therapy, the epidemiological features of various microor-
ganisms, and an interference of the most likely pathogen. In patients with severe CAP and who 
have recently travelled abroad Legionella infection should be considered [126].
Routine susceptibility testing of the antimicrobials active against L. pneumophila is usually 
not performed due to the lack of an easy to perform test and widely accepted cut-off values, and 
resistance in clinical strains has not been described. 
7. Outline of the thesis
In 2002 a National Legionella Outbreak Detection Programme (NLODP) was implemented. The 
objective of this cost-effective programme is to detect and eliminate potential sources of infec-
tion that Legionnaires’ disease patients have been exposed to during their incubation  period. In 
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eight years of source investigation in the Netherlands we describe that wellness  centers are an 
important source of Legionnaires’ disease (Chapter 2). 
The clinical isolate from the patients, sent to the Regional Public Health Laboratory 
 Kennemerland (Haarlem) by microbiology laboratories in The Netherlands, were genotypically 
compared to the patient-related environmental strains that were collected during source inves-
tigation. L. pneumophila serogroup 1 patient and environmental isolates were genotyped by AFLP 
analysis, as recommended by EWGLI (Chapter 3).  
To evaluate the prevention strategies we compared the distribution of L. pneumophila 
 serogroup 1 isolated from patients with the distribution resulting from prevention actions. 
Sources identified within the NLOPD were sampled and Legionella strains found in these 
 samples were genotypically compared with the genotypic distribution of patient-derived isolates. 
The  sequence type (ST) profiles were generated using the HiMLST method that employs Next 
 Generation Sequencing (Chapter 4).
In the Netherlands around 300 LD cases per year were reported between 2000 and 2008, but 
in 2009 the number dropped to 251: the lowest number in the previous 5 years of surveillance. 
We analyzed the number of tests performed between 2007-2009 in three, large, microbiological 
laboratories in different geographical regions in the Netherlands (Chapter 5).
The detection of Legionella antigenuria was already described shortly after the outbreak in 
Philadelphia in 1976. The rapid immunochromatographic membrane assays reduces the time to 
detect antigen and requires no specialized laboratory equipment, making it the most commonly 
used test for diagnosis of Legionnaires’ disease. We evaluated new immunochromatographic 
assays for their ability to detect L. pneumophila serogroup 1 antigen in urine. Test devices were 
read at various time points to determine the optimum incubation time regarding performance 
(Chapter 6-9).
Given the severe course of some Legionella infections, prompt identification of any common 
environmental source of infection is critical. Molecular diagnostics methods for Legionella are 
not well understood by clinicians but are a critical tool in the public health management of cases 
of Legionellosis (Chapter 10).
The antimicrobial agents most commonly used for treatment of Legionnaires’ disease are 
fluoroquinolones, macrolides and rifampicin. However, the activity of these antibiotics against 
a large collection of strains has not been well described and MIC wild type (WT) distributions 
are unavailable. In addition, it is unknown whether emergence of resistance is a problem, be-
cause epidemiological cut off values (ECOFF) to detect resistance have not been described for 
L. pneumophila. We determined MIC values (Chapter 11), disk inhibition zone diameters and 
their correlation (Chapter 12) in a large well described collection of clinical L. pneumophila 
serogroup 1 isolates.
Resistance in clinical L. pneumophila SG1 strains has not been described. We describe the 
first isolation of a ciprofloxacin resistant L. pneumophila SG1 clinical isolate, with an identified 
point mutation in the quinolone resistance-determining region (QRDR) of gyrA (Chapter 13).
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Abstract
Visiting wellness centres is considered safe and relaxing and might provide health benefits for 
visitors with certain cardiovascular, dermatological or respiratory diseases. On the other hand, 
wellness centres could pose health risks, especially with respect to Legionnaires’ disease. We 
investigated the role of wellness centres in the occurrence of Legionnaires’ disease by analysing 
the data of eight years (2002–2010) of source investigation in the Netherlands. There were 15 
wellness centres identified as potential sources of infection for a total of 35 Legionnaires’ disease 
patients. Twelve of these centres were positive for Legionella spp.: six for Legionella pneumophila, 
six for non-pneumophila Legionella spp. Of the 65 positive environmental samples found during 
the wellness centre investigations, 41 were derived from shower heads. For two centres, the 
Legionella pneumophila strains in the collected samples had a genotype that was indistinguish-
able from the patient isolates. These results show that wellness centres are potential sources of 
Legionnaires’ disease. 
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Introduction
Apart from massages and beauty care most wellness centres offer a mix of saunas, swimming 
pools, whirlpools, and other bathing facilities to the general public. Visiting these wellness cen-
tres is considered safe and relaxing and might even provide health benefits for visitors with 
certain cardiovascular, dermatological or respiratory diseases [1, 2]. On the other hand, is has 
been shown that facilities with whirlpools or saunas could comprise health risks, for example 
with respect to Legionnaires’ disease [3-5]. This acute pneumonia is caused by Legionella spp., 
which are thought to be responsible for two to 15% of all community-acquired pneumonias 
[6-8]. Legionella spp. live in aquatic environments and are particularly prevalent in man-made 
habitats [9]. The major route of transmission for Legionnaires’ disease is inhalation of the bac-
terium that is spread into the air as an aerosol from either natural or man-made sources [10]. 
Modern use of devices that aerosolise water or settings with such devices (e.g. air conditioners, 
showers, cooling towers, fountains, wellness centres), largely contribute to the emergence of 
Legionnaires’ disease as an important waterborne disease. 
Previous reports showed that in several cases of Legionnaires’ disease, wellness centres (with 
saunas and/or whirlpools) were indeed identified as the source of infection [3-5]. However, 
further clarification of the role of these centres in Legionella infections warrants a systematic 
identification and investigation of potential sources of Legionnaires’ disease. In 2002, based on 
the observation that outbreaks of Legionnaires’ disease are often preceded and followed by small 
clusters of cases [11], the Netherlands established the Legionella Source Identification Unit 
(LSIU) as part of a National Legionella Outbreak Detection Programme (NLODP) [12]. The 
aim of this programme was to improve source identification, thereby preventing or controlling 
outbreaks of Legionnaires’ disease by swift elimination of the source. 
In this study we aimed to assess the importance of wellness centres in the occurrence of 
Legionnaires’ disease by analysing the data of eight years (2002–2010) of systematic source 
investigation within the NLODP in the Netherlands.
35
Part I  Epidemiology
Methods
National Legionella Outbreak Detection Programme
As part of the NLODP, a LSIU was available to all Municipal Health Services for sampling of 
potential sources of Legionella infection in reported cases of Legionnaires’ disease. Between 2002 
and 2006, all identified potential sources of infection were investigated. From 2006 onwards, the 
LSIU has only investigated potential sources if at least one of the following four sampling-cri-
teria was met: (i) A patient isolate of Legionella spp. from respiratory secretions or lung tissue 
is available; (ii) one of the potential sources of infection identified by a Legionnaires’ disease 
patient was previously identified as a potential source of a different Legionnaires’ disease patient; 
(iii) the residence of a reported Legionnaires’ disease patient is situated within a range of less 
than one kilometre from the residences of at least two other Legionnaires’ disease patients who 
were reported in the last six months; (iv) the patient stayed in a hospital during the incubation 
period.
Patients
Legionnaires’ disease has been notifiable in the Netherlands since 1987. Treating physicians are 
required to report cases of Legionnaires’ disease to a public health physician at one of the 29 
Municipal Health Services within 24 hours of diagnosis. The public health physicians are then 
required to report all confirmed and probable cases of Legionnaires’ disease to the Ministry of 
Health and, since 2006, to the Centre for Infectious Disease Control, within 24 hours. A con-
firmed case of Legionnaires’ disease is defined as a patient suffering from symptoms compatible 
with pneumonia, with radiological signs of infiltration, and with laboratory evidence of Le-
gionella spp. infection (including isolation of Legionella spp. from respiratory secretions or lung 
tissue, detection of L. pneumophila antigen in urine, seroconversion or a four-fold or higher rise 
in antibody titres to Legionella spp. in paired acute- and convalescent-phase sera). A probable 
case of Legionnaires’ disease is defined as a patient suffering from symptoms compatible with 
pneumonia, with radiological signs of infiltration, and with laboratory findings suggestive of 
Legionella spp. infections (including a high antibody titre to Legionella spp. in a single serum, 
direct fluorescent antibody staining of the organism or detection of Legionella species DNA by 
polymerase chain reaction (PCR) in respiratory secretions or lung tissue). All 62 microbiological 
laboratories in the Netherlands involved in the diagnosis and treatment of patients with pneu-
monia are requested to send the available isolates of Legionella spp. from respiratory secretions 
or lung tissue of patients to the LSIU.
Given the purpose of the programme to identify Dutch sources of infection, patients who 
had stayed abroad for five days or more during their incubation period of two to 10 days were 
not considered for source identification. 
36
Chapter 2
Source identification and sampling procedure
Potential sources of infection were identified by public health physicians and nurses from the 
Municipal Health Service who interviewed the patient and/or a relative. The interview focused 
on tracking each patient’s exposure to potential sources of infection during the two weeks  before 
their first symptoms occurred. If at least one of the four sampling criteria was met, trained lab-
oratory staff from the LSIU took water and swab samples from the  identified  potential sources. 
For each location, sampling points were selected by the LSIU staff in  cooperation with the tech-
nical team of a facility (when available) to obtain a comprehensive collection of water and swab 
samples for further analysis. The sampling procedure was in accordance with national guidelines 
[13, 14]. It is noteworthy that the LSIU sampling method differs slightly from the European 
guidelines, which recommend samples of one litre in volume to be collected immediately after 
the opening of the water outlet [15], while the LSIU samples 500 ml in volume.
Laboratory investigations
The water samples were concentrated by filtration and filtered residues were resuspended in 1 
ml sterile water. Of this suspension, 100 µl samples were cultured without dilution and after 
10-fold dilution on two media at 35°C, with increased humidity. The two media used were buff-
ered charcoal yeast extract supplemented with α-ketogluterate (BCYE-α) and (i) the  antibiotics 
polymyxin B, cefazolin, and pimaricin; and (ii) the antibiotics polymyxin B, anisomysin, and va-
nomycin. In cases of bacterial overgrowth, cultures were repeated after pre-treatment by heating 
30 minutes at 50°C. Swab samples were dispersed by immersion in 1 ml sterile water and cul-
tured as described above. Both patient and environmental Legionella isolates were serogrouped 
by using commercially available kits containing antisera against L. pneumophila serogroups 1-14, 
L. longbeachae 1 and 2, L. bozemanii 1 and 2, L. dumoffii,  L. gormanii, L. jordanis, L. micdadei, and 
L. anisa (Legionella latex test, Oxoid Limited,  Hampshire, England; Legionella antisera “Seiken,” 
Denka Seiken Co. Ltd., Tokyo, Japan). All Legionella pneumophila serogroup 1 strains that were 
found in patient isolates or in the collected samples were subsequently genotyped by amplified 
fragment length polymorphism (AFLP) analysis, and by sequence based typing (SBT), as recom-
mended by the  European  Working Group for Legionella Infections (EWGLI) [16-18]. Patient 
isolates were then  compared with environmental strains that were found in the samples of po-
tential sources that were investigated.
Control measures
Whenever a wellness centre was found positive for Legionella spp. after sampling, the responsible 
government agency (usually the Inspectorate of the Ministry of Housing, Spatial Planning and 
the Environment (VROM Inspectorate)) was informed by the Municipal Health Services. They 
assessed how codes of practice and legal regulations concerning the prevention of Legionnaires’ 
37
Part I  Epidemiology
disease had been followed, and recommended or enforced control measures such as thermal or 
chemical disinfection and adaptation of the plumbing system to prevent new cases of Legion-
naires’ disease. 
Table 1: Probable or confirmed cases of Legionnaires’ disease, by age group, the Netherlands, 1 
August 2002-1 August 2010 (n=1,457)
Age Group (years) Female n (%) Male n (%)
0-25 7 (1.7) 8 (0.8)
26-50 87 (20.7) 238 (23.0)
51-75 244 (58,1) 640 (61,7)
>75 82 (19.5) 151 (14.6)
Total 420 (100.0) 1,037 (100.0)
Results
Patients
From 1 August 2002 until 1 August 2010, 2,076 confirmed or probable cases of Legionnaires’ 
disease were notified to the Centre for Infectious Disease Control. The 619 (30%) patients who 
had stayed abroad for five days or more during their incubation period (2–10 days) were exclud-
ed from the analyses. The remaining 1,457 patients were investigated by the Municipal Health 
Services and the LSIU. Patient characteristics are shown in Table 1. Patients had a median age of 
59.5 (interquartile range (IQR): 50.7–70.0) years, and 29% were female. 
The 2,343 potential sources of infection that were mentioned by the patients during the in-
terviews with the Municipal Health Service are shown in Table 2. Patient homes were mentioned 
by the majority of patients, followed by garden centres, workplaces, hospitals, cooling towers, 
and sports facilities. Wellness centres ranked 11th on the list of most often mentioned potential 
sources.
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Table 2: Potential sources of infection (n=2,343) reported by Legionnaires’ disease cases 
(n=1,457), the Netherlands, 1 August 2002-1 August 2010
Reported potential sources of infection n (%)
Home residence 1,149 (49.0)
Garden centre 146 (6.2)
Workplace 138 (5.9)
Hospital 115 (4.9)
Cooling tower 89 (3.8)
Sports facility 68 (2.9)
Swimming pool 59 (2.5)
Holiday park 48 (2.0)
Hotel 47 (2.0)
Car wash installation 47 (2.0)
Wellness centre 44 (1.9)
Campsite 39 (1.7)
Fountain 38 (1.6)
Other 316 (13.5)
Source investigation
Source investigation resulted in the sampling of 1,317 of the 2,343 potential sources by the 
LSIU that were related to one or more of the 1,457 patients. Some of the potential sources were 
more frequently associated with Legionella findings than others, which is reflected in the pro-
portion of investigations where Legionella was found in the investigated source. The sampling 
results are shown in Table 3, where the sources are ranked by the percentage of positive source 
investigations (from high to low). It should be noted that an individual source was sometimes 
investigated more than once (some sources were repeatedly identified by new patients during 
the study period).
The proportion of potential source investigations that were positive for Legionella spp. was 
highest for wellness centres (28 of 33 source investigations), followed by cooling towers, hos-
pitals, hotels, swimming pools, sports facilities, holiday parks, and home residences (Table 3).
When the different species of Legionella are considered, the data show that in 21 of the 33 
wellness centre investigations Legionella pneumophila was found in one or more of the investi-
gated samples, ranking wellness centres first before cooling towers, hospitals, hotels, swimming 
pools, sport facilities, and holiday parks (Table 3). 
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The majority of the 65 positive samples found during the wellness centre investigations were 
derived from shower heads (n=41). Other positive sample locations within the wellness centres 
were: taps (n=12) and whirlpools (n=3).
The 33 investigations of wellness centres were performed at 15 unique sites. Twelve of these 
centres were positive for Legionella spp. (six centres for Legionella pneumophila, and six centres for 
non-pneumophila Legionella spp.). The number of investigations on individual wellness centres 
testing positive for Legionella spp. ranged from one to seven. The 15 investigated wellness centres 
were identified by 35 patients, of whom 25 were part of different clusters associated with seven 
large and small wellness centres all positive for Legionella. There was one wellness centre with 
seven clustered patients, two centres with four patients, two centres with three patients, and two 
centres with two patients.
Genotype comparison
For 129 of the 333 positive source investigations that were performed between 2002 and 2010, 
there was a patient isolate available for genotyping which allowed comparison with the geno-
types of the environmental strains found in the samples. In 33 cases the available patient isolate 
had an indistinguishable genotype from those of the environmental strains reflecting a success 
rate of 25 % (33/129). The majority of these ‘matches’ were made with strains from investigat-
ed hospitals (13 matches of 13 positive investigation with an available patient isolate), home 
residences (nine matches of 47), hotels (two matches of two), swimming pools (two matches of 
seven), and wellness centres (two matches of 13).
Discussion
Given the low ranking of potential sources mentioned by Legionnaires’ disease patients,  wellness 
centres do not seem to contribute much to Legionnaires’ disease transmission.  However, our 
data show that in 85% (28 of 33) of all investigations wellness centres were positive for Legionel-
la spp. This rate is remarkably higher compared to other types of potential sources like cooling 
towers (18 of 33 (55%)), hospitals (34 of 68 (50%)), homes (139 of 693 (20%)) and garden 
centres (eight of 63 (13%)) that were identified, investigated and sampled under identical con-
ditions. Moreover, typing results indicate that in more than 60% (six of 33) of all wellness cen-
tre investigations, Legionella pneumophila, which is thought to be the etiologic agent in over 90% 
of all Legionnaires’ disease patients [19], was found in at least one of the samples. Compared 
to the other potential sources that were investigated, wellness centres account for the highest 
percentage of Legionella pneumophila positive source  investigations, which further indicates the 
relatively high potential of wellness centres as sources of Legionnaires’ disease. 
There are several possible explanations for our findings. One of them is that the circum-
stances in wellness centres contribute to a Legionella-friendly environment. The abundant pres-
ence of showers, whirlpools, swimming pools and even air-perfused footbaths can clearly form 
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a Legionella-friendly habitat and lead to free Legionella in the air. Additionally, the complexity of 
water piping systems due to subsequent enlargements of wellness centres could lead to standing 
or slow-flowing water and thereby create a stable micro-environment for growth of Legionella.
Another possibility is that the visitors of wellness centres may be more at risk for Legionnaires’ 
disease compared to individuals who do not visit these centres. Underlying chronic diseases and 
smoking status are known risk factors for Legionnaires’ disease [20]. If an overrepresentation 
of individuals who are at higher risk for Legionnaires’ disease among wellness centres visitors 
is confirmed, a possible public health intervention would be to inform this group on the risks 
of wellness recreation. We were unfortunately not able to study this possibility in the current 
study setting. However, considering the remarkable source investigation results we do think that 
there is a role awaiting for public health education aimed at wellness centre visitors who are at 
increased risk for Legionnaires’ disease.
It is difficult to compare our results with previous European studies on surveillance of Le-
gionnaires’ disease because of the absence of a systematic source identification and investigation 
programme in other countries. Although several outbreak reports have acknowledged wellness 
centres as an important source of exposure in Legionnaires’ disease outbreaks [4,5], most Eu-
ropean surveillance programmes do not include these specific potential sources in their surveil-
lance data [21,22]. The installation of a European surveillance programme in which systematic 
environmental investigations are incorporated could elucidate the role of different potential 
sources in Legionnaires’ disease cases. 
The strengths of this study are the nationwide detection and registration of new Legion-
naires’ disease cases and additional source identification within the NLODP, which resulted in a 
systematic and uniform collection of data. Together with the systematic sampling procedure of 
potential sources and the advanced serotyping and genotyping (AFLP and SBT) techniques, this 
enabled us to further clarify the role of wellness centres in Legionella infections in eight years of 
Legionnaires’ disease source identification efforts in the Netherlands.
Nevertheless, it should be kept in mind that the investigated wellness centres were not a 
random selection of all available centres in the Netherlands. Sampling of wellness centres was 
only performed according to the protocol of the NLODP. Furthermore, the ranking of the po-
tential sources of infection that were mentioned by the patients is influenced by the overall 
presence of particular sources (there are clearly more home residences than wellness centres or 
car wash installations present in the environment). Random sampling of centres that are not 
directly linked to Legionnaires’ disease patients, for presence of Legionella could further elucidate 
the contribution of these centres to Legionnaires’ disease in the Netherlands. It should also be 
noted that despite the large number of positive source investigations in wellness centres, only 
two matches in genotype were found during the eight years of this study period. Although this 
is partly a reflection of the limited number of clinical isolates that were available for genotype 
comparison in case of a positive source investigation, a larger number of genotype matches that 
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actually linked cases to wellness centres would have strengthened the evidence for the role of 
wellness centres in Legionnaires’ disease.
In conclusion, wellness centres are not merely the health promoting facilities they are of-
ten seen as, but also potential sources for Legionnaires’ disease. Despite control measures that 
are taken after identification of a first patient, some individual centres have been related to an 
accumulating number of Legionnaires’ disease patients over time. This questionable role of well-
ness centres requires increased attention from wellness centre owners, the VROM Inspectorate, 
water companies, and Municipal Public Health Services. Furthermore, as many sources remain 
unknown at the moment this could increase the number of identified sources of Legionnaires’ 
disease.
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Abstract
This study investigated the hypothesis that the genotype distribution of Legionella isolates from 
sporadic patients with Legionnaires’ disease differs from that of Legionella strains in the envi-
ronment. An amplified fragment-length polymorphism (AFLP) assay was used to genotype pa-
tient-derived and environmental Legionella isolates. The three Legionella pneumophila genotypes 
isolated most frequently from human respiratory secretions were AFLP types 004 Lyon, 010 
London and 006 Copenhagen. These genotypes were cultured significantly less frequently from 
environmental samples (50% vs. 4%; p <0.001). The most frequently observed L. pneumophila 
serogroup 1 genotype among patient-derived isolates was 004 Lyon (32%). This genotype was 
cultured from only one of 6458 environmental samples. The positive sample contained 1.26 x 106 
CFU ⁄L and originated from a whirlpool spa that had not been disinfected and had been main-
tained at 36°C for several months. Overall, the distribution of genotypes differed significantly 
among patient and environmental isolates. A possible explanation is that virulent strains may 
exist in potential environmental sources at undetectable concentrations.  
Key words: AFLP profiles, distribution, environment, genotypes, Legionella spp., pneumonia
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Introduction
Legionnaires’ disease (LD) is an acute bacterial pneumonia caused by Legionella spp., and ac-
counts for 8–13%of community-acquired pneumonias [1,2]. Worldwide, >90% of cases of LD 
are caused by Legionella pneumophila, of which 92% are caused by L. pneumophila serogroup 1 
[3]. A major transmission route for LD involves inhalation of the bacterium [4], but drinking 
and subsequent aspiration of contaminated water has also been shown to be a route of trans-
mission [5,6]. For inhalation to occur, the bacterium must be disseminated as an aerosol from 
either natural or man-made sources in aquatic environments. Legionella spp. have been cultured 
from surface water [7] and ground water [8], where they flourish as parasites of amoebae and 
other proto protozoa [9]. Inadequate filtering and disinfection of water sources for drinking 
water production can lead to the colonisation of water systems by Legionella spp. [10]. Stagnant 
water, biofilm formation and favourable growth conditions can subsequently lead to high bacte-
rial concentrations. Transmission to humans becomes possible if aerosol-producing devices are 
connected to such contaminated water systems. 
Contaminated water systems and devices associated with LD patients include cooling towers 
of air-conditioning systems [11], whirlpool spas [12], showerheads [13], evaporative condensers 
[14], humidifiers [15] and mist-making machines [16]. These sources were revealed in outbreak 
investigations that included epidemiological studies and comparison of Legionella genotypes iso-
lated from patient specimens and the environment. Genotype comparisons have an important 
role in judging the likelihood of a source of infection being the true source of LD, since indistin-
guishable genotypes have been identified from sources over periods of up to 17 years [17]. Such 
interpretations are often made without a full understanding of the underlying distribution of 
genotypes in the patient-derived and environmental populations [18]. However, this distribu-
tion can vary from a single endemic genotype, such as that found in the entire water distribution 
system in Paris, France [19], to the occurrence of several different environmental genotypes in 
a single hospital in Italy [20]. 
The aim of the present study was to test the hypothesis that the genotype distribution of 
Legionella isolates from sporadic patients with LD differs from the genotype distribution of Le-
gionella isolates from the environment. This reflects the observation that virulence factors are 
more prominent in patient-derived Legionella isolates [21]. Accordingly, a 4-year prospective 
national study was performed to systematically compare the genotype distribution of Legionella 
isolates from sporadic cases to the genotype distribution of Legionella isolates cultured from the 
environmental sources to which the LD patients were exposed during their incubation period. 
Potential sources of bias and confounding (diagnostic, sampling, seasonal) were also evaluated.
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Material and methods
Epidemiological data
LD has been a notifiable disease in The Netherlands since 1 July 1987. Attending physicians 
are required to report cases of LD to a public health physician at one of the 38 Regional Public 
Health Services within 24 h of diagnosis. The public health physicians are then required to report 
all confirmed and probable cases of LD to the Ministry of Health within 24 h. The international 
criteria specified by the European Working Group for Legionella Infections (EWGLI) for con-
firmed and probable cases of LD [22] are used in The Netherlands. The present study included 
cases of LD notified between 1 August 2002 and 30 October 2006 that had a laboratory diag-
nosis which included isolation of Legionella spp. from sputum or lung secretions. As the aim of 
the study was to investigate differences in the distribution of Legionella genotypes in The Nether-
lands, patients who had travelled abroad for ≥5 days during their incubation period of 2–10 days 
were excluded. In addition, to avoid an overrepresentation of genotypes associated with clusters 
or outbreaks, only one randomly selected LD patient was included from each EWGLI-defined 
cluster or outbreak of infection [23]. A subgroup of patients whose pulmonary secretions yielded 
the most frequently observed amplified fragment-length polymorphism (AFLP) Legionella geno-
type (see Results) was compared with a control group of LD patients using a nine-page question-
naire. The questionnaire requested information concerning general health status and exposure 
to aerosols originating from any water source (e.g., shower, whirlpool, sprinkler, hose, fountain, 
air-conditioning system, heating system) at home, at work, during leisure activities and during 
holiday periods. The same data had been systematically collected previously from 68 patients 
with community-acquired LD who had been resident in The Netherlands for ≥5 days during the 
incubation period [24].  
Bacteria 
Following a large outbreak of infection in The Netherlands that involved 188 patients with LD 
[25], a national outbreak detection programme (NODP) was started on 1 August 2002 [26], 
with the aim of providing a short response time between the diagnosis of LD patients and the 
inspection and sampling of potential sources of infection. To identify potential sources during 
the incubation period, medical specialists in infectious disease control at the Regional Public 
Health Services carry out structured interviews (using a questionnaire) with the patient and ⁄ or 
a contact. The interviews focus on tracking each patient’s exposure to potential sources of infec-
tion. Certain potential sources mentioned specifically in the questionnaire, e.g., swimming pools 
and saunas, were included on the basis of previous epidemiological and outbreak studies [26]. 
Following the identification of a potential source, trained laboratory staff from the NODP 
take water and swab samples, which are then cultured for the presence of Legionella spp. The 
sampling yield is expressed as the number of isolates included in the study divided by the num-
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ber of samples taken. Criteria for sampling were revised for budgetary reasons from 1 June 2006 
onwards, thereby creating a natural end to the inclusion period for environmental Legionella 
isolates in the present study. 
Isolate characteristics 
Patient isolates were sent by all 62 medical microbiology laboratories in The Netherlands that 
are involved in the diagnosis and treatment of pneumonia patients to the Regional Public Health 
Laboratory Kennemerland (Haarlem), where they were stored at) 70°C. L. pneumophila was 
cultured on buffered charcoal yeast extract agar supplemented with a-ketoglutarate [27], with 
dyes and with and without the antibiotics polymyxin B, anisomysin and vancomycin  (Legionella 
MWY Selective Supplement SR 110, 111, and 118; Oxoid, Basingstoke, UK). Water and swab 
samples from potential sources that had been collected by environmental sampling were cul-
tured and serotyped as described previously [26]. 
L. pneumophila serogroup 1 patient and environmental isolates were genotyped by AFLP 
 analysis, as recommended by EWGLI [28]. Profiles for 31 defined EWGLI AFLP types are  available 
from the EWGLI website (http://www.ewgli.org). The entire NODP dataset, including isolates 
from previous studies, contains 42 genotypes that have not yet been designated by EWGLI. 
Therefore, for the purpose of this study using the EWGLI AFLP protocol, provisional Not Yet 
Designated (NYD) numbers were assigned, starting with NYD01 and ending with NYD42. 
 
Inclusion bias 
The residence of a patient was used as a proxy for the place of infection unless a patient had 
resided elsewhere for ≥5 days during the incubation period. The place of infection was subse-
quently classified, using the province of residence as the geographical subunit, into four regions 
that conformed to the criteria of Statistics Netherlands [29], i.e., North (Friesland, Groningen, 
Drenthe), East (Overijssel, Gelderland, Flevoland), West (Noord-Holland, Utrecht, Zuid-Hol-
land, Zeeland) and South (Noord-Brabant, Limburg). The environmental isolates were similarly 
grouped. To explore any potential diagnostic bias, incidence rates for culture-proven LD were 
calculated for the four regions and compared to the mean incidence rate of LD for 2002–2006 
in these regions. To explore any potential inclusion bias for environmental isolates, the number 
of identified and sampled potential sources was compared for the four regions. 
Temperature has an influence on the growth of Legionella spp., both in the natural environ-
ment [30] and in the manmade environment [31]. The level of humidity may also be a factor 
in the transmission of LD [32]. Therefore, data concerning temperature and humidity were in-
cluded as a potential source of bias and confounding in the analyses. A proxy was used as the day 
of infection, for which the humidity and temperature were determined. This was calculated by 
subtracting a median incubation period of 5 days from the first day of illness. In practice, there is 
a delay between the day of diagnosis and the day of sampling. If the delay is distributed unevenly 
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Table 1: Serotyping and genotyping results for 117 Legionella isolates from  patients with 
 Legionnaires’ disease and 245 environmental Legionella isolates
Patient isolates Environmental isolates
  Legionella non-pneumophila 2 (2) 140 (57)
L. pneumophila non-serogroup 1 12 (10) 55 (23)
L. pneumophila serogroup 1, AFLP type 004 Lyon 33 (28) 1 (0,4)
L. pneumophila serogroup 1, AFLP type ’not yet designated’ 22 (19) 11 (4)
L. pneumophila serogroup 1 AFLP type NYD01 - 2 (0)
L. pneumophila serogroup 1 AFLP type NYD02 1 (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD03 1 (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD04 3 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD06 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD09 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD11 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD16 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD17 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD20 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD22 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD23 2 (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD24 - (0) 2 (0)
L. pneumophila serogroup 1 AFLP type NYD25 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD28 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD31 - (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD32 - (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD33 1 (0) -  (0)
L. pneumophila serogroup 1 AFLP type NYD34 - (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD36 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD38 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD39 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD40 1 (0) - (0)
L. pneumophila serogroup 1 AFLP type NYD41 - (0) 1 (0)
L. pneumophila serogroup 1 AFLP type NYD42 1 (0) - (0)
L. pneumophila serogroup 1, AFLP type 010 London 11(9) - (0)
L. pneumophila serogroup 1, AFLP type 006 Copenhagen 8 (6) 1 (0.4)
L. pneumophila serogroup 1, AFLP type 003 Glasgow 7 (6) 5 (2)
L. pneumophila serogroup 1, AFLP type 013 London 7 (6) 7 (3) 
L. pneumophila serogroup 1, AFLP type 028 Rome 4 (3) 12 (5) 
L. pneumophila serogroup 1, AFLP type 001 Lugano 3 (3) 6 (2) 
L. pneumophila serogroup 1, AFLP type 008 Stockholm 3 (3) 2 (0.8)
L. pneumophila serogroup 1, AFLP type 009 London 2 (2) 4 (2) 
L. pneumophila serogroup 1, AFLP type 017 Lugano 2 (2) 1 (0.4)
L. pneumophila serogroup 1, AFLP type 015 Dresden 1 (1) -
Total 117 (100) 245 (100)
Values in parentheses are percentages.
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over the different regions of The Netherlands, bias caused by seasonal differences could occur. 
The mean, minimum and maximum temperatures, and the relative degree of humidity, were 
recorded for the calculated day of infection and for the day of sampling. These were compared to 
those of the other days of the study period.
Statistical analyses 
Univariate analysis was used to estimate crude regional differences in AFLP genotype  distribution 
among patient and environmental isolates. Comparison of risk-factors for LD  between two 
groups of LD patients was analysed by univariate analysis, using Student’s t-test for continuous 
variables and the Pearson chi-square test for dichotomous and nominal  variables. For continu-
ous variables, the distributions were checked for normality. Statistical analyses were performed 
using SPSS v.14.0 (SPSS Inc., Chicago, IL, USA).  
Results
Epidemiological data
Between 1 August 2002 and 30 October 2006, 1133 patients with LD were notified by the Min-
istry of Health. Of these, 691 (61%) had been abroad for ≥5 days during the incubation period 
and were therefore excluded. Of the remaining 442 patients, 128 (29%) diagnoses were con-
firmed by isolation of Legionella spp. from sputum or lung secretions. Eleven of these  patients 
were representatives of outbreaks. Serotyping and genotyping results for the isolates from the 
remaining 117 patients are summarised in Table 1.
Clinical and environmental isolates 
Between 1 August 2002 and 30 May 2006, sampling was required for 442 notified cases of 
LD who had spent ³5 days in The Netherlands. Of these, four foreign visitors could not be 
interviewed because they had already left the country, and 35 (8%) patients refused sampling 
for various reasons, mostly privacy-related. For the remaining 403 LD patients, 875 potential 
sources of infection were identified, all of which were sampled. In total, 185 (21%) potential 
sources yielded one or more different Legionella strains, giving a total of 245 patient-related en-
vironmental isolates to be serotyped and genotyped. These 245 isolates were cultured from 6458 
samples, giving a yield of 3.8%. The yield was significantly higher in the western region than in 
the other regions (4.7% vs. 3.1%; p 0.001; Table 2). Also, the yield for L. pneumophila serogroup 
1 was significantly higher in this region (1.0% vs. 0.6%; p 0.02; Table 2). The origins of the 6458 
samples are shown in Table 3. 
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Inclusion bias 
The results shown in Table 2 reveal that LD patients living in the West region were more likely 
to have their diagnosis confirmed by isolation of Legionella spp. than patients living in other 
regions (34% vs. 22%; p 0.05). Therefore, isolates from the western part of the country were 
overrepresented in the collection of patient isolates. However, since the genotype distribution of 
the isolates from the West region did not differ from that in the rest of the country, the overall 
genotype distribution was not influenced. 
The results in Table 2 revealed no significant differences between the percentage of samples 
taken in each region and the percentages of notified LD patients. Therefore, no selection bias in 
sampling procedure was apparent. 
Isolate characteristics 
In 18 instances, a clinical isolate was genotypically indistinguishable from an environmental 
Legionella isolate. In total, 13 sources were involved, nine of which were related to sporadic 
cases of LD. Four of the sources were related to clusters involving two to four patients, totalling 
13 LD patients. As shown in Table 1, serogroup 1 accounted for 88% of all patient isolates, 
compared to only 20% of all environmental isolates (p <0.001). The three genotypes isolated 
most frequently from human sputum or lung secretions were AFLP types 004 Lyon, 010 London 
and 006 Copenhagen, and these genotypes were also cultured significantly less frequently from 
environmental samples (50% vs. 4%, p <0.001). The over-representation of LD patients from 
the western part of The Netherlands did not influence the overall distribution pattern. When 
33 patients whose pulmonary secretions yielded AFLP genotype 004 Lyon were compared with 
68 control LD patients, the mean age of the AFLP 004 Lyon patients was significantly higher 
than that of the controls (mean difference 8 years; t-test for equality of means, p 0.03), and the 
male-to-female ratio was 3.7, compared with 3.5 for controls (p 0.64), but none of the other 
host or environmental risk-factors included in the questionnaire differed significantly between 
the two groups. AFLP 004 Lyon was cultured from only one of the 6458 environmental samples. 
This sample originated from an outdoor whirlpool spa in the eastern region of The Netherlands. 
The spa had not been disinfected and was maintained at 36°C for several months, resulting in 
a bacterial concentration of 1.26 x 106 CFU⁄ L at the time of sampling. AFLP 010 London was 
not found in any of the environmental samples. AFLP 006 Copenhagen was cultured on one 
occasion from a fire hose that was used for cleaning purposes. The AFLP type ‘not yet designat-
ed’ was further divided into subtypes NYD01–NYD42. Seventeen of the 19 different NYD types 
were isolated from lung secretions and were unique, while NYD04 and NYD23 were isolated 
on three and two occasions, respectively. Type NYD04 was not cultured from environmental 
samples. Of nine different NYD types cultured from environmental samples, only three were 
also cultured from lung secretions (Table 1).
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There were no significant differences in the maximum or mean temperatures, relative hu-
midity or hours of sunshine between the day of sampling and the other days of the study period. 
Similarly, there was no difference in terms of the calculated days of infection compared with the 
other days of the study period. However, significant differences were observed on the days on 
which two LD patients were presumed to have been infected (Table 4). 
Discussion
Based on the results of this study, it was concluded that the genotype distribution of Legionella 
isolates from sporadic LD patients in The Netherlands differs from the genotype distribution of 
Legionella isolates in the environment. Previous studies in various countries have suggested that 
differences in distribution patterns may exist [33– 36], but these studies were not based on a 
systematic collection of both patient and environmental Legionella isolates. 
In total, 50% of the L. pneumophila serogroup 1 isolates from LD patients were represented 
by only three EWGLI AFLP genotypes, but these genotypes represented only 4% of environmental 
serogroup 1 isolates. This finding suggests that these genotypes are more virulent than others. 
AFLP genotype 004 Lyon, which was isolated most frequently from human lung secretions, does 
not seem to define a clinically or environmentally distinct subgroup of LD patients, except with 
respect to age.
L. pneumophila serogroup 1 was isolated from the environment less frequently than expected, 
with only 50 isolates being cultured from 6458 patient-related environmental samples. Un-
fortunately, there are no previous reports concerning prospective collections of patient-related 
environmental isolates. It seems that AFLP is sufficiently discriminating for the Dutch setting, 
as can be inferred from the numerous unique NYD AFLP types. 
The present study is the first to systematically collect patient-related environmental samples 
and Legionella isolates. The potential types of bias and confounding that were assessed seemed 
to have little effect on the principal findings of the study. Among the weaknesses of the study is 
the low number (mean 2.2) of potential sources identified for each LD patient. Given that the 
Table 4: Comparison of meteorological parameters on the calculated day of Legionella 
infection, the day of environmental sampling and control days, 2002-2006.
Day 
with one 
infected 
patient
Day 
with two 
infected 
patients
Day of 
sampling
Control 
days
Average maximum day temperature (°C) 15.5 22.1a 13.6 14.8
Average mean day temperature (°C) 11.1 17.7a 9.5 10.6
Average relative humidity (%) 83 85a 81 82
Average no. of hours of sunshine 4.8 1.9a 4.4 4.9
a significance difference.
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patients’ own home was one of the potential sources sampled in 91% of cases, few additional 
sources were included in the study. A non-systematic study in the UK that involved 401 unrelat-
ed LD patient and environmental isolates revealed that some strains were more likely to cause 
human infection than would be expected from their distribution in the environment [33]. The 
same conclusion was reached by French researchers who investigated 3387 unrelated patient 
and environmental isolates [36]. The present results are in accord with these studies, but the 
differences between the patient and environmental isolates identified in the present study were 
more prominent. 
Two possible explanations can be proposed for these findings. First, the source investigations, 
based on a standardised questionnaire, may not identify the true sources of LD. Nevertheless, 
all previously documented outbreak- or cluster-related LD sources were included in the ques-
tionnaire. It is also reasonable to assume that the collection of environmental isolates was rep-
resentative for the country. However, it is possible that virulent strains should not be sought in 
the aquatic environment, but rather in the air, as they are spread by various sources on days of 
increased humidity [32]. The humidity findings seemed to confirm this hypothesis, but should 
be assessed using a more sophisticated analysis [37]. The second possible explanation is that 
the Legionella genotypes isolated most commonly from human respiratory secretions are also 
present in the sources sampled, but at undetectable concentrations. This alternative hypothesis 
is supported by the finding that the most common human-derived Legionella genotypes revealed 
in the present study were also the only genotypes cultured in 1999 from a display whirlpool 
that caused a large outbreak of LD infection in The Netherlands involving 188 cases. Despite 
extensive efforts, none of the samples taken from the effluent water distribution system were 
found to contain Legionella bacteria at a detectable concentration. However, indirect evidence 
showed that the whirlpool had been contaminated by the building’s water supply [24]. The sec-
ond hypothesis is also in accord with a recent report suggesting that Legionella anisa may be an 
indicator of water contamination with undetectable numbers of L. pneumophila [38], and with 
the concept that the infectious dose for LD is very low, based mainly on the observation that 
humans can become infected at a distance of several hundred metres from a source [39]. 
These findings require further confirmation, since this is the first study to systematically 
collect patient isolates and patient-related environmental samples. Most importantly, there is 
a need to systematically collect environmental Legionella strains and to determine the distri-
bution of Legionella AFLP genotypes among LD patients in Europe. To date, only restriction 
fragment-length polymorphism results are available. It remains to be determined whether the 
quotient of relative frequencies for human and environmental L. pneumophila isolates, as found 
in distributions that have been collected systematically, is a measure of virulence. In this respect, 
genotyping of isolates using a virulence-associated epitope, e.g., that recognised by MAb 3 ⁄ 1 
(Dresden Panel) [40], should perhaps be included in such an evaluation.
Table 4: Comparison of meteorological parameters on the calculated day of Legionella 
infection, the day of environmental sampling and control days, 2002-2006.
Day 
with one 
infected 
patient
Day 
with two 
infected 
patients
Day of 
sampling
Control 
days
Average maximum day temperature (°C) 15.5 22.1a 13.6 14.8
Average mean day temperature (°C) 11.1 17.7a 9.5 10.6
Average relative humidity (%) 83 85a 81 82
Average no. of hours of sunshine 4.8 1.9a 4.4 4.9
a significance difference.
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Abstract
Legionnaires’ disease (LD) is an acute pneumonia caused by inhalation or aspiration of aerosols 
contaminated with Legionella bacteria. The watery environment is considered to be the natural 
habitat for these bacteria. Therefore, drinking water legislation is used in the primary preven-
tion of LD, focusing on the different water sources the general public is exposed to. Since ten 
years, secondary prevention of LD in the Netherlands is organised using an outbreak detection 
programme that eliminates potential sources of infection that LD patients have been exposed 
to during their incubation period. To evaluate the two prevention strategies, we compared the 
distribution of Legionella pneumophila serogroup 1 genotypes isolated from patient material 
(n=179) with the distribution resulting from primary (n=182) and secondary (n=60) preven-
tion actions, respectively. The sequence type profiles were generated using the HiMLST method 
that employs Next Generation Sequencing. We found that genotypes collected during primary 
prevention differ to a large extend from those isolated from patients. Genotypes collected dur-
ing secondary prevention efforts, had a larger similarity to that of patient isolates, but could 
be further improved. Our results suggest that primary prevention is not aiming at the correct 
reservoir, whereas secondary prevention is only partially focussed. It seems that there is a still 
unknown reservoir.
Keywords: Legionnaires’ disease; Legionella; prevention; genotypic variation 
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Introduction
Legionnaires’ disease (LD) is an acute pneumonia caused by Legionella spp., with the major route 
of transmission being inhalation of the bacterium that is disseminated into the air as an aerosol 
from either natural or man-made sources [1]. It was named after a point-source outbreak in a 
hotel that hosted the convention of the American Legion in 1976 [2,3]. The disease is character-
ized by an acute pneumonia, a low attack rate (0.1-5%) and an average incubation time of 2-10 
days, although it may even exceed this period [1-4]. Legionnaires’ disease is thought to account 
for 2-15% of all community-acquired pneumonias [1,5,6], and proves fatal in about 6% of cases 
[7]. The majority (>90%) of LD cases are caused by the species Legionella pneumophila, and about 
85% more specifically by L. pneumophila serogroup 1 [8,9]. In source investigations, genotypic 
comparisons between clinical and environmental isolates are essential [10,11].
After a large outbreak in the Netherlands in 1999 [12], elaborate control measures aimed at 
Legionella were introduced in a new drinking water law [13,14]. Among them, owners of aero-
sol producing devices (e.g. shower heads, whirlpools) to which third parties are exposed to, are 
obliged to make a risk analysis, develop a control plan, keep logs of the specific measures taken, 
and perform sampling for Legionella. It has been estimated that these control measures initially 
costed an average of 500 million euro’s per year from 2002-2005 [15]. Despite these primary 
prevention efforts, the LD incidence in the Netherlands continued to rise in the ten years fol-
lowing the 1999 outbreak [16].
In addition to the primary prevention programme, secondary preventive measures were in-
stalled as a National Legionella Outbreak Detection Programme (NLODP), that was imple-
mented in 2002 [17]. The rationale behind the NLODP was based on the observation that out-
breaks of Legionnaires’ disease are often preceded and followed by small clusters of solitary cases 
[18]. The objective of this cost-effective programme is to detect and eliminate potential sources 
of infection that LD patients have been exposed to during their incubation period [17]. These 
sources are sampled and Legionella strains found in these samples are compared with the clinical 
isolate from the patient related to this source. As an important effect, source identification has 
improved in the last years [19].
To determine whether the primary and secondary prevention programmes have been aim-
ing at the correct reservoirs, we hypothesised that the sampling results of an ideal prevention 
programme would show high similarity to the distribution of patient-derived L. pneumophila 
genotypes. To verify our hypothesis, we compared the genotypic distribution of patient-derived 
isolates to that of environmental strains that were collected during primary prevention efforts. 
Also, the distribution of strains that were collected during secondary prevention efforts (sam-
pling of LD patient-related sources) was compared. We restricted our study to L. pneumophila 
serogroup 1.
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Methods
Patient isolates
Legionnaires’ disease has been notifiable in the Netherlands since 1987. Treating physicians 
are required to report cases of Legionnaires’ disease to a public health physician at one of the 
28 Municipal Health Services within 24 hours of diagnosis. The public health physicians are 
then required to report all confirmed and probable cases of Legionnaires’ disease to the Minis-
try of Health and, since 2006, to the Centre for Infectious Disease Control, within 24 hours. 
 Epidemiological data were collected for these patients and included information on whether the 
patient was hospitalised during the incubation period, and spent time abroad in the two weeks 
before onset of disease. All 62 microbiological laboratories in the Netherlands involved in the 
diagnosis and treatment of patients with pneumonia are requested to send the available isolates 
of Legionella spp. from respiratory secretions or lung tissue of patients to the Legionella Source 
Identification Unit (LSIU) of the NLODP [19]. 
L. pneumophila serogroup 1 strains collected during primary prevention activities
In accordance with new legislative obligations [13,14], primary prevention activities (including 
sampling for Legionella) were enrolled in the Netherlands after the 1999 outbreak [12]. We 
asked 48 companies offering Legionella prevention services and other water-testing providers to 
submit all L. pneumophila serogroup 1 isolates cultured from water samples that were analyzed 
for their clients between November 1, 2009 and March 1, 2011. Instructions for companies in-
cluded: that isolates were derived from unique sample locations, and that a description of place 
of origin, and type of installation was available.
L. pneumophila serogroup 1 strains collected during secondary prevention activities
As part of the National Legionella Outbreak Detection Programme (NLODP), a Legionella 
Source Identification Unit (LSIU) is available to all Municipal Health Services for sampling of 
potential sources of Legionella infection in reported cases of Legionnaires’ disease. Between 2002 
and 2006, all identified potential sources of infection were investigated. From 2006 onwards, the 
LSIU only investigates potential sources if at least one of the following sampling-criteria is met:
1. A patient isolate of Legionella spp. from respiratory secretions or lung tissue is available ; 
2. One of the identified potential sources of infection was previously identified as a potential 
 source of another Legionnaires’ disease patient within the last 2 years ; 
3. The residence of a reported Legionnaires’ disease patient is situated within a range of less 
 than 1 kilometre of the residences of at least two other Legionnaires’ disease patients who 
 were reported in the last 6 months ; 
4. The patient stayed in a hospital or health care setting during the incubation period.  
Potential sources of infection are identified by public health physicians and nurses from the 
Municipal Health Service who interview the patient and/or a relative. The interview focuses on 
tracking each patients’ exposure to potential sources of infection during the two weeks before 
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their first symptoms occurred. If at least one of the four sampling criteria is met, trained labora-
tory staff from the LSIU takes water and swab samples from the identified potential sources. For 
each location, sampling points were selected by the LSIU staff in cooperation with the technical 
team of a facility (when available) to obtain a comprehensive collection of water and swab sam-
ples for further analysis. The sampling procedure was in accordance with national guidelines 
[20,21]. The water samples were concentrated by filtration and filtered residues were resuspend-
ed in 1 ml sterile water. Of this suspension, 100 µl samples were cultured without dilution and 
after 10-fold dilution on two media at 35°C, with increased humidity. The two media used were 
buffered charcoal yeast extract supplemented with α-ketogluterate (BCYE-α) and (i) the anti-
biotics polymyxin B, cefazolin, and pimaricin; and (ii) the antibiotics polymyxin B, anisomysin, 
and vancomycin. In cases of bacterial overgrowth, cultures were repeated after pre-treatment by 
heating 30 minutes at 50°C. Swab samples were dispersed by immersion in 1 ml sterile water 
and cultured as described above. 
Serotyping and genotyping
Both clinical isolates, as well as primary prevention and secondary prevention environmen-
tal  Legionella strains were serogrouped by using commercially available kits containing antisera 
against L. pneumophila serogroups 1-14, L. longbeachae 1 and 2, L. bozemanii 1 and 2,  L.  dumoffii, 
L. gormanii, L. jordanis, L. micdadei, and L. anisa (Legionella latex test, Oxoid  Limited, Hamp-
shire, England; Legionella antisera “Seiken,” Denka Seiken Co. Ltd., Tokyo,  Japan). All  Legionella 
pneumophila serogroup 1 strains that were found in patient isolates or in the  collected samples 
were subsequently genotyped by sequence based typing (SBT), as recommended by the European 
Working Group for Legionella Infections (EWGLI) [11,22,23]. The SBT profiles were generated 
using the cost effective HiMLST method that employs Next Generation Sequencing [24].
Index of diversity
To compare the distribution of L. pneumophila serogroup 1 genotypes between the three groups: 
(1) the patient-derived isolates, (2) the environmental strains that were collected during pri-
mary prevention and (3) the environmental strains collected during the secondary prevention 
efforts (sampling of LD patient-related sources), we used the Simpson’s index of diversity (IOD) 
[25,26]. This single numerical index of discrimination ranges from 0 to 1 and was developed for 
the description of species diversity within an ecological habitat. It is based on the probability that 
two unrelated strains sampled from a test population will be placed into different typing groups. 
For example, an index of 0.746 indicates that if two strains were sampled randomly from the 
population, then on 74.6% of the occasions they would fall into different types. In other words, 
the higher the index, the larger the variation of genotypes within a sample.
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Table 1: Genotypic results
L. pneumophila SG1, ST
Patient 
isolates 
(n=179)
Environmental strains
Primary 
prevention 
strains 
(n=182)
Secondary 
prevention 
strains 
(n=60)
X2 test 
p-value
47 74 - - NA
62 23 1 - 0.565
23 5 - 1 0.081
42 3 - 9 <0.001
46 12 1 - 0.565
1 7 123 25 <0.001
9 6 2 2 0.239
45 10 1 - 0.565
82 8 - 1 0.081
37 4 - 1 0.081
109 4 - - NA
48 1 1 - 0.565
146 2 - 1 0.081
207 3 - - NA
479 2 - - NA
36 1 2 - 0.415
534 1 1 2 0.091
953 1 - 1 0.081
7 - 4 1 0.802
59 - 8 2 0.720
188 - 9 1 0.269
492 - - 2 0.013
866 - - 2 0.013
177 - 5 - 0.195
1066 - 2 - 0.415
1120 - 2 - 0.415
Other sequence types 12 20 9 NA
The data shown are numbers
Only sequence types that were available more than once are presented in this table. The
p-value reflects the difference in the distribution of genotypes between the primary  
prevention strains and the secondary prevention strains (x2 test)
NA not applicable
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Statistical analyses
The proportion of the each genotype was compared between primary prevention environmental 
strains, and the secondary prevention environmental strains that were collected, using a two-
tailed χ2-test (PASW Statistics 18.0, SPSS inc., Chicago, Illinois). The indexes of diversity (IOD) 
for clinical isolates, primary and secondary prevention environmental strains were compared 
using an independent t-test (PASW Statistics 18.0, SPSS inc., Chicago, Illinois).
Results
Patient isolates
Between January 1, 2007 and December 31, 2011, 1688 Legionnaires’ disease cases were report-
ed in the Netherlands [27,28]. In total, 308 patients had their diagnosis confirmed by isolation 
of Legionella species from respiratory secretions or lung tissue. Legionella pneumophila isolates 
from these patients were serotyped, which resulted in 286 L. pneumophila serogroup 1 isolates, 
of which 179 were isolated from cases who were considered to be community-acquired. Of these 
community acquired cases, 167 had their diagnosis additionally confirmed by urinary antigen 
testing, 11 cases were confirmed by polymerase chain reaction (PCR), 2 cases by serology testing, 
and one case by a direct fluorescent antibody test (DFA). The 179 available community-acquired 
L. pneumophila serogroup 1 isolates were evenly distributed over the study period. For this study 
we examined the genotypic variation of these patient isolates, that is presented in Table 1.  
L. pneumophila serogroup 1 strains collected during primary prevention activities
In total, we received 182 primary prevention environmental strains that were isolated from 
unique sample locations, such as taps, showers, cooling towers, pools, etc. from different com-
plexes (Table 2) by 8 different companies.  
L. pneumophila serogroup 1 strains collected during secondary prevention activities
Between January 1, 2007 and December 31, 2011, the trained laboratory staff from the LSIU 
sampled 491 potential sources of infection that were reported in relation to 287 LD patients. 
Samples of 122 (24.8%) potential sources contained one or more Legionella strains, giving a 
total of 216 secondary prevention environmental strains to be serotyped. These strains consisted 
of 155 L. pneumophila strains and 61 L. non-pneumophila strains. Of the 155 L. pneumophila 
strains, 128 strains belonged to the L. pneumophila serogroup 1. From each unique source that 
was investigated, only one L. pneumophila serogroup 1 strain was selected for genotyping. This 
resulted in 60 secondary prevention environmental L. pneumophila serogroup 1 strains that were 
available for the comparison. There was a reasonable distribution of isolates by year of isolation 
(2007:19 isolates, 2008:16 isolates, 2009:7 isolates, 2010:17 isolates), with the exception of 
2011 when only one isolate was available. The origin of these 60 secondary prevention environ-
mental strains is shown in Table 2.
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Table 2: Environmental strain characteristics
Origin of samples
Primary prevention 
environmental strains 
(n=182)
Secondary prevention 
environmental strains 
(n=60)
Industry and commerce a 40 (22) 3 (5)
Complex building b 57 (31) 43 (72)
Private house 44 (24) 9 (15)
Other 41 (23) 5 (8)
Total 182 (100) 60 (100)
The data shown are numbers (%)
a Industrial factories, cooling towers
b Office buildings, health care facilities, sports facilities, hotels, saunas, swimming pools.
Comparison of patient isolates, primary and secondary prevention environmental 
isolates
Table 1 shows the genotypic variation in patient isolates (n=179) and secondary prevention 
environmental strains (n=60) that were collected between 2007-2011, as well as the variation 
in the 182 primary prevention environmental strains. Within the 179 patient isolates, ST47 is 
the predominant isolate, representing 41% of culture-positive LD patients in the Netherlands, 
but this sequence type was not found in the environmental strains between 2007-2011. ST47, 
ST62 and ST46 represent 61% of patient isolates, the top five (adding ST45 and ST82) repre-
sent 71% of isolates. These sequence types are found significantly less often in the primary and 
secondary prevention associated collections: 1.1% (ST47, ST62, ST46), 1.6% (ST47, ST62, ST46, 
ST45, ST82), 0.0% (ST47, ST62, ST46), and 1.7% (ST47, ST62, ST46, ST45, ST82), respectively. 
The distribution of two sequence types was significantly different between the two samples of 
environmental strains. The proportion of ST1 isolates was higher in the primary prevention en-
vironmental strains (67.6% vs. 41.7%, Chi-square, p-value <0.001), while the proportion of the 
ST42 strains was significantly higher in the secondary prevention environmental strains (15.0% 
vs. 0.0%, Chi-square, p-value<0.001).
Index of diversity of patient isolates, primary and secondary prevention environmen-
tal isolates
The patient isolates and the secondary prevention environmental strains showed a comparable 
diversity: IOD (SE): 0.802 (0.03) for patient-isolates vs. 0.807 (0.05) for secondary prevention 
environmental strains (independent t-test, p-value<0.917). Furthermore, the primary preven-
tion environmental strains showed a much lower level of genotypic diversity (IOD (SE): 0.539 
(0.05) which was significantly lower compared to both patient isolates (independent t-test, 
p-value<0.001), and secondary prevention environmental strains (independent t-test, p-val-
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ue<0.002). Restricting the comparison between the primary prevention environmental strains 
and the secondary prevention environmental strains to those strains that were found in samples 
of complex buildings only (Table 2), did not markedly change these results (primary prevention 
strains (n=57), IOD(SE): 0.484 (0.08); secondary prevention strains (n=43), IOD(SE): 0.718 
(0.07), independent t-test, p-value=0.040). 
Discussion
In general, the variation in sequence types of the secondary prevention strains (indicated by the 
index of diversity (IOD) was in line with the variation seen in patient isolates, although there is 
still room for improvement. However, the genotypic variation of the primary prevention strains 
was substantially lower compared to the patient isolates and secondary prevention strains, which 
was unexpected given the much larger number of primary prevention strains (n=182).
The difference in genotypic variation between the primary and secondary prevention strains 
was supported by the comparison of sequence types distributions. There were significant dif-
ferences in the proportion of ST1 and ST42 isolates, where the proportion of ST1 isolates was 
higher in the primary prevention environmental strains while the proportion of the ST42 strains 
was significantly higher in the secondary prevention environmental strains. It should be noted 
that ST1 was abundantly present in both samples of environmental strains (123 (67.6%) in 
primary prevention strains, 25 (41.7%) in secondary prevention strains), while only 7 (3.9%) 
of the patient isolates were ST1. 
Overall, we found that the genotypic distribution of clinical isolates largely differs from 
environmental isolates, which is in line with previous studies of that showed little overlap in se-
quence distribution between clinical and environmental L. pneumophila isolates [9,26,29]. Fur-
thermore, the genotypic variation in the analyzed patient isolates was better represented by the 
secondary prevention strains than by the primary prevention strains. A possible explanations for 
this discrepancy in genotypic variation could be the difference in sampled locations: the majority 
of secondary prevention samples were collected in complex buildings and private homes (87%), 
where only 55% of the primary prevention strains were derived from these sources. Additionally, 
the differences in the methodology of analyzing the samples between the companies and the 
NLODP could have influenced these findings. For instance, the selection of those L. pneumophila 
strains from a positive environmental sample that are sequence typed is a random procedure. 
Assuming that the presence of certain infectious strains may be rare in environmental samples 
(as our data suggest), it might be necessary to analyze several colonies within the same environ-
mental sample. For this purpose, the analyses of monoclonal antibodies [30] could be included 
in the selection procedure to increase the chance of finding L. pneumophila sequence types that 
are now rarely seen in samples from potential sources. Finally, it is possible that current primary 
prevention efforts do not include the most important reservoir causing of Legionella pneumophila 
in the Netherlands.
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In conclusion, given our hypothesis it seems that primary prevention efforts do not include 
the most important reservoir causing transmission of Legionella pneumophila in the Netherlands. 
Secondary prevention efforts seem to be aimed better, but could be further improved. This raises 
the question what the right place is to look for Legionella, and emphasizes the need for explor-
ative studies on yet undiscovered reservoirs and transmission routes of Legionella, for instance 
pluvial floods after heavy rainfall [31]. Ideally, preventive efforts focus on the niches that har-
bour the Legionella genotypes that cause human disease. Given our results, it is questionable if 
the current efforts are effective. Alternatively, the absence of certain sequence types in the envi-
ronmental samples (e.g. ST47) may be an artefact of the current environmental sample isolation 
techniques that possibly favour the chance of other STs (e.g. ST1) to be isolated from investigat-
ed samples. Future investigations should focus on these alternative explanations of our findings.
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Abstract
Legionnaires’ disease (LD) is an acute pneumonia caused by inhalation or aspiration of aerosols 
contaminated with the Legionella bacteria. In the Netherlands around 300 LD cases per year were 
reported between 2000 and 2008, but in 2009 the number dropped to 251: the lowest number 
in the previous 5 years of surveillance. We investigated if this decrease could be explained by the 
number of performed Legionella diagnostic tests in this year. We analyzed the number of tests 
performed between 2007-2009 in three, large, microbiological laboratories in different geo-
graphical regions in the Netherlands. Our data showed that there was no decrease in the number 
of patients for whom a diagnostic test for Legionella was performed in this period. These results 
are not in line with our hypothesis that the decrease in reported  Legionella-pneumonia patients 
in 2009 would be due to a decrease in patients for whom a diagnostic test was performed. We 
conclude that it is more likely that other factors such as the influence of weather patterns might 
explain the sudden drop in reported Legionella-pneumonia patients in 2009 compared to the 
previous years, and it would be interesting to investigate this for the period described.
Keywords: Legionnaires’ disease ; diagnostic testing 
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Introduction
Legionnaires’ disease (LD) is an acute pneumonia caused by inhalation or aspiration of aero-
sols contaminated with the Legionella bacteria. It was named after a point-source outbreak in a 
hotel that hosted the convention of the American Legion, in 1976 [1, 2]. Legionnaires’ disease 
is characterized by an acute pneumonia, a low attack rate (0.1-5%) and an average incubation 
time of 2-10 days, although it may extend to even longer than 10 days [1-4]. The disease proves 
fatal in about 6% of cases [5].
In the Netherlands, LD has been a notifiable disease since 1987. Treating physicians report 
cases of LD to the Municipal Health Services, who then report them to the Centre for Infectious 
Disease Control, where a national database is situated [6]. Around 100-300 LD cases per year 
were reported between 1999 and 2008 (with an unexpected peak of 436 reported cases in 2006) 
[7-10]. In 2009, the number of reported LD cases dropped to 251, which was the lowest number 
in the previous 5 years of surveillance [9]. This sudden drop gave rise to several hypotheses that 
might explain the decrease of reported LD cases, ranging from the influence of weather patterns, 
to the effect of the concurrent occurrence of the influenza A (H1N1) pandemic and the Q fever 
outbreak in 2009 [11-14]. Several studies have suggested that specific meteorological variables 
like relative humidity and temperature are related to the LD-incidence, as these factors might in-
fluence the outdoor survival of the Legionella bacteria [15-17]. Weather conditions in 2009 may 
therefore have affected the LD-incidence. Furthermore, the influenza A (H1N1) pandemic was 
spread around the Netherlands from April 2009 onwards [11, 12], and competed for the daily 
headlines with the Q fever outbreak that started in the southern part of the country and peaked 
in the spring of 2009 [13, 14]. The nationwide increased attention for these two respiratory in-
fectious diseases may have diminished the interest of both public and health care employees for 
LD. As a consequence, changes in laboratory practices with respect to LD diagnostics could have 
resulted in a diagnostic bias and an underreported number of LD cases in 2009. 
The aim of this study was to investigate if the number of requests for Legionella diagnostics in 
the Netherlands between 2007 and 2009 could explain the number of reported LD cases in these 
years. We therefore analyzed the Legionella diagnostics data from three, large, microbiological 
laboratories from different geographical regions in the Netherlands, between 2007 and 2009. 
Methods
Patient
Legionnaires’ disease has been notifiable in the Netherlands since 1987. Treating physicians are 
required to report cases of LD to a public health physician at one of the 28 Municipal Health 
Services within 24 hours of diagnosis. The public health physicians are then required to report 
all confirmed and probable cases of LD to the Ministry of Health and more recently to the 
Centre for Infectious Disease Control within 24 hours. The LD cases diagnosed in this present 
study were defined according to the standardized case definitions of the European Legionnaires 
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Disease Surveillance Network (ELDSNet) [18]. A confirmed case of LD is a patient presenting 
clinical and/or radiological signs of pneumonia with at least one of the following laboratory cri-
teria: (1) isolation of Legionella spp. from respiratory secretions or any normally sterile site, (2) 
detection of L. pneumophila antigen in urine, or (3) L. pneumophila serogroup 1 specific antibody 
response. A probable case of Legionnaires’ disease is defined as a patient presenting clinical and/
or radiological signs of pneumonia with at least one of the following laboratory criteria: (1) 
detection of L. pneumophila antigen in respiratory secretions or lung tissue e.g. by direct fluores-
cent antibody staining, (2) detection of Legionella spp. nucleic acid in a clinical specimen, (3) 
L. pneumophila non-serogroup 1 or other Legionella spp. specific antibody response, (4) a single 
high titre in specific antibody response for L. pneumophila serogroup 1, other serogroups or other 
Legionella spp.  
Laboratories
Three, large, microbiological laboratories in the Netherlands participated in this study and pro-
vided data on all requested diagnostic LD tests in 2007, 2008, and 2009. The Izore Centre of 
Infectious Diseases Friesland is situated in the city of Leeuwarden in the North of the Nether-
lands, and performs LD diagnostic tests for the 650.000 inhabitants of its adherence region. The 
Laboratory of Medical Microbiology and Immunology of the Sint Elisabeth Hospital in Tilburg 
is situated in the southern part of the Netherlands, and performs LD diagnostic tests for the 
800.000 inhabitants of its adherence region. The Regional Public Health Laboratory Kennemer-
land, in Haarlem is situated in the western part of the country, and has an adherence region of 
about 700.000 inhabitants.
Diagnostic tests
Each laboratory performed a spectrum of different tests on the available patient materials for 
which Legionella diagnosis was requested by the treating physician of the patient.
Urinary antigen test
In all three laboratories, a commercial urinary antigen test (Binax NOW, Portland, USA) was 
used to test urine samples on the presence of L. pneumophila antigens. The BinaxNOW test has 
been recommended as a rapid specific test for LD caused by L. pneumophila serogroup 1, with 
technical advantages over a conventional enzyme immunoassay test: there is no need for expen-
sive laboratory equipment, and the processing speed is higher [19]. However, the detection of 
non- L. pneumophila serogroup 1 cases is higher for the Binax EIA [19, 20]. 
Serological investigation
All laboratories used a commercially enzyme-linked immunosorbent assay (ELISA) to detect IgM 
and IgG serotype 1-7 antibodies to L. pneumophila in acute- and (when available) in convales-
cent-phase sera of patients (Serion ELISA; Institute Verion/Serion GmbH, Würzburg, Germany). 
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Culture
In all laboratories, available respiratory secretion, bronchoalveolar lavage specimen, or lung tis-
sue of patients were used to culture Legionella spp. The available specimen was cultured on two 
media at 35°C, with increased humidity. In Haarlem and Tilburg, the two media used were buff-
ered charcoal yeast extract supplemented with α-ketogluterate (BCYE-α) and (1) the antibiotics 
polymyxine B, cefazoline, and pimaricine; and (2) the antibiotics polymyxine B, anisomysine, 
and vanomycine (Oxoid Ltd., Hampshire, UK). In Leeuwarden the available specimen (bron-
choalveolar lavage specimen or respiratory secretion) was cultured on two media at 35°C, with 
increased humidity. The two media used were buffered charcoal yeast extract (1) without antibi-
otics; and (2) with the antibiotics polymyxine B and cefazoline (Mediaproducts BV, Groningen, 
the Netherlands).
Polymerase chain reaction (PCR)
In the laboratory of Haarlem [21,22] and Leeuwarden [23], a PCR-assay that targeted the 16S 
ribosomal DNA gene was used to detect Legionella nucleic acid in the available patient materials. 
In Tilburg, samples were tested for Legionella spp. DNA in a 16S rRNA-based PCR and in a mip 
gene-based PCR for L. pneumophila [24]. 
Data collection
For each laboratory, we first calculated the total number of patients for whom one or more 
Legionella diagnostic tests were requested in 2007, 2008, and 2009. Additionally, the number of 
different diagnostic tests that were performed was calculated for the three laboratories over the 
same period.
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Table 1: Diagnostic tests performed between 2007-2009
Diagnostic tests performed
Year
2007 2008 2009
Leeuwarden
PCR 88 (13) 137 (16) 117 (12)
Culture 118 (17) 146 (17) 110 (11)
Urinary antigen test 184 (26) 200 (23) 202 (21)
Serological test 313 (45) 393 (45) 534 (55)
Total number of tests 703 (100) 876 (100) 963 (100)
Tilburg
PCR 60 (4) 88 (4) 72 (3)
Culture 160 (10) 218 (9) 191 (7)
Urinary antigen test 471 (28) 971 (42) 1433 (52)
Serological test 970 (58) 1049 (45) 1066 (39)
Total number of tests 1661 (100) 2326 (100) 2762 (100)
Haarlem
PCR 78 (4) 55 (3) 81 (4)
Culture 94 (5) 33 (3) 81 (4)
Urinary antigen test 806 (42) 833 (46) 923 (49)
Serological test 961 (50) 859 (48) 806 (43)
Total number of tests 1939 (100) 1800 (100) 1891 (100)
Data are numbers (%)
Statistical analyses
The trend over time of the incidence rate of LD cases (between 1999-2008) was assessed by use 
of the Cochran-Armitage trend test (R Foundation for Statistical Computing, Vienna, Austria) 
[25]. Incidence rates were compared between different years, using a two-tailed χ2-test (PASW 
Statistics release 18.0, SPSS inc., Chicago, Illinois). The trend over time of the number of pa-
tients for whom a diagnostic test for Legionella was performed between 2007 and 2009 was 
assessed by use of linear regression analysis (PASW Statistics release 18.0, SPSS inc., Chicago, 
Illinois). The trend over time (between 2007-2009) of the patients with a positive diagnostic test 
for Legionella as a proportion of the total number of patients with a diagnostic test was assessed 
by use of the Cochran-Armitage trend test [25].
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Results
From 1987 to 2009, in total 3393 LD cases (probable or confirmed) were reported in the Neth-
erlands, which corresponds with an average annual incidence rate of 0.94 per 100.000 pop-
ulation (Figure 1) [7-10]. Between 1999 and 2008, there has been a significant increase in 
incidence rate (p<0.001, Cochran-Armitage trend-test) with two peaks: one in 2002 (incidence 
rate (95%CI): 1.79 (1.64-1.94), and one in 2006 (incidence rate (95%CI): 2.67 (2.52-2.82). In 
2009, the lowest incidence rate was reported in 5 years of surveillance: 1.52 per 100.000 popu-
lation (95%CI: 1.32-1.73). This rate was significantly lower (p=0.001, χ2-test) compared to the 
other two years of the study period 2007-2009: in 2007 the incidence rate (95%CI) was 1.97 
(1.76-2.17), and in 2008 the incidence rate was 2.05 (1.85-2.26).
Figure 2 A shows the total number of patients for whom one or more diagnostic tests for 
Legionella were performed between 2007 and 2009 in the three laboratories. Overall, the number 
of patients for whom one or more tests were performed increased between 2007 and 2009: 3914 
patients in 2007, 4484 patients in 2008, and 4978 patients in 2009 (p=0.026, linear regression). 
Figure 2 A shows the data for the three laboratories separately.
Figure 2 B shows the patients with a positive diagnostic test for Legionella as a proportion of 
the total number of patients with a diagnostic test. In total, there were 197 cases (96 probable ; 
101 confirmed) reported by the three laboratories between 2007-2009: 64 cases (32 probable ; 
32 confirmed) in 2007, 80 cases (35 probable ; 45 confirmed) in 2008, and 53 cases (29 proba-
ble ; 24 confirmed) in 2009. The corresponding incidence rates (95%CI) for the three laborato-
ries were 2.98 (2.24-3.72) per 100.000 population of the adherence region in 2007, 3.72 (2.98-
4.46) per 100.000 in 2008, and 2.47 (1.73-3.20) per 100.000 in 2009. The data from all three 
laboratories taken together showed that the proportion of patients with a positive diagnostic test 
(95%CI) decreased between 2007 and 2009: 1.64 (1.26-2.01) in 2007 (64 cases in 3914 tested 
patients), 1.78 (1.43-2.14) in 2008 (80 cases in 4484 tested patients), and 1.06  (0.73-1.39) in 
2009 (53 cases in 4978 tested patients) (p=0.019, Cochran-Armitage trend-test). The data from 
Tilburg showed a slight increase in the proportion of patients with a positive test between 2007 
and 2008, which was followed by a decrease between 2008 and 2009. In Table 1, data are shown 
for the number of different diagnostic tests that were performed in the three laboratory between 
2007 and 2009. Several patients were diagnosed by more than one diagnostic method, which is 
reflected by the higher total number of tests that were annually performed compared to the total 
number of tested patients (Figure 2A).
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In all three laboratories, the majority of diagnostic tests consisted of either a serological test or 
a urinary antigen test. Culture was the third most common test, followed by PCR. The increase 
between 2007 and 2009 in the total number of diagnostic tests that were performed in Leeu-
warden and Tilburg was mostly due to the increase in serological tests (both labs) and in urinary 
antigen tests (Tilburg only), but remained when only the urinary antigen tests were considered: 
in total 1461 urinary antigen tests were performed in 2007; 2004 tests in 2008, and 2558 tests 
in 2009 (Table 1).
Discussion 
Our data show that there was no decrease in the number of patients for whom a diagnostic 
test for Legionella was performed in the three large microbiological laboratories from different 
geographical regions in the Netherlands between 2007 and 2009. In contrary, the number of 
patients with a diagnostic test increased in two of the three laboratories in this period. There 
was an overall decrease in the proportion of patients with a positive diagnostic test for Legionella.
One of the strengths of our study was the large amount of diagnostic data provided by the 
three different laboratories. Their large adherence regions and the location of the laboratories in 
three different geographical regions in the Netherlands strengthens our believe that the avail-
able data on diagnostic tests formed a representative sample of the total number of performed 
diagnostic tests in the Netherlands.
The results are not in agreement with our hypothesis that the decrease in the number of 
reported Legionella-pneumonia patients in 2009 could be due to a decrease in the number of 
patients for whom a diagnostic test was performed. We therefore conclude that it is more likely 
that other factors might explain the sudden drop in reported Legionella-pneumonia patients in 
2009 compared to the previous years, and it would be interesting to investigate this for the peri-
od described in this current study.
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 Abstract
We evaluated a new immunochromatographic assay (Oxoid Xpect Legionella test kit) for the 
ability to detect Legionella pneumophila serogroup 1 antigen in urine. The results were compared 
with those obtained with the Binax NOW urinary antigen test by following the manufacturers’ 
instructions. The sensitivities and specificities were estimated to be 89 and 100%, respectively, 
for the Oxoid Xpect Legionella test kit and 86 and 100%, respectively, for the Binax NOW test.
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Since the initial description of Legionnaires’ disease (LD) in1976, Legionella pneumophila has 
been increasingly recognized as a pathogen causing community-acquired, travel-associated, and 
nosocomial pneumonias [2,4]. LD is an acute pneumonia caused by Legionella spp., which are 
responsible for 2 to 5% of community-acquired pneumonias [6]. More than 90% of LD cases are 
caused by L. pneumophila, and 70 to 80% of these belong to serogroup type 1 [2,4].
The aim of our study was to evaluate a newly developed commercially available immuno-
chromatographic urine antigen test (IC test), the Oxoid Xpect Legionella test kit (Thermo Fisher 
Scientific), for the detection of L. pneumophila serogroup 1 in nonconcentrated urine samples.
(This study was presented at the 19th European Congress of Clinical Microbiology and In-
fectious Diseases, Helsinki, Finland, 2009.)
We studied a panel of frozen nonconcentrated urine samples collected between 1995 and 
2005 from 86 patients with pneumonia caused by L. pneumophila (cases) [3]. LD patients were 
admitted with pneumonia, had radiological signs of infiltration, and showed laboratory evidence 
of infection with L. pneumophila. At least one of the following criteria constituted laboratory 
evidence of infection with L. pneumophila: isolation of L. pneumophila from a lower respiratory 
tract sample, a positive PCR result with a lower respiratory tract sample by a 16S rRNA-based as-
say, or seroconversion to positivity for specific immunoglobulin M (IgM) and/or IgG antibodies 
with the Serion enzyme-linked immunosorbent assay classic L. pneumophila 1-7 IgM and IgG 
kit (Virion Serion). The laboratory results for these patients were as follows [number of patients 
positive/number of patients tested (percent positive)]: serology, 61/69 (88%); isolation, 11/21 
(53%); PCR, 43/46 (93%).
Urine samples from 87 patients with respiratory tract infections other than Legionella in-
fections were tested in a similar manner to test the specificity of the assays. The laboratory test 
results for these patients were as follows: Streptococcus pneumoniae (total, 57 patients; bacteria 
cultured from blood [blood], pneumococcal antigen [PAG; Binax NOW; Binax, Portland, ME] 
detected in urine, and bacteria cultured from sputum [sputum], 8 patients; blood and PAG, 
23 patients; blood, 18 patients; sputum and PAG, 2 patients; sputum, 4 patients; PAG, 2 pa-
tients), Haemophilus influenzae (total, 8 patients; blood, 2 patients; sputum, 6 patients), Morax-
ella catarrhalis (sputum, 1 patient), Staphylococcus aureus (total, 4 patients; blood and sputum, 
2 patients; sputum, 2 patients), Escherichia coli (total, 2 patients; blood and sputum, 1 patient; 
sputum, 1 patient), Acinetobacter baumannii (blood and sputum, 1 patient), Streptococcus pyo-
genes (blood and sputum, 2 patients), Mycobacterium tuberculosis (sputum, 1 patient), and Pneu-
mocystis jirovecii (Giemsa and silver stain positive, 1 patient). Ten patients who had a fourfold 
or greater rise in (complement-fixing) antibodies against influenza A virus (n = 2) adenovirus 
(n = 1) Chlamydia psittaci (n = 2) Mycoplasma pneumoniae (n = 4), and parainfluenza virus (n 
= 1) were included.
89
Part 2  Diagnostics
Table 1: Results of Binax NOW and Oxoid Xpect tests after 15 min and 1 h of incubation 
Test and incubation 
time (min) % Sensitivity % Specificity
Xpect
15 81 (69/85)a 100 (0/86)
60 89 (76/85) 98 (2/86)
NOW
15 86 (74/86) 100 (0/87)
60 93 (80/86) 100 (0/87)
a The values in parentheses are the number of samples positive/total
Nonconcentrated urine samples were investigated for the presence of L. pneumophila antigen 
by using the Oxoid Xpect Legionella test kit, a qualitative IC test. We compared the sensitivities 
and specificities of these assays to those of a widely used IC test, the Binax NOW urinary anti-
gen test (Binax NOW; Binax). Both tests were performed simultaneously and according to the 
manufacturers’ instructions. All Legionella positive and -negative urine samples were read at 15 
and 60 min. Subsets of Legionella-positive samples (n = 54) and Legionella- negative samples (n 
= 69) were also read at 30 and 45 min. The clinical sensitivity and specificity of the assays were 
determined by using two-by-two contingency tables. Diagnostic sensitivity was defined as the 
fraction of the patients correctly identified by the IC test as having LD compared to determi-
nation by the standard (patients with LD). Diagnostic specificity was defined as the fraction of 
patients correctly identified by the IC test as not having LD compared to determination by the 
standard (patients with respiratory tract infections other than Legionella infections). The over-
all percent agreement represents the proportion of samples similarly classified by the standard 
Binax NOW test and the Oxoid Xpect Legionella test. Samples that gave nonvalid results were 
not included in the calculations. 
Fisher’s exact test was used to compare categorical data. A result with a P value of <0.05 was 
considered statistically significant. The results obtained are shown in Tables 1 and 2. A total of 
173 samples were tested with the Oxoid Xpect and Binax NOW tests (Table 1). Two samples 
yielded nonvalid results in the Oxoid Xpect IC test; these samples were not included in the calcu-
lations. Sensitivity and specificity were estimated as, respectively, 81% (69/85; 95% confidence 
interval [CI], 71 to 88%) and 100% (0/86; 95% CI, 95 to 100%) for the Oxoid Xpect test and 
86% (74/86; 95% CI, 77 to 92%) and 100% (0/87; 95% CI, 95 to 100%) for the Binax NOW 
urinary antigen test after 15 min of incubation. The sensitivities of the Oxoid Xpect and Binax 
NOW tests increased to 89% (76/85; 95% CI, 81 to 95%) and 93% (80/86; 95% CI, 85 to 
97%), respectively, when the tests were examined after 60 min of incubation. The specificity of 
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the Oxoid Xpect was 100% after 15 min of incubation and decreased to 98% (84/86; 95% CI, 
91 to 100%) after 1 h of incubation. The difference in sensitivity between the Oxoid Xpect and 
Binax NOW tests did not reach statistical significance. Samples from 54 patients with proven 
LD and 69 with respiratory tract infections other than Legionella infections were read at 15, 30, 
45, and 60 min of incubation to determine the optimal incubation time (Table 2). The optimal 
incubation time of the Oxoid Xpect test was determined to be 45 min; maximum sensitivity is 
observed without any loss of specificity. The two false positives obtained with the Oxoid Xpect 
test after 60 min of incubation were not observed after 45 min of incubation. Calculated agree-
ment percentages of 96 and 97% (after 15 and 60 min of incubation, respectively) for the Oxoid 
Xpect test compared to the Binax NOW test were found.
Table 2: Results of Oxoid Xpect and Binax NOW IC tests with a subset of Legionella-posi-
tive urine samples at 15, 30, 45, and 60 min of incubation
Test No. of urine samples with positive test results/total (% positive) after incubation for:
15 min 30 min 45 min 60 min
Oxoid Xpect 45/54 (83) 47/54 (87) 48/%4 (89) 48/54 (89)
Binax NOW 46/54 (85) 51/54 (94) 51/54 (94) 51/54 (94)
Detection of Legionella antigenuria was already used shortly after the first outbreak in Phil-
adelphia [1]. It has revolutionized the laboratory diagnosis of LD, making it the most common 
laboratory test for diagnosis [4]. Commercial kits that use both radioimmunoassay and enzyme 
immunoassay methodologies have been available for several years and have similar performance 
characteristics [2,4]. Agglutination assays have also been introduced, but they have not demon-
strated acceptable sensitivity and specificity [4]. In addition, immunochromatographic assays 
have been developed that have sensitivities and specificities similar to those of enzyme immuno-
assays [5]. The majority are most sensitive for the detection of the Pontiac monoclonal antibody 
type of L. pneumophila serogroup 1 (up to 90%), less sensitive for other monoclonal antibody 
types of L. pneumophila serogroup 1, and poorly sensitive for other L. pneumophila serogroups 
and other Legionella species [2]. In most Western countries, the majority (about 90%) of cases 
of community-acquired LD are caused by the Pontiac subtype of L. pneumophila serogroup 1, and 
therefore the average sensitivity of this test is in the range of 70 to 80%. An important feature of 
these assays is their high specificity (99%), which is a requirement when testing for a relatively 
rare disease.
We evaluated a new IC test, the Thermo Fisher Scientific (Oxoid) Xpect Legionella test kit, 
developed for the detection of L. pneumophila antigen in human urine. The data suggest that the 
Oxoid Xpect test has high degrees of sensitivity and specificity, with a performance compara-
ble to that of the Binax NOW test. A limitation of this study was the relatively small group of 
91
Part 2  Diagnostics
 patients that was evaluated, as this could influence both sensitivity and specificity. In  addition, 
the included LD positive patients were probably infected with L. pneumophila serogroup 1, 
 making it impossible to reach conclusions concerning infections caused by other L. pneumophila 
serogroups or Legionella species.
By evaluating four different read time points, we showed that reading the Xpect test after 
45 min of incubation returned results that gave optimal performance and this has now been 
adopted in the manufacturer’s instructions. After 60 min of incubation, two false positives were 
detected, reducing the specificity and positive predictive value of the test. Although sensitivity is 
highest (94%) after 30 min of incubation, Binax recommends that the NOW test be read at 15 
min of incubation. When comparing the two tests and using them according to the manufactur-
ers’ instructions, the relative sensitivity of the Xpect test was 89% (48/54; 95% CI, 77 to 95%) 
and that of the Binax NOW test was 85% (74/86; 95% CI, 77 to 93%).
In conclusion, the Oxoid Xpect test has performance comparable to that of the Binax NOW 
test and could be a good alternative for the detection of L. pneumophila antigen in urine from 
patients suspected of having LD.
This work was supported by Thermo Fisher Scientific and The Regional Laboratory of Public 
Health, Haarlem, The Netherlands. 
References
1. Berdal, B. P., C. E. Farshy, and J. C. Feely. 1979. Detection of Legionella pneumophila antigen in urine by 
enzyme-linked immunospecific assay. J. Clin. Microbiol. 9:575–578.
2. Diederen, B. M. 2008. Legionella spp. and Legionnaires’ disease. J. Infect.56:1–12.
3. Diederen, B. M., and M. F. Peeters. 2006. Evaluation of two new immunochromatographic assays 
(Rapid U Legionella antigen test and SD Bioline Legionella antigen test) for detection of Legionella 
pneumophila serogroup 1 antigen in urine. J. Clin. Microbiol. 44:2991–2993.
4. Fields, B. S., R. F. Benson, and R. E. Besser. 2002. Legionella and Legionnaires’ disease: 25 years of 
investigation. Clin. Microbiol. Rev. 15:506–526.
5. Helbig, J. H., S. A. Uldum, S. Bernander, P. C. Lu¨ck, G. Wewalka, B. Abraham V. Gaia, and T. G. 
Harrison. 2003. Clinical utility of urinary antigen detection for diagnosis of community-acquired, 
travel-associated, and nosocomial Legionnaires’ disease. J. Clin. Microbiol. 41:838–840.
6. Van der Eerden, M. M., F. Vlaspolder, C. S. de Graaff, T. Groot, W. Bronsveld, H. M. Jansen, and W. G. 
Boersma. 2005. Value of intensive microbiological investigation in how- and high-risk patients with 
community acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 24:241–249.
92
Chapter 6
Chapter 7
Evaluation of Legionella V-Test for detection of Legionella pneumophila 
antigen in urine samples
Bruin J.P.
Peeters M.F.
IJzerman E.P.F.
Diederen B.M.W.
Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):899-900
93
Part 2  Diagnostics
Abstract
We evaluated a new immunochromatographic assay (Legionella V-TesT, Coris BioConcept, 
Gembloux, Belgium) for its ability to detect Legionella pneumophila serogroup 1 antigen in 
urine. Test devices were read at various time points to determine the optimum incubation time 
 regarding performance. The results were compared with those obtained with the BinaxNOW 
urinary antigen test. The sensitivity and specificity were 82.2% and 98.6% respectively, for the 
Legionella V-TesT and 83.9% and 100%, respectively, for the BinaxNOW urinary antigen test 
after 15 minutes of incubation. When tests were examined after 60 min, the sensitivity for both 
tests increased to 91.5%.
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Legionnaires’ disease (LD) is an acute pneumonia caused by Legionella spp., a rod-shaped ubiq-
uitous Gram-negative bacillus which can be found in (man-made) aquatic reservoirs. Legionella 
spp. are responsible for 1-5% of cases of community-acquired pneumonia (CAP) requiring hos-
pitalisation [1]. Clinically and radiographically, LD cannot be distinguished from pneumonia 
caused by other microbial pathogens [2]. Early diagnosis of LD enables adequate antimicrobial 
treatment and is potentially life-saving [3].
Antigen detection in urine is widely used for the diagnosis of LD and has proved to be a sen-
sitive, specific and rapid method for detecting L. pneumophila serogroup 1 [4-6]. The aim of this 
study was to evaluate a new immunochromatographic assay (Legionella V-TesT, Coris BioCon-
cept, Gembloux, Belgium) for its ability to detect L. pneumophila serogroup 1 antigen in urine. 
The Legionella V-TesT was evaluated using non-concentrated frozen urine samples. Urine 
samples were collected by the laboratory for Medical Microbiology and Immunology, St. Elis-
abeth Hospital, Tilburg and the Regional Laboratory of Public Health, Haarlem, The Netherlands 
between 1999 and 2007 and stored at -70°C until processing was performed. The urine samples 
originated from the same collection as described earlier [7,8]. We investigated 118 urine sam-
ples obtained from 118 patients with LD (cases) and 71 urine samples from 71 patients with 
respiratory tract infections caused by pathogens other than legionellae (non-cases). A case of 
confirmed Legionella pneumonia was defined according to the European Working Group on 
Legionella Infections (EWGLI) criteria (http://www.ewgli.org). An LD-positive patient was de-
fined as a patient with laboratory evidence for LD and included at least one of the following 
criteria: (i) Isolation of Legionella spp. from a respiratory sample and/or (ii) the presence of  
L. pneumophila antigens in urine specimens and/or (iii) seroconversion to positivity for specific 
immunoglobulin M (IgM) and/or IgG antibodies with the SERION ELISA classic L. pneumophila 
1-7 IgM and IgG kit (Virion Serion).
Urine samples from 71 patients with respiratory tract infections caused by other pathogens 
than legionellae were tested in a similar manner to assess the specificity of the assays. The  laboratory 
results for these patients were diagnosed with infections caused by:  Streptococcus  pneumoniae 
(n=41), Haemophilus influenzae (n=8), Mycoplasma pneumoniae (n=4),  Chlamydophila psittaci 
(n=3), Mycobacterium tuberculosis (n=2), Moraxella catharrhalis (n=2),  Streptococcus  pyogenes 
(n=2), Staphylococcus aureus (n=2), Escherichia coli (n=1), Acinetobacter baumanii (n=1), Klebsiel-
la pneumoniae (n=1), adenovirus (n=1), influenza A virus A (n=1), parainfluenza virus (n=1), 
and Pneumocystis jiroveci (n=1). The results were compared with those obtained by the Binax-
NOW urinary antigen test. Test devices were read at various time points to determine the opti-
mum incubation time regarding performance. All Legionella positive and negative urine samples 
were read at 15, 30, 45 and 60 minutes after incubation. Confidence intervals (CIs) were deter-
mined by using the adjusted Wald method.
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Table 1: Results of the BinaxNow test and Legionella V-TesT after 15, 30, 45 and 60 min 
of incubation
Test and incubation time (min) % sensitivity % specificity
Legionella V-TesT
 15 82.2 (97/118) 98.6 (1/71)
 30 88.1 (104/118) 98.6 (1/71)
 45 89.0 (105/118) 98.6 (1/71)
 60 91.5 (108/118) 98.6 (1/71)
BinaxNOW
 15 83.9 (99/118) 100 (0/71)
 30 89.0 (105/118) 100 (0/71)
 45 91.5 (108/118) 100 (0/71)
 60 91.5 (108/118) 98.6 (1/71) 
A total of 193 samples were tested. A test is considered invalid if no control line  develops. 
Four samples yielded invalid results in the Legionella V-Test and these were not included in the 
 calculations. This resulted in a total of 189 samples used for the analysis. Sensitivity and  specificity 
were estimated as, respectively, 82.2% (97/118; 95% CI, 74 to 88%) and 98.6% (1/71; 95% CI, 
91 to 100%) for the Legionella V-TesT test and 83.9% (99/118; 95% CI, 76 to 90%) and 100% 
(0/71; 95% CI, 94 to 100%) for the BinaxNOW urinary antigen test  after 15 min of incubation 
(Table 1). The sensitivities of the Legionella V-TesT and BinaxNOW tests increased to 91.5% 
(108/118; 95% CI, 85 to 95%) and 91.5% (108/118; 95% CI, 85 to 95%),  respectively, when 
the tests were examined after 60 min of incubation. The differences in  sensitivities  between 15 
and 60 min of incubation were not statistically significant (p= 0.053, Fisher’s exact test).
The first urinary antigen test for the detection of L. pneumophila infection was introduced 
during the late 1970s and numerous studies have followed [9,10]. The captured antibody used 
in the majority of these assays is considered to be specific for L. pneumophila serogroup 1. All of 
these qualitative assays have the disadvantage not to being able to detect legionellae other than 
L. pneumophila serogroup 1. In the current evaluation, all LD-positive patients were infected 
with L. pneumophila serogroup 1, making it impossible to draw any conclusions about the assay’s 
ability to detect L. pneumophila infections caused by other serogroups or Legionella species.
The specificity of the assays used in this evaluation was determined using single urine speci-
mens from 71 patients with respiratory tract infections of known aetiology. One none-case pa-
tient tested positive by the Legionella V-TesT; this patient had proven pneumococcal pneumonia 
(blood culture positive).
The performance of the Legionella V-TesT is comparable to that of the BinaxNOW test. 
Furthermore, a prolonged incubation time for both the Legionella V-TesT and the BinaxNow 
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increased test performance. These findings are in line with previous studies [2,7,8] that also 
demonstrated an increased sensitivity after prolonged incubation. Therefore, we suggest to 
 routinely incubate these tests longer (i.e. 60 min) than recommended by the manufacturer.
In conclusion, the findings of this study indicate that the Legionella V-TesT is both sensitive and 
specific and could be a good alternative for the detection of L. pneumophila serogroup 1 antigen 
in urine from patients suspected of having LD. Further research is needed to develop qualitative 
assays that detect Legionella other than L. pneumophila serogroup 1.
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Letter to the editor
Laboratory diagnosis of Legionella pneumophila infections in patients with pneumonia is based 
on culture, serological testing, molecular testing and detection of soluble Legionella pneumo-
phila antigen in urine [1]. Since we published our review of diagnostic approaches to Legion-
naires’ disease (LD) [1] a number of new urinary antigen assays have become available. LD is an 
acute pneumonia caused by Legionella spp., which are non-spore-forming Gram-negative rods. 
L. pneumophila serogroup 1 accounts for more than 90% of human infections and is the most 
important etiological agent of LD [1,2]. Other species are rarely found as the causative agent of 
LD with an exception for Legionella longbeachae. In Australia and New Zealand L. longbeachae is 
responsible for approximately 30% of the cases of LD [3].
 We evaluated the ability of a new antigen test (SD Bioline Legionella Urinary Antigen test; 
Kyonggi-do; Korea) to diagnose LD using frozen urine samples from a well-described sample of 
patients with and without LD. Urine samples were collected between 1997 and 2010 and were 
stored at –70°C until processing was performed. We included 58 urine samples from 58 patients 
with LD (cases). A case of confirmed Legionella pneumonia was defined according to the Euro-
pean Working Group on Legionella Infections (EWGLI) criteria (www.ewgli.org). The specificity 
of the test was determined by using urine samples collected from 38 patients with respiratory 
tract infections other than Legionella infections (Streptococcus pneumoniae (n=19), Haemophilus 
influenzae (n=4), Mycoplasma pneumoniae (n=3), Chlamydophila psittaci (n=2), Mycobacterium 
 tuberculosis (n=2), Moraxella catharrhalis (n=1), Staphylococcus aureus (n=3),  Escherichia coli 
(n=2), Acinetobacter baumanii (n=1) and Klebsiella pneumoniae (n=1). The results were com-
pared with those obtained by the BinaxNOW urinary antigen test. The urinary antigen tests 
were performed simultaneously and the results were interpreted according the manufacturers’ 
instructions. A total of 96 samples were tested with the SD Bioline and BinaxNOW test. A test 
is considered invalid if no control line develops. None of the samples tested yielded non-valid 
results. None of the samples tested yielded a non-valid results. The sensitivity and specificity 
were estimated as respectively 79% (46/58) and 100% (0/38) for the SD Bioline test and 81% 
(47/58) and 100% (0/38) for the BinaxNOW urinary antigen test after 15 min of incubation. 
The difference in sensitivity between SD Bioline test and BinaxNOW is comparable (mcNemar 
test p =1.00).
 Urine antigen tests detecting L. pneumophila combines a reasonable sensitivity and high 
specificity with rapid results and these tests have become the most-used tools for the diagnosis of 
LD [1,4]. Urine antigen tests permit a rapid diagnosis and initiating of appropriate antimicrobial 
treatment. The antibody capture technique used in the majority of these immunochromato-
graphic assays (ICT) is considered specific for L. pneumophila serogroup 1. A disadvantage with 
these tests is their inability to detect other serogroups and Legionella species than L. pneumophila 
serogroup 1. In a previous evaluation [5] of an earlier version of SD Bioline test sensitivity was 
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not high enough for detecting LD. The findings of the current evaluation indicate that the SD 
Bioline test is both sensitive and specific and could be a good alternative for the detection of  
L. pneumophila serogroup 1 antigen in urine from patients suspected of having LD.
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Abstract
We evaluated the ability of a new antigen test (TRU Legionella assay, Meridian Bioscience, 
Cincinnatti, USA) to detect Legionella pneumophila serogroup 1 antigen in urine. The results 
were compared with those obtained with the Binax NOW® urinary antigen test (Binax, Port-
land, ME, USA). The sensitivities and specificities were 73% [95% confidence interval (CI), 65 
to 81%] and 100%, respectively, for the Meridian TRU Legionella test and 77% (95% CI, 68 to 
84%) and 100%, respectively, for the Binax NOW urinary antigen test. The sensitivity of the 
Meridian TRU Legionella test increased to 81% if tests were re-examined after 60 min of incuba-
tion. Prolonged incubation did not effect the specificity. We conclude that both assays evaluated 
have similar performance characteristics and are suitable for the rapid diagnosis of Legionnaires’ 
disease.
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Introduction
Since the historic outbreak of Legionnaires’ disease (LD) in Philadelphia in 1976 [1], Legionella 
pneumophila has been recognized worldwide as a pathogen causing community-acquired,  travel–
associated, and nosocomial pneumonia [2,3]. More than 90 % of the LD cases are caused by 
L. pneumophila, and 70-80 % more specifically by L. pneumophila serogroup 1 [2,3]. 
The aim of this study was to evaluate a newly developed commercially available immun-
ochromatographic urine antigen test (ICT), the TRU Legionella® assay, (Meridian Biociense, 
Cincinnatti, OH, USA), for the detection of Legionella pneumophila serogroup 1.
Material and methods
We evaluated 213 frozen unconcentrated urine samples from a well-described sample collection 
of patients with and without LD [4,5]. Urine samples were collected between 2000 and 2011 
and were stored at -70°C until processing was performed. We included 139 urine samples from 
139 patients with LD (cases). A case of confirmed Legionella pneumonia was defined according 
to the European Legionnaires’ Disease Surveillance Network (ELDSNet) criteria. 
 The specificities of the tests were determined by using single urine samples collected from 
73 patients with respiratory tract infections other than Legionella [4,5]. Patients were  diagnosed 
with infections caused by: Streptococcus pneumoniae (40 patients), Haemophilus  influenzae (9), 
Moraxella catarrhalis (2), Staphylococcus aureus (3), Escherichia coli (2),  Acinetobacter baumanii 
(1), Streptococcus pyogenes (2), Mycobacterium tuberculosis (2) and Pneumocystes jirovecii (1), 
 influenza A virus (2), adenovirus (1), Chlamydia psittaci (3), Mycoplasma pneumoniae (4), and 
parainfluenzae virus (1). 
The sensitivity and specificity of the Meridian TRU Legionella assay were compared with the 
test results obtained by the widely used ICT assay, the Binax NOW® urinary antigen test (Binax, 
Portland, ME, USA). Both tests were performed simultaneously and the results were interpreted 
according the manufacturers’ instructions. Samples were read at 15 min (Binax NOW) and 20 
min (Meridian TRU Legionella). Discrepant analysis was performed for samples positive in the 
Binax NOW test and negative in the Meridian TRU Legionella test using the Binax Legionella 
Urinary Antigen EIA test (Binax, Portland, ME, USA). To investigate if a prolonged incubation 
time would affect sensitivity, the samples were also read at 30, 45, and 60 min of incubation. 
Results
The results are shown in Table 1. A total of 213 unconcentrated urine samples were tested. The 
sensitivity was estimated as 73.3% [102/139; 95% confidence interval (CI), 65 to 81%] for the 
Meridian TRU Legionella test and 76.3% (107/139; 95% CI, 68 to 84%) for the Binax NOW 
urine antigen test. The specificity was 100% for both assays. Calculated agreement percentages 
for the Meridian TRU test and to the Binax NOW test after 15 to 60 min of incubation of 96 
and 99% were found respectively. 
105
Part 2  Diagnostics
Table 1: Results of Meridian TRU Legionella test and Binax Now Immunochromatographic 
urine antigen tests with a subset of Legionella positive urine samples at prolonged incuba-
tion time. Readings taken after 15, 20, 30, 45 and 60 min of incubation
% sensitivity % specificity
Meridian TRU Legionella test
 20 73.4 % 100 %
 30 77.0 % 100 %
 45 79.9 % 100 %
 60 80.6 % 100 %
Binax NOW
 15 77.0 % 100 %
 30 79.9 % 100 %
 45 80.6 % 100 %
 60 81.3 % 100 %
There were 5 samples positive in the Binax NOW and negative in the Meridian TRU Legionel-
la test, and those 5 samples were all in the Binax EIA test. After a prolonged incubation, the same 
5 samples were also positive in the Meridian TRU Legionella test.
 The sensitivity of the Meridian TRU Legionella test and the Binax NOW urine antigen test 
increased to, respectively 80.6% (112/139; 95% CI 74-87%) and 81.3% (113/139; 95% CI 75-
88%) when tests were re-examined after 60 min of incubation. Prolonged incubation time did 
not effect the specificity of either of the tests.
Discussion 
The detection of Legionella antigenuria was already described shortly after the outbreak in Phil-
adelphia in 1976 [6]. The rapid immunochromatographic membrane assays reduces the time to 
detect antigen and requires no specialized laboratory equipment, making it the most commonly 
used test for diagnosis of LD [3]. A major disadvantage of these rapid tests is their inability to 
detect organisms other than L. pneumophila serogroup 1. However, L. pneumophila serogroup 
1 is the predominant cause of LD in the Netherlands and, therefore, urine antigen detection 
in urine is recommended for all patients with severe community-acquired pneumonia and in 
patients clinically or epidemiologically suspected having LD [7,8]. In case of a negative antigen 
test, other diagnostic tests should be used to rule out LD, and treatment must include antibiotic 
coverage against Legionella.
The study shows that the Meridian TRU Legionella test has a high degree of sensitivity and 
specificity, with a sensitivity that increases with incubation time. The assays evaluated have 
 similar performance characteristics and are suitable for the detection of L. pneumophila antigen 
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in urine from patients suspected of having LD. Because the prolongation of incubation does not 
effect the specificity, it is recommended that an incubation time longer than that recommended 
by the manufacturer is used routinely.
Conflict of interest: The authors declare that they have no conflict of interest.
References
1. Fraser DW, Tsai TR, Orenstein W, et al. 1977 Legionnaires’ disease: description of an epidemic of 
pneumonia. N Engl J Med Dec 1;297(22):1189-97.
2. Diederen BM. 2008 Legionella spp. and Legionnaires’ disease. J Infect Jan;56(1):1-12.
3. Fields BS, Benson RF, Besser RE. 2002 Legionella and Legionnaires’ disease: 25 years of investigation. 
Clin Microbiol Rev Jul;15(3):506-26.
4. Diederen BM, Peeters MF 2006. Evaluation of two new immunochromotgraphic assays (Rapid U 
Legionella antigen test and SD Bioline Legionella antgen test) for detection of Legionella pneumophila 
serogroup 1 antgen in urine, J. Clin Microbiol 44:2991-2993.
5. Diederen BM, Bruin JP, Scopes E, Peeters MF, IJzerman EP. 2009 Evaluation of the Oxoid Xpect 
Legionella test kit for detectin of Legionella pneumophila serogroup 1 antigen in urine. J. Clin Microbiol 
47:2272-2274.
6. Berdal BP, Farcy CE anfd Feely JC. 1979 Detection of Legionella pneumophila antigen in urine by enzyme-
linked immunospecific assay. J. Clin. Microbiol.9:575-578.
7. Yzerman EP, DEN Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M. 2002 Sensitivity of three 
urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires’ disease in The 
Netherlands. J Clin Microbiol Sep;40(9):3232-6.
8. Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, Schouten JA, Degener 
JE, Janknegt R, Verheij TJ, Sachs AP, Prins JM; Dutch Working Party on Antibiotic Policy; Dutch 
Association of Chest Physicans 2012. SWAB/NVALT guidelines on the management of community-
acquired pneumonia in adults. Neth J Med 70:90-101.
107
Part 2  Diagnostics

Chapter 10
Molecular diagnostics and the public health management of Legionellosis
Tom A. Yates
Jacob P. Bruin
Timothy G. Harrison
Trish Mannes
BMJ Case reports BMJ 2013 Apr 19
109
Part 2  Diagnostics
Abstract
In 2009-10, we investigated four Legionella cases notified over an eight-month period in two 
adjacent villages in South East England. 
Molecular techniques enabled us to conclude that three of the cases had distinct infections. 
The absence of an adequate respiratory sample in one case necessitated epidemiological investi-
gations to exclude a potential common environmental source of further infections. 
One of the cases had spent part of their incubation period in a country in South East Asia. 
DNA-sequence based typing of their isolate showed it to be L. pneumophila serogroup 1 (LP1) 
sequence type (ST) 481. Intriguingly, the only other two ST 481 isolates in the European Work-
ing Group for Legionella Infections (EWGLI) database were among Dutch travellers to the same 
country in 2003 and 2006. 
This case makes clear the value of molecular diagnostics and the importance of obtaining 
adequate clinical specimens. Potential future uses for typing data are discussed.
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Background
Legionella is a relatively common cause of community-acquired pneumonia [1,2]. Legionella is 
not spread from human to human. Rather spread is via aerosolised water from an environ-
mental reservoir [3], such as a water cooling tower, an air conditioning system, domestic water 
supplies or [4] windscreen washer fluid.
Given the severe course of some Legionella infections [3], prompt identification of any com-
mon environmental source of infection is critical. Molecular diagnostics methods for Legionella 
are not well understood by clinicians but are a critical tool in the public health management of 
cases of Legionellosis. This case demonstrates their value.
Case presentation
In an eight-month period in 2009-10, Thames Valley Health Protection Unit was notified of four 
cases of Legionnaire’s Disease, one fatal, among residents of two adjacent villages in South East 
England. Two lived on the same street.
Investigations
All cases were L. pneumophila urinary antigen test positive in the admitting hospital. Further 
testing, using a L. pneumophila serogroup 1 MAb2 specific urinary antigen assay [5] at the Na-
tional Legionella Reference Laboratory, enabled us to exclude a common source in one of the 
four cases. Typeable respiratory isolates [6] from two of the other three cases again suggested an 
independent source in each.
The absence of an adequate respiratory sample in one case necessitated detailed epidemio-
logical investigations to exclude a potential source of further infections in the Thames Valley. 
These included obtaining a detailed account of movements during patients’ incubation periods; 
colleagues from local environmental health departments visiting the street on which two of the 
patients lived, as well as a healthcare facility visited by one of the patients during their incuba-
tion period, to look for sources of aerosolised water; inspection of water testing records at that 
healthcare facility and local cooling towers; and, given one of our cases had spent part of their 
incubation period in a South East Asian country, a discussion with the European Centre for 
Disease Control to check there were no other reported cases among travellers to the same places.
DNA-sequence based typing (SBT) [6] of a respiratory isolate from this cluster showed it to 
be LP1 ST 481. This was the patient who had spent part of their incubation period in South East 
Asia. Intriguingly, the only other two ST 481 isolates in the EWGLI SBT typing database (com-
prising more than 6000 isolates from more than 50 countries) were among Dutch travellers 
to the same country in 2003 and 2006. Whether this is a chance finding or a reflection of the 
geographical distribution of this ST cannot be assessed from so few cases.
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Outcome and follow-up
Three of the four cases made a good recovery and there have been no further cases diagnosed in 
these villages.
Discussion
Legionella is a common cause of community acquired pneumonia, responsible for 3.7% of am-
bulatory and 3.8% of hospitalised cases in a recent German multi-centre study [1]. Ten percent 
of cases are caused by species not detectable using the urinary antigen test [1]. Recent events 
in Stoke-on-Trent [7] and Edinburgh [8] demonstrate the potential human cost of outbreaks 
of Legionellosis. The financial costs of the investigation and management of fourteen cases in 
London in 2005 was estimated to be £455,856, with 86% of costs being hospital treatment of 
disease [9].
There are many published reports describing the utility of typeable respiratory isolates in 
both determining and excluding common environmental sources of infection in apparently 
clustered cases of Legionellosis [e.g., 7,9-12].
To date only a few hundred clinical L. pneumophila isolates have undergone typing in the UK. 
As a small subset of environmental isolates are responsible for clinical disease [13,14], environ-
mental typing alone cannot describe the clinical epidemiology of Legionellosis. Respiratory spec-
imens not only have clinical and public health value but will, with time, allow the distribution 
of Sequence types responsible for human disease to be better mapped. In the future, such data 
may allow the search for environmental sources of infection to be better targeted.
Learning points/ take home messages
Legionella, including species not detected using the urinary antigen test, are a relatively common 
cause of both severe and mild community acquired pneumonia.
-  Respiratory isolates, ideally obtained early in the course of disease, allow diagnosis of  
 non LP-1 Legionellosis as well as sequenced-based typing, which can inform a public  
 health response.
-  Apparently clustered cases of Legionellosis may be ‘pseudo-outbreaks’ and   
 ascertaining this using sequence-based typing can avoid unwarranted investigations.
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Abstract
Objectives: 
The purpose of this study was to establish wild type (WT) distributions and determine epidemi-
ological cut off values (ECOFF) in clinical L. pneumophila serogroup 1 isolates for ten antimi-
crobials commonly used for the treatment of Legionella infections using a method feasible in a 
routine clinical laboratory.
Methods: 
MICs of 183 clinical L. pneumophila serogroup 1 isolates, collected as part of an outbreak 
 detection program, were tested using E-test methodology on buffered charcoal yeast extract agar 
supplemented with α-ketogluturate (BCYE-α). The MICs were read after two days of  incubation 
at 35ºC with increased humidity and without CO2. ECOFFs were determined according to 
 EUCAST methodology and expressed as WT ≤ X mg/L.
Results: 
All antimicrobials showed a WT distribution, although the width varied from 2 two fold dilu-
tions to 8 dilutions, depending on antibiotic class. The ECOFFs determined were 1.0 mg/L for 
ciprofloxacin, 0.50 mg/L for levofloxacin, 1.0 mg/L for moxifloxacin, 1.0 mg/L for erythromy-
cin, 1.0 mg/L for azithromycin, 0.50 mg/L for clarithromycin 1.0 mg/L for cefotaxim, 0.032 
mg/L for rifampicin, 16 mg/L for tigecycline, and 8 mg/L for doxycycline.
Conclusion: 
All isolates were inhibited by low concentrations of the fluoroquinolones and macrolides tested, 
with somewhat higher MICs for the fluoroquinolones. Rifampicin was found to be the most 
active against L. pneumophila isolates in vitro. These data can be used as a reference for the de-
tection of resistance in clinical L. pneumophila isolates and as setting of clinical breakpoints.
Keywords: L. pneumophila, epidemiological cut off values, macrolides, fluoro-quinolones, 
 susceptibility 
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1. Introduction
Legionella species are responsible for 1% to 5% of cases of community-acquired pneumonia 
(CAP) [1]. There are more than 50 Legionella spp. with over 70 serogroups [1, 2] only some 
of which are associated with human disease. L. pneumophila serogroup 1 accounts for more 
than 90% of human infections and is the most important etiological agent of Legionnaires’ 
Disease (LD) [3, 4]. The mortality rate among patients with LD caused by L. pneumophila var-
ies from 0% to 26 %, depending on the clinical setting, patient population and antimicrobial 
treatment [5, 6, 7]. Legionella spp. are facultative intracellular bacteria that can survive and 
multiply in human macrophages. The intracellular location of this pathogen is thought to be 
relevant for the efficacy of the antimicrobial agent in the treatment of the disease. Antimicrobi-
als that achieve intracellular concentrations higher than the minimal inhibitory concentration 
(MIC) are regarded as more effective than antibiotics with poor intracellular penetration [1]. 
The antimicrobial agents most commonly used for treatment are fluoroquinolones, macrolides 
and rifampicin [8, 9, 10]. However, the activity of these antibiotics against a large collection of 
strains has not been well described and MIC wild type (WT) distributions are unavailable. In 
addition, it is unknown whether emergence of resistance is a problem, because epidemiological 
cut off values (ECOFF) to detect resistance have not been described for L. pneumophila and in 
vitro tested activity of the antimicrobial agents is therefore difficult to interpret. Furthermore, 
even if MICs were determined, there is at present no clear correlation with clinical outcome. The 
major reason WT distributions are unavailable is the lack of a reproducible method that can be 
used in routine clinical laboratories. Legionella spp. are difficult to culture unless specific media 
are used. Buffered charcoal yeast extract medium supplemented with L-cysteine is the specific 
media for culturing of Legionella spp.. Legionella spp. have an absolute nutritional requirement 
for L-cysteine and the primary function of charcoal is to absorb inhibiters formed during growth 
of the organism. Thus, detection of resistance is hardly feasible at present and changes in sus-
ceptibility rates to detect resistance in clinical L. pneumophila isolates virtually impossible using 
MIC based methods.
The purpose of this study therefore was to determine MICs in clinical L. pneumophila isolates 
collected from patient materials to allow the description of WT distributions and to determine 
ECOFFs for ten antimicrobials using a method that is feasible in clinical microbiology labora-
tories.
2. Material and methods 
2.1 Bacterial strains
Legionella pneumophila strains were isolated from clinical specimens collected from August 2002 
to November 2008 in the Netherlands as part of a national outbreak detection program (NODP) 
[11, 12]. All strains were received from various microbiological laboratories in the Netherlands 
and stored at -70ºC at the Regional Laboratory of Public Health, Haarlem, The Netherlands. The 
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clinical isolates of L. pneumophila serogroup 1 (LP1) were categorized according to the available 
epidemiological information as either nosocomial, community-acquired or travel associated. 
These categories of Legionella infection have been previously defined by the European Working 
Group for Legionella infection (www.ewgli.org). The 183 strains tested are from unique patients 
and single, non outbreak related cases. Only nosocomial and community-acquired cases were 
included in the present study. The 183 strains were genotyped using Amplification Fragment 
Length Polymorphism (AFLP) and/ or Sequence Based Typing (SBT) according EWGLI guide-
lines [13, 14].
2.2 Antimicrobial agents
Susceptibility testing was performed for ten antimicrobials using E-tests with the lowest availa-
ble MIC range. The tested antimicrobials were ciprofloxacin, levofloxacin, moxifloxacin, erythro-
mycin, azithromycin, clarithromycin, cefotaxim, rifampicin, doxycycline and tigecycline.
2.3. Methodology
Buffered charcoal yeast extract agar supplemented with ∝-ketoglutarate (BCYE-α; Oxoid, Baing-
stoke, UK) was used for susceptibility testing. This base medium contains yeast extract which 
supply the nutrients necessary to support bacterial growth and is not supplemented with anti-
biotics. Legionellae specific nutritional requirements, L-cysteine HCl and ferric pyrophosphate, 
are also incorporated for supporting the growth [15]. Antimicrobial susceptibility testing (AST) 
is performed by E-test methodology, as this method provides a simple, readily available, and 
accurate method for routine AST. All strains were re-cultured for two to three days at 35ºC with 
increased humidity. For the in vitro testing of the antimicrobials, colonies were suspended in 
sterile tap water to a concentration of approximately 107 colony forming units (CFU) per mL, 
and adjusted to a density of McFarland 0,5. The swab was dipped into the suspension to inoc-
ulate the entire surface of the 90-mm plate. One E-test strip with antimicrobial gradient was 
applied to the swabbed surface and the plates were incubated at 35ºC with an increased humid-
ity. Using a stereomicroscope the MICs were read after 2 days of incubation from the scale on 
the strip at the point were the ellipse of growth inhibition intercepted the strip. Epidemiological 
cut off values (ECOFF) were determined according to EUCAST guidelines and expressed as WT 
≤ X mg/L [16].
2.4 Controls
The L. pneumophila strains ATCC 12821 and ATCC 33152 were used as reference strains. In order 
to determine the influence of charcoal on the activity of the antimicrobials, reference strains 
Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) were also selected for 
testing. The MICs were determined on Mueller Hinton agar and were read after 24 hours of 
incubation at 35ºC.
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Table 1: List of the L. pneumophila SG1 AFLP/ ST-types used in this study. 
AFLP-type (n) ST-type (n)
001 Lugano (5) 1 (5)
003 Glasgow (8) 9 (6); 37 (1); 485 (1)
004 Lyon (56) 45 (1); 46 (1); 47 (54)
006 Copenhagen (15) 45 (2); 46 (9); 47 (1); 82 (1); 109 (1); 117 (1)
008 Stockholm (2) 334 (2)
009 London (11) 42 (11)
010 London (24) 62 (24)
013 London/030 Stockholm (5) 37 (5)
015 Dresden (2) 345 (1); 509 (1)
017 Lugano (7) 23 (7)
028 Rome (4) 1 (2); 177 (2)
Not Yet Designated (44)1
1 corresponding ST-types: 1, 23, 36, 45, 46, 47, 59, 62, 75, 82, 84, 110, 115, 170, 188,  
      207, 256,296, 477, 479, 482, 484, 493, 494, 496, 498, 504, 524, 555.
3. Results
The L. pneumophila serogroups 1 strains used in the study belonged to 13 different  EWGLI-types 
(Table 1), including AFLP 004 Lyon (ST47), AFLP 010 London (ST62) and AFLP 006  Copenhagen 
(6 different ST-types). These are the most prominent clinical isolated EWGLI–AFLP-types 
found in the Netherlands [17]. The cumulative percentages of isolates inhibited by different 
 concentrations of the ten antimicrobials tested are shown in Table 2, while Table 3 shows 
the susceptibility range (mg/L), MIC50, MIC90 and ECOFF for the 183 clinical L. pneumophila 
 serogroup 1 isolates. 
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The MIC50, MIC90 and ECOFF determined for fluoroquinolones were 0.50, 0.50 (range 0.25-2) 
and 1.0 mg/L for ciprofloxacin, 0.25, 0.25 (range 0.064-1.0) and 0.50 mg/L for levofloxacin, 
0.50, 0.50 (range 0.25-1.0) and 1.0 mg/L for moxifloxacin, respectively. One isolate (#123) 
showed an MIC outside of the WT distribution (2 mg/L) for ciprofloxacin. 
The MIC50, MIC90 and the wild-type cut-off values for macrolides were 0.125, 0.25 (range 
0.032-2) and 1.0 mg/L for erythromycin, 0.125, 0.25 (range 0.032-8) and 1.0 mg/L for azith-
romycin, 0.125, 0.25 (range 0.064-1) and 0.50 mg/L for clarithromycin. One isolate (#123) 
showed an MIC outside of the WT distribution (8 mg/L) for azithromycin, and this was the 
same isolate that showed an increased MIC for ciprofloxacin. The MIC50, MIC90 and the wild-
type cut-off values were determined to be 0.016, 0.032 (range 0.004-0.032) and 0.032 mg/L for 
rifampicin, 0.064, 0.25 (range 0.008-0.50) and 0.25 mg/L for cefotaxim, 4, 8 (range 1-16) and 
16 mg/L for tigecycline, 4, 8 (range 1-8) and 8 mg/L for doxycycline.
Table 4: MICs of 2 reference strains on 2 different media showing the 
 influence of charcoal
E. coli (ATCC 25922) S. aureus (ATCC 25923)
Media MH BCYE-α MH BCYE-α
Antibiotics (mg/L) (mg/L) (mg/L) (mg/L)
cefotaxim 0.125 0.125 0.50 0.50
rifampicin 16 4 0.016 4
ciprofloxacin 0.008 0.125 0.25 4
levofloxacin 0.032 2 0.125 0.50
moxifloxacin 0.016 0.25 0.032 0.5
erythromycin 24 16 0.5 24
azithromycin 4 8 4 64
clarithromycin 32 12 0.25 8
tigecycline 0.25 1 2 2
doxycycline 4 8 0.5 8
MH= Mueller Hinton agar; BCYE-α = buffered charcoal yeast extract agar.
The MICs (Table 4) of the control strains Escherichia coli and Staphylococcus aureus on Mu-
eller-Hinton agar fell within the range of published values. On BCYE-α media for the control 
strain S. aureus eight of the ten antimicrobials showed an elevated MIC. Four of the ten antimi-
crobials showed an elevated MIC with the control strain E. coli tested on BCYE-α media. 
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The MIC determined for the tested ATCC strains 12821 and 33152 for the fluoroquinolones 
were 0.50, 0.50 mg/L for ciprofloxacin, 0.25, 0.25 mg/L for levofloxacin, 0.50, 0.50 mg/L for 
moxifloxacin, respectively. The determined MIC values for macrolides were 0.25, 0.50 mg/L for 
erythromycin, 0.125, 0.25 mg/L for azithromycin and 0.25, 0.25 mg/L for clarithromycin. The 
MIC determined were 0.16, 0.16 mg/L for rifampicin, 0.50, 0.50 mg/L for cefotaxim, 2, 2 mg/L 
for tigecycline and 2, 4 mg/L for doxycycline.
4. Discussion
All antimicrobials showed a WT distribution, although the width varied from 2 two fold dilu-
tions to 8 dilutions (Table 2), depending on antibiotic class. In this study rifampicin was found 
to be most active against Legionella pneumophila in vitro. All the isolates tested were inhibited 
by low concentrations of fluoroquinolones and macrolides, with somewhat higher MICs for the 
fluoroquinolones. For the fluoroquinolones levofloxacin was slightly more active than the two 
other tested fluoroquinolones. The difference for levofloxacin being one dilution step compared 
of levofloxacin to ciprofloxacin and moxifloxacin. Of the macrolides clarithromycin was the 
most active. On average the MICs for clarithromycin were one dilution step lower than for 
erythromycin and azithromycin. 
There was only one isolate (#123; L. pneumophila SG1; AFLP-type: Not Yet Designated; SBT-
type ST477) that showed a MIC outside the WT distribution for ciprofloxacin (MIC 2 mg/L) and 
also for azithromycin (MIC 6 mg/L). The findings of this strain outside the WT distribution has 
no influence to determine the ECOFF for ciprofloxacin and azithromycin.
To our knowledge, a clinical L. pneumophila strain both resistant to fluoroquinolones and 
macrolides, the most commonly used antimicrobials for treatment of LD, has never been de-
scribed. It is well known that pathogens can become resistant during the course of a patient’s 
therapy and induction of resistance upon exposure to antibiotics has been described [18, 6]. To 
determine whether increased resistance to macrolides, rifampicin or fluoroquinolones would ex-
plain the high mortality rate in LD, Onody et al. examined 98 clinical isolates for antimicrobial 
susceptibility [19]. The ninety-eight consecutive clinical isolates of L. pneumophila were tested 
by agar dilution on charcoal-free medium for erythromycin, rifampicin and ciprofloxacin. All 
isolates were inhibited by low concentrations of ciprofloxacin, rifampicin, and erythromycin 
and no resistance against the antibiotics tested was detected. These results indicate that ther-
apeutic failures were not related to reduced susceptibility to the commonly used antimicrobial 
agents. Nielsen at al reported point mutations in the rpoB gene for rifampicin [20] within the 
family  Legionellaceae as a possible resistance mechanism comparable to other bacterial species. 
Although development of resistance in vitro for rifampicin has been sporadicly reported [21], 
there are no reports of resistance to rifampicin in a clinical setting. 
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E-test on BCYE agar, agar dilution, broth dilution, in vivo animal studies and in vitro cell cul-
ture models have been used to determine the MICs of antimicrobials active against Legionella 
spp. [22-27]. None of these methods is considered a gold standard. We searched MEDLINE 
for published research between 1995 and 2010 on Legionella susceptibility testing. We only in-
cluded articles in which the following susceptibility testing methods were used: micro-dilution, 
agar-dilution, E-test and/or agar diffusion (Table 5). Published data show that by using different 
methodology there is some variability in the MIC50, MIC90 results and range (see Table 5).
Garcia et al. performed susceptibility testing of the antimicrobials ciprofloxacin, erythro-
mycin, rifampicin and doxycycline using the E-test method [23]. Our results using the same 
method for those antimicrobials are comparable with the results Garcia et al found.
Susceptibility testing for Legionella spp. is difficult because of the specific growth require-
ments of this organism. The primary function of charcoal is that of an absorbent of inhibitors 
that can be formed during autoclaving or during growth of the organism [28]. Hoffman et al 
demonstrate that activated charcoals prevent photochemical oxidation in complex media and 
decompose hydrogen peroxide and superoxide radicals [29]. Failure to remove such inhibitor 
substances has been recognized as a problem for culturing L. pneumophila. It is known that char-
coal in BCYE-α agar can inhibit various antibiotics including tetracyclines, fluoroquinolones 
and macrolides [25]. Garcia et al has studied the influence of decreasing the charcoal concentra-
tion in BCYE-α media [23]. The decreasing of charcoal concentration up to 75% had no effect 
on the MIC50s and MIC90s of the two macrolides (erythromycin, claritromycin) or levofloxacin. 
For ciprofloxacin an eightfold decrease in MIC was detected.
Although performing the E-test on BCYE-α agar may yield elevated MICs, the E-test on 
BCYE-α provides a simple, readily available, and accurate method for routine susceptibility test-
ing of Legionella spp.. The E-test has proven itself over de years, and importantly can be used in 
most labs, precluding the need to send the strains to reference labs for susceptibility testing. It 
should be realized however, that a correlation between MIC and clinical and microbiological ef-
ficacy should be established in future research. At present this has not been done, and therefore 
clinical breakpoints have not been proposed. The present study does show that using BCYE-α 
agar for susceptibility testing results in WT distributions that can be used to detect resistance. 
They can also be used in the process of setting clinical breakpoints if more efficacy data become 
available. The MIC value itself however should be interpreted with caution and not directly 
translated to serum concentrations of antibiotics.
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Abstract 
Objectives: 
Routine use of disk diffusion tests for detecting antibiotic resistance in Legionella pneumophila 
has not been described. The goal of this study was to determine the correlation of MIC values 
and inhibition zone diameter (MDcorr) in clinical L. pneumophila isolates.
Methods: 
Inhibition zone diameter of 183 L. pneumophila clinical isolates were determined for ten anti-
microbials. Disk diffusion results were correlated with MICs as determined earlier with E-tests.
Results: 
Overall the correlation of MIC values and inhibition zone diameters (MDcorr) of the tested 
antimicrobials is good and all antimicrobials showed a WT distribution. Of the tested fluoro-
quinolones levofloxacin showed the best MDcorr. All macrolides showed a wide MIC distribu-
tion and good MDcorr. The MDcorr for cefotaxim, doxycycline and tigecycline was good, while 
for rifampicin and moxifloxacin, they were not.
Conclusion: 
Overall good correlation between MIC value and disk inhibition zone were found for the fluoro-
quinolones, macrolides and cefotaxim. 
Keywords: Legionella pneumophila, MDcorr, quinolones, macrolides, disk diffusion
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Introduction
The most important etiological agent of Legionnaires’ disease (LD) [1, 2] is L. pneumophila 
 serogroup 1, accounting for more than 90% of human infections in North America and Europe. 
The mortality rate among patients with L. pneumophila infections continues be high up to 26% 
[3-5]. Therapeutic failure and unsuccessful treatment of L. pneumophila infection has also been 
documented, but delay in medical attention or untimely or inappropriate antimicrobial treat-
ment is probably the main cause [5, 6]. Legionella species are facultative intracellular bacteria 
that can survive and multiply in human macrophages and the intracellular location of this 
pathogen is thought to be relevant for the efficacy of the antimicrobial agent in the treatment of 
LD. Antimicrobial agents that achieve relatively high intracellular concentrations are regarded as 
more effective than antibiotics with poor intracellular penetration [7]. Thus, fluoroquinolones, 
macrolides and rifampicin are the antimicrobials most commonly used for treatment of LD [8-
10], although susceptibility to these agents is usually not known, nor tested. 
The major reasons routine susceptibility testing of L. pneumophila is usually not performed is 
the lack of an easy to perform test and widely accepted cut-off values. In an earlier study [11], 
we established wild-type (WT) distributions and determined the epidemiological cut-off values 
(ECOFF) in clinical L. pneumophila serogroup 1 isolates for 10 antimicrobials commonly used 
for the treatment of Legionella infections [12]. In this study, our purpose was to evaluate the 
correlation of MIC values and disk diffusion zone diameters in clinical Legionella pneumophila 
serogroup 1 isolates. 
Material and Methods 
Bacterial strains
Legionella pneumophila strains used were isolated from clinical specimens collected since August 
2002 to November 2008 in the Netherlands as part of a national outbreak detection program 
(NODP)[13]. All strains were received from various microbiological laboratory in the Nether-
lands and were from unique, single non outbreak related cases. The L. pneumophila serogroup 
1 strains used in the study belonged to 13 different EWGLI-types, including AFLP 004 Lyon 
(ST47), AFLP 010 London (ST62) and AFLP 006 Copenhagen (6 different ST-types), the most 
prominent clinical isolated EWGLI–AFLP-types in the Netherlands [14].
Antimicrobial agents
For the disk diffusion tests (antimicrobial susceptibility test discs Becton, Dickinson and Com-
pany, USA) the tested antimicrobials with the following potency were used: ciprofloxacin (5µg), 
levofloxacin (5µg), moxifloxacin (5µg), erythromycin (15µg), azithromycin (15µg), clarithro-
mycin (15µg), cefotaxim (30µg), rifampicin (5µg), doxycycline (30µg) and tigecycline (30µg). 
The inhibition zone diameters of those clinical Legionella pneumophila serogroup 1 strains were 
evaluated in relation with the earlier described MIC and ECOFF values [11].
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Table 1: Determined range mm and mm cut off values for clinical isolates of Legionella 
pneumophila serogroup 1 isolates
Drug MIC Range (mg/L)
(ECOFF) 
WT(mg/L)
Disk 
Range mm
MM cut 
off <=R
Spearman’s 
Correlation 
Coefficient (Rs)
P-value
ciprofloxacin 0.50-2 1.0 18-24 20 0.138 0.063
levofloxacin 0.064-1 0.50 24-36 24 0.157 0.033
moxifloxacin 0.25-1 1.0 20-24 20 0.056 0.451
erythromycin 0.032-8 1.0 22-54 36 0.499 <0.001
azithromycin 0.032-8 1.0 24-54 32 0.428 <0.001
clarithromycin 0.064-1 0.50 34-54 40 0.507 <0.001
rifampicin 0.016-0.032 0.032 22-28 22 0.007 0.927
cefotaxim 0.016-1.0 1.0 34-62 35 0.722 < 0.001
tigecycline 2-16 16 18-26 18 0.351 <0.001
doxycycline 1-8 16 20-36 20 0.218 0.003
P-value reflects significance of Spearman’s correlation coefficient (Rs)
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Methodology
Buffered charcoal yeast extract agar (BCYE-α; Oxoid, Basingstoke, UK) media supplemented 
with ∝-ketoglutarate was used for susceptibility testing.
All strains were re-cultured for two to three days on BCYE-∝ at 35ºC with increased humidi-
ty. For the in vitro testing of the antimicrobials, the colonies were suspended in sterile tap water 
to a concentration of approximately 107 colony forming units (CFU) per mL, and adjusted to 
a density of McFarland 0,5. The swab was dipped into the suspension to inoculate the entire 
surface of two 90-mm plates. The inhibition zone diameter were read by eye and were measured 
with a ruler and the result were interpreted as susceptible (S), intermediate (I) or resistance (R). 
Disk diffusion results were correlated with MICs as determined earlier with E-tests, correlation 
was tested by using Spearman correlation coefficient (PASW Statistics 18.0, SPSS inc., Chicago, 
Illinois). The results of the MICs determined by E-test and inhibition zone diameter were put in 
a scatter diagram for analyzing the two variables MIC and mm. If there were found categorical 
differences in outcome both the disk diffusion and E-test were retested.
Controls
The L. pneumophila strains ATCC 12821 and ATCC 33152 were used as reference strains.
Results
All tested antimicrobials showed a close to normal WT distribution, although the width varied 
depending on the antibiotic class. The distribution of the inhibition zone diameters of ten an-
timicrobials tested are shown in figure 1. Table 1 shows the susceptibility range (mg/L and mm 
cut off) for the 183 clinical Legionella pneumophila serogroup 1 isolates. The correlation of MIC 
values and inhibition zone diameters (MDcorr) is different for the tested antimicrobials. 
The MDcorr results of the tested fluoroquinolones is for ciprofloxacin (Rs 0.138; p-value 
0.063), for levofloxacin (Rs 0.157; p-value 0.033) and for moxifloxacin (Rs 0.056; p-value 
0.451). The disk inhibition zones of the macrolides were relatively wide, 22-54 mm for eryth-
romycin and 24-54 mm for azithromycin, and less for clarithromycin 34-54 mm. The Rs values 
for the three macrolides erythromycin, azithromycin and clarithromycin were 0.499, 0.428 and 
0.507 respectively (P< 0.001) for each indicating a good correlation. For rifampicin the inhibi-
tion zone diameters were relatively small 22- 28 mm and there was no correlation (Rs 0.007, 
p-value 0.927). For cefotaxim the distribution range of the zone diameters was wide 34-62 mm 
with a correlation coefficient 0.722 and a p-value <0.001. For tigecycline and doxycycline a 
strong positive correlation were found, p-value <0.001 and 0.002 with a correlation coefficient 
0.351 and 0.218 respectively. Using the ECOFF suggested in Table 1, we determined whether 
there would be any major (resistant strains misinterpreted as susceptible) or minor (susceptible 
or resistant strains misinterpreted as intermediately susceptible) errors in testing the strains. Six 
strains showed a inhibition zone diameter outside the WT distribution range and were retested
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with disk diffusion test and with E-test. For each antimicrobial no error occurred after retesting 
(Table 2).
Table 2: Results of retested strains initial outside of the WT distribution range
Drug Strain# Initial zone diameter 
in mm
Result after retesting 
in mm (MIC)
cefotaxim 77 35 35 (0.38)
levofloxacin 102 24 30 (0.19)
levofloxacin 84 25 29 (0.19)
erythromycin 84 26 42 (0.125)
erythromycin 28 32 38 (0.25)
clarithromycin 73 36 52 (0.064)
doxycycline 156 36 30 (4)
Discussion
In this paper we describe, for the first time the correlation of MIC values and inhibition zone 
diameter (MDcorr) in clinical L. pneumophila isolates. The ten used antibiotics tested showed 
a disk inhibition zone diameter distribution that was close to normality with the exception of 
azithromycin. Of the tested fluoroquinolones levofloxacin showed the best MDcorr (Rs 0.195; 
p-value 0.008) and no major or minor errors were observed. The distribution of inhibition zone 
diameter were comparable for ciprofloxacin and moxifloxacin. For all the fluoroquinolones the 
MIC values were evenly distributed over the inhibition zone sizes within the susceptible popula-
tion, indicating random errors. Ciprofloxacin can be tested as a class representative of the fluo-
roquinolones. The three macrolides, erythromycin, azithromycin and clarithromycin showed a 
much wider inhibition zone diameter distribution and there is also a much clearer correlation 
between inhibition zone size and MIC value, indicating a much more varied susceptible popu-
lation, in particular for clarithromycin. Resistance could be differentiated from susceptible for 
azithromycin and erythromycin, but not for clarithromycin. Azithromycin or erythromycin can 
be used in susceptibility testing as a class representative for the other macrolides. For cefotaxim 
the MDcorr was good (Rs 0.722; p-value < 0.001). Rifampicin was found to be most active 
against L. pneumophila, although the MDcorr was not good (Rs 0.007; p-value 0.927). 
For ciprofloxacin there was only one isolate (#123; L. pneumophila; AFLP-type: Not Yet Des-
ignated; SBT-type ST477) that showed a MIC value outside the WT distribution (MIC 2mg/L) 
and also for the inhibition zone diameter (18 mm) outside the range. The same strain is found 
for azithromycin with a MIC value outside the WT distribution (MIC 6 mg/L) and with a diam-
eter inhibition zone (24 mm) outside the range (32-54 mm) [11]. It is known that, in general, 
pathogens can become resistant during the course of a patient’s therapy and also induction of 
FI
G
. 1
: S
ca
tt
er
 d
ia
gr
am
 o
f 
M
IC
s 
an
d 
th
e 
si
ze
s 
of
 t
h
e 
in
h
ib
it
io
n
 z
on
e 
di
am
et
er
. M
IC
s 
de
te
rm
in
at
ed
 b
y 
th
e 
E-
te
st
 m
et
h
od
 a
n
d 
 in
h
ib
it
io
n
 z
on
e 
di
am
et
er
 b
y 
di
sk
 d
if
fu
si
on
 m
et
h
od
. T
h
e 
n
um
be
rs
 in
 t
h
e 
sc
at
te
r 
di
ag
ra
m
 in
di
ca
te
 t
h
e 
n
um
be
r 
of
 c
lin
ic
al
 L
P1
 
 is
ol
at
es
 in
 e
ac
h
 in
te
rs
ec
ti
on
. 
139
Part 3  Antimicrobial Susceptibility
resistance upon exposure to antibiotics has been described. Disk diffusion tests for ciprofloxacin 
(class of fluoroquinolones) and either azithromycin or erythromycin (class of macrolides) can 
be used as an indicator for class resistance. Although resistance as such has not been described 
for Legionella, this disk diffusion test may help in distinguishing WT from non WT and thereby 
recognizing potential resistance in clinical practice.
Conclusion
In conclusion this is the first report of determined correlation between MIC values and disk 
inhibition zone diameters (MDcorr) in a large well described collection of clinical L. pneumo-
phila serogroup 1 isolates. Good MDcorr were found for the fluoroquinolones, macrolides and 
cefotaxim. For fluoroquinolones ciprofloxacin and for macrolides either azithromycin or eryth-
romycin could be used as an indicator for class resistance. Disk diffusion is an accurate method 
for susceptibility testing of Legionella species in routine practice. 
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Abstract
Legionella species are responsible for 1 to 5% of cases of community-acquired pneumonia. 
L. pneumophila serogroup 1 accounts for more than 90% of these and is the cause of  significant 
mortality. The antimicrobial agents most commonly used for treatment are  fluoroquinolones 
(e.g. ciprofloxacin or levofloxacin) and macrolides. In previous studies resistance against these 
drugs was never reported. Therefore, susceptibility testing is not common. In a study  looking at 
 susceptibility patterns of commonly used antibiotics for treatment, we detected one  isolate that 
showed a MIC value for ciprofloxacin (MIC 2mg/L) outside the WT distribution (ECOFF=1mg/L). 
A point mutation in the quinolone resistance-determining region (QRDR) of gyrA was detected. 
The strain was isolated from a patient with a severe double-sided  pneumonia. Clinicians should 
become aware of the emergence of quinolone resistance in Legionella  pneumophila.
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Introduction 
The most important etiological agent of Legionnaires’ disease (LD) is L. pneumophila serogroup 
1, accounting for more than 90% of human infections in North America and Europe [1,2]. The 
mortality rate among patients with L. pneumophila infections continues be high up to 26% [3,5].
Therapeutic failure and unsuccessful treatment of L. pneumophila infection has also been doc-
umented, but delay in medical attention or untimely or inappropriate antimicrobial treatment 
has usually been attributed as the main cause[5,6]. Legionella species are facultative intracellular 
bacteria that can survive and multiply in human macrophages and the intracellular location of 
this pathogen is thought to be relevant for the efficacy of the antimicrobial agent in the treat-
ment of LD. Antimicrobial agents that achieve relatively high intracellular concentrations than 
the minimal inhibitory concentration (MIC) are regarded as more effective than antibiotics 
with poor intracellular penetration[7]. Thus, fluoroquinolones, macrolides and rifampicin are 
the antimicrobials most commonly used for treatment of LD[8,10]. Routine susceptibility test-
ing of the antimicrobials active against L. pneumophila is usually not performed due to the lack 
of an easy to perform test and widely accepted cut-off values, and resistance in clinical strains 
has not been described. In recent studies, we established wild-type (WT) distributions and de-
termined the epidemiological cut-off values (ECOFF) in clinical L. pneumophila serogroup 1 iso-
lates for 10 antimicrobials commonly used for the treatment of Legionella infections.[12,13]. We 
detected one clinical isolate that showed a MIC value outside the WT distribution and also an 
inhibition zone diameter outside the WT range for ciprofloxacin and therefore was potentially 
resistant. We here present the clinical case, the results of susceptibility testing for ciprofloxacin, 
and the detection of a point mutation with gyrA gene that elucidate the genetic background for 
the elevated MIC.
Material and Methods
The L. pneumophila strain was isolated from a clinical specimen collected from a patient in 
the Netherlands and sent, as part of a national outbreak detection program (NODP), to the 
reference laboratory for Legionella in Haarlem the Netherlands [11]. This clinical isolate was 
stored at -70ºC in our laboratory. In 2011 and 2012 we tested the susceptibility of 183 clinical 
L.  pneumophila serogroup 1 strains to define the WT distribution. All strains were received from 
various microbiological laboratories in the Netherlands and, were from unique patients and 
single not outbreak related cases. More details are described elsewhere [12,13]. For ciprofloxa-
cin, we detected one isolate that showed a MIC value outside the WT distribution and also an 
inhibition zone diameter outside the range. This strain (#123) was typed as L. pneumophila SG1; 
SBT-type ST477; MAb-subtype Allentown/France; MAb 3/1 positive.
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Molecular investigations
Sequencing of gyrA, gyrB (DNA Gyrase) and parC, parE (Topoisomerase IV) genes
For the extraction of L. pneumophila DNA, bacteria were cultured at 37°C on buffered charcoal 
yeast extract α-ketoglutarate (BCYEα) agar (Oxoid, Wesel, Germany) in humidified air with 5% 
CO2 for 48h. The DNA extraction was performed by use of Qiagen’s BioRobot® EZ1 (Hilden, 
Germany), according to the manufacturer’s instructions. 
The sequencing reaction was performed twice by using primer systems previously described 
for the L. pneumophila SG1 strain Paris [14]. A comparative analysis of the obtained sequences 
was done using the already published L. pneumophila genomes and data from the literature 
describing mutations in the quinolone resistance-determining region (QRDR) of type II Topoi-
somerase of L. pneumophila by using the software DNA-Star (Wisconcin, USA) and the NCBI 
database [14,15].
Control strains
For control experiments the wild type strain MTZ OLDA and a spontaneous quinolone resistant 
mutant of this strain were used. MTZ OLDA is an environmental isolate (L. pneumophila, SG1, 
MAb subtype OLDA, ST1) isolated from the water supply of a large building [16]. The quinolone 
resistant mutant was selected by spreading of an inoculum of 100 µL McFarland standard 4 on 
ciprofloxacin (1,5 µg/mL) containing BCYEα agar under laboratory conditions in the reference 
laboratory for Legionella in Dresden (Germany). 
Case report
A 50-year-old male sought care at his general practitioner with a several day history of falling 
and body pains. His medical history included multiple myeloma, primary amyloidosis, allogenic 
bone marrow transplantation, steroid induced diabetes mellitus. At presentation the patient 
was on graft versus host therapy with steroids and anti CD 20 antibodies. On examination, 
the patient appeared ill and was sent to the emergency department of a nearby hospital in The 
Netherlands.
In the hospital, blood pressure and heart rate were 102/82 mm Hg and 99 beats per minute, 
respectively. His temperature was 37.1°C and respiratory rate was normal. However, at his left 
lower long field wheezes were present. Abdominal examination disclosed some tenderness; per-
istaltic sounds were normal.
Laboratory investigation showed a leukocyte count of 7.0 cells/L. Renal function was slightly 
impaired with a creatinine of 131 μmol/L. Liver enzyme levels were moderately elevated (alka-
line phosphatase 121 U/L, gamma-glutamyltransferase 729 U/L, aspartate aminotransferase 32 
U/L, alanine aminotransferase 87 U/L, lactate dehydrogenase 441 U/L). His blood glucosis was 
high: 33.7 mmol/L. Arterial blood gas analysis was, at this point, not disturbing with pH 7.34, 
pCO2 5.3 kPa, HCO3 21 mmol/L, base excess -4.3 mmol/L and pO2 34.0 kPa, O2 saturation 
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was 1.00. The initial chest radiograph demonstrated an infiltrate of the left lower long field. 
The patient was admitted to the ICU. Based on the recent allogenic transplantation, followed by 
pulmonary complaints, the graft versus host therapy was continued. Blood cultures were taken 
and antibiotic treatment was started with cefazolin and gentamicin. Urine was examined for the 
presence of Legionella antigens and when this test was reported positive, treatment was switched 
to ciprofloxacin 400 mg IV q12h. 
After initial improvement the clinical condition of the patient deteriorated, leading to intu-
bation and mechanical ventilation. A new chest radiograph revealed a diffuse interstitial pneu-
monia. Bronchoalveolar lavage (BAL) was performed 4 days after treatment with ciprofloxa-
cin was started. Blood cultures stayed negative; preliminary results of BAL examination were 
negative for CMV, PCP, HSV. Ciprofloxacin was continued and the patient slowly recovered. 
Eventually, culture of the BAL grew L. pneumophila SG1 after 4 days of ciprofloxacin treatment. 
After 10 days the patient could be transferred to the ward. Therapy was then switched to oral 
clarithromycin 500 mg bid. His further recovery was uncomplicated.
Results
Susceptibility testing
Susceptibility testing for ciprofloxacin, moxifloxacin and levofloxacin was performed with E-tests 
for strain #123 and as well as the MTZ OLDA wild type and mutant strains. The clinical isolate 
#123 showed the same MIC value for ciprofloxacin of 2 mg/L as the selected in vitro mutant of 
MTZ OLDA isolate. This value is outside the WT distribution range ECOFF= 1mg/L as previously 
described.12 The MIC of the parent isolate MTZ OLDA was within the WT distribution. MIC 
values of the in vitro mutant in comparison to the wild type MTZ OLDA were increased 5-fold 
for ciprofloxacin/levofloxacin and 4-fold for moxifloxacin, respectively (Table 1).
Molecular investigations
To determine whether the elevated MIC was due to a point mutation, sequencing of amino acid 
position 83 the quinolone resistance-determining region (QRDR) of the clinical isolate #123, 
environmental isolate MTZ OLDA and its selected mutant were amplified and sequenced in two 
separate tests A point mutation in the quinolone resistance-determining region (QRDR) of the 
gyrA gene was identified and this mutation led to an amino acid exchange at the position aa83 
(E. coli numbering system). Mutation at the same position aa83 were also reported for other 
spontaneous quinolone resistant mutants (Table 1). No mutations were detected in the QRDRs 
of the gyrB, parC and parE genes (data not shown). 
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Discussion 
We describe the first isolation of a ciprofloxacin resistant L. pneumophila SG1 clinical isolate, 
with a identified point mutation in the quinolone resistance-determining region (QRDR) of 
gyrA. The finding of this mutation in the gyrA topoisomerase gene led to an amino exchange 
and therefore a change in mechanisms of quinolone resistance and elevated MIC. The accumu-
lation of multiple mutations in the QRDRs confers significant resistance to the quinolones. The 
quinolones are antibacterial agents that have as target two essential enzymes, DNA Gyrase and 
DNA Topoisomerase IV. DNA gyrase is the bacterial enzyme that introduces negative supercoils 
into DNA. The protein binds as a tetramer to DNA in which two A and two B subunits wrap 
DNA into a positive supercoil [19]. The two subunits of gyrase are encoded by gyrA and gyrB. 
It is known that, in general, pathogens can become resistant during the course of a pa-
tient’s therapy and also induction of resistance upon exposure to antibiotics has been described.
[14,15,17,18] Jonas et al. studied in vitro the potential for selection in vitro of L. pneumophila 
mutants resistant to fluoroquinolones [15]. Six human isolates of L. pneumophila were sub cul-
tured in sub inhibitory concentrations of different fluoroquinolones until MICs increased at 
least eight-fold. The numbers of serial passages required in micro broth dilution series were de-
termined and the gyrA gene of the parental strains, and selected mutant strains, was sequenced. 
The average number of serial passages required was low in the cases of clinafloxacin (n = 10.6), 
ciprofloxacin and levofloxacin (both n = 13), but notably higher for trovafloxacin (n = 26.6) 
and moxifloxacin (n = 22.5). Five mutants exposed to ciprofloxacin and three treated with 
moxifloxacin showed similar mutation at aa Thr83, àLys or Thr83àIle amino acid changes in 
the gyrA gene. These authors conclude that different quinolones lose their antimicrobial effect 
after a varying number of passages and that gyrA in L. pneumophila is a potential target of fluo-
roquinolones. This concurs well with the finding s in this study. 
For isolate #123, a point mutation in the quinolone resistance-determining region (QRDR) 
of gyrA was identified and this mutation led also to an amino acid exchange at the position aa 
Thr83(E. coli numbering system). The result of the amino acid exchange is a change in of cipro-
floxacin susceptibility. That it was specifically this change that resulted in the MIC change was 
demonstrated by a similar change in MIC for the spontaneous in vitro mutant of MTZ OLDA 
isolate. MIC values of the in vitro mutant in comparison to the wild type MTZ OLDA were in-
creased 5-fold for ciprofloxacin/levofloxacin and 4-fold for moxifloxacin, respectively. 
The origin of resistance in strain #123 is as yet unclear. There are two possibilities, the first 
is that the patient contracted an L. pneumophila SG1 strain with this point mutation from the 
environment. Alternatively, the mutation occurred during the course of patients ciprofloxacin 
therapy. The start of antimicrobial therapy with ciprofloxacin was 4 days before collecting bron-
choalveolar lavage material for culturing on Legionella and it could well be that the mutation 
did occur during that period. However, the initial response of the patient to therapy was poor, 
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and it was only with sustaining therapy on the Intensive Care that recovery occurred. Although 
 Legionella infections often result in severe disease, the elevated MIC of ciprofloxacin in strain 
#123 may have contributed here. Of note, the correlation between in- vitro testing and in-vivo 
activity is not exactly known. There are case reports describing persistent culture positive L. 
pneumophila despite administration of treatment with appropriate antimicrobial agents, and 
the patients ultimately recovered completely [20-22].  Vice versa it might be that the individual 
concentration of the ciprofloxacin might be still partly effective. Our study emphasizes the need 
of culturing of clinical samples for Legionella and susceptibility testing of Legionella strains espe-
cially in case of delayed clinical response as reduced susceptibility might have been the cause of 
reduced response to therapy.
Conclusion
This is the first report of a ciprofloxacin-resistant L. pneumophila isolated from a clinical spec-
imen. Clinicians should become aware that a lack of clinical response during treatment with 
quinolones could be due to resistance. There is a clear need to perform susceptibility testing for 
clinical L. pneumophila isolates.
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General Discussion
When Legionnaires’ disease had been discovered, after the explosive outbreak in July and August 
1976, it was thought to be an atypical and easily recognizable form of pneumonia [1,2]. Since 
then, however, the clinical spectrum of Legionnaires’ disease has expanded, and numerous stud-
ies have found that Legionnaires’ disease cannot be distinguished from pneumonia caused by 
other pathogens on clinical grounds alone; special laboratory tests are necessary [3-8].
Legionella spp. are widespread in natural environments and survive extreme ranges of envi-
ronmental conditions [9,10]. A large number of free-living protozoa has been identified as hosts 
for L. pneumophila [11-15]. Various studies described the ability of Legionella spp. to survive 
and to multiply in species of amoeba, especially Acanthamoeba, Naegleria and Hartmanella. The 
different protozoa species protect Legionella from adverse conditions, and serve as a vehicle for 
the colonization of new habitats. The intracellular location of this pathogen is relevant for the 
efficacy of the antimicrobial therapy in the treatment of the disease. 
Diagnostic tests for Legionella should routinely be requested to identify the causative agent in 
community-acquired as well as nosocomial pneumonia. The most important method in clinical 
microbiology is culture. Using the culture, sources of infection can be identified [16,17].  Culture 
allows the comparison by typing methods of clinical and environmental Legionella strains and 
thereby confirming or excluding a potential environmental reservoir as the source of the infec-
tion [18]. Culturing Legionella spp. requires special media, adequate processing and technical 
experience. The standard medium for culture is buffered charcoal yeast extract (BCYE) agar, 
mostly supplemented with antibiotics and dyes to suppress other bacteria or to prevent over-
growth of contaminating flora. Overgrowth of contaminating flora can also be prevented by acid 
or heat treatment in combination with selective media. By using culture, all cultivable Legionella 
spp. can be detected, and it is still the “gold standard” to define a case (100% specificity) [16]. 
Culturing respiratory secretions has the advantage that it can detect more species and sero-
groups other than L. pneumophila serogroup 1 as compared to urinary antigen tests. A limitation 
of culture is the relative low sensitivity which varies from 6 to 65% [19-22]. As a diagnostic tool, 
culture has the disadvantage of delay, because a positive result is not available until after 3 or 
more days of incubation [23]. Moreover, epidemiological investigations are needed to recognize 
the sources of Legionnaires’ disease. For analyzing environmental samples, different laboratory 
methods for the recovery of Legionella spp. are available. In 1998, an international standard (ISO 
11731) was developed for efficient recovery and detection of Legionella spp. In the Netherlands, 
a different standard is in use for the detection of Legionella, NEN 6265, in drinking water. 
The usefulness of culturing is also influenced by local Legionella environmental distribution. L. 
pneumophila SG1 is the predominant cause of Legionellosis in many areas of the world, but in 
some regions, other species and serogroups are more important [19,24]. For example, Legionella 
longbeachae is a major cause of Legionellosis in Australia and New Zealand, where it is often 
associated with exposure to potting mix [25,26]. 
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Isolates of L. pneumophila can be serotyped using commercially available kits containing an-
tiserum against fourteen L. pneumophila serogroups and L. dumoffii, L. gormanii, L. micdadei, and 
L. bozemanii. For epidemiological investigations, L. pneumophila SG1 can be further sub-typed 
by means of monoclonal antibodies. [24,27-29]. This subtyping technique allows recognizing 
the virulence-associated epitope MAb 3/1. Almost all clinical isolates are MAb 3/1 positive 
(80-88%), and in contrast with the environmental L. pneumophila isolates, it accounts for a 
much smaller percentage (20-43%) [28,30]. So far, all community-acquired outbreaks have 
been caused by MAb 3/1 positive strains. 
In addition to these phenotypic typing methods, genotyping methods are in use. According 
to the European Working Group on Legionella infections (EWGLI now ESGLI) Legionella strains 
belonging to serogroup 1 can be genotyped by amplified fragment length polymorphism (AFLP) 
technique. If the environmental isolate and the patient isolate are indistinguishable by AFLP 
genotyping, the potential source is considered a true source [31,32]. Since 2005, sequence based 
typing (SBT), based on the sequencing of seven genes, is in use for the epidemiological typing of 
L. pneumophila [33,34]. DNA-sequence-based-typing (SBT) methods allow L. pneumophila to be 
distinguish into many sequence-types (STs). New data suggest that whole-genome sequencing 
(WGS) and targeting genetic markers associated with virulence could become valuable tools for 
laboratory investigation and can be used in outbreaks [35]. If no isolates are available, a direct 
SBT-based sub-typing technique can also be performed direct on clinical samples. This so called 
Nested-PCR Sequence-Based-typing method (NPSBT), can provide rapid and robust discrimina-
tory epidemiological data when no isolates are available [34].
Shortly after the historic outbreak of Legionnaires’ disease in Philadelphia in 1976, the detec-
tion of Legionella antigenuria was described [35]. The first urinary antigen tests, based on ELISA, 
were described in 1979 [37]. Since then, numerous commercially urinary antigen tests are avail-
able. Rapid immunochromatographic membrane assays reduce the time to detect antigen in the 
urine, and require no specialized laboratory equipment. These technical advantages make these 
tests the most commonly used tests for the diagnosis of Legionnaires’ disease. The urinary anti-
gen tests combine high specificity with rapid results. The major disadvantage of these rapid tests 
is their inability or low ability to detect Legionellaceae other then L. pneumophila SG1 [36-38]. 
There is an association between the severity of Legionnaires’ disease and the test sensitivity: 
the test sensitivity is higher in patients with severe pneumonia [46]. The sensitivity also depends 
on whether infections are caused by L. pneumophila SG1 strains that do or do not belong to the 
monoclonal subgroup MAb 3/1 [42]. In case of a negative antigen test, other tests such as mo-
lecular testing and attempts to culture Legionella spp. remain important to rule out Legionnaires’ 
disease. Hence, immunochromatographic assays should not be used as the sole method for the 
diagnosis of Legionnaires’ disease, since this may lead to under diagnosis of cases with Legionella 
non-pneumophila and non-serogroup 1.
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In many European countries Legionellosis is a notifiable disease. In the Netherlands this is 
the case since 1 July 1987. Most European countries participate in an international surveillance 
scheme. In 1986, the European Working Group for Legionella Infections (EWGLI) was formed. 
In 2010, the surveillance scheme EWGLINET has been renamed as the European Legionnaires’ 
Disease Surveillance Network (ELDSNet), which is coordinated and managed by the European 
Centre for Disease Prevention and Control (ECDC). Since 2012, the European Study Group for 
Legionella Infections (ESGLI) has been a member of the European Society of Clinical Microbi-
ology and Infectious Disease (ESCMID).
The surveillance by ELDSNET has led to improvement and higher detection rates of sources 
in many countries. Legionella spp. are found in natural aquatic environments, groundwater, 
lakes, ponds, rivers, streams and thermal pools, in moist soil and in mud. The organism can 
also be found in many different artificial aquatic environments, such as water systems in private 
homes, hotels, ships and factories, cooling towers, showers, fountains, misting devices and spa 
pools. Combined microbiological and epidemiological case definitions are used for surveillance 
of Legionnaires’ disease. Cases of Legionnaires’ disease are reported, and entered in a database, 
and a review of possible sources is started, eventually followed by environmental sampling. In 
the Netherlands a National Legionella Outbreak Detection Programme (NLODP) has been ac-
tive since 1 August 2002 [46]. This national detection programme is aimed at creating a short 
response time between the diagnosis of Legionnaires’ disease in patients and sampling of poten-
tial sources of infection. 
As part of this detection programme (NLODP), we describe in Chapter 2 that wellness 
centres are an important but overlooked source of Legionnaires’ disease. The proportion of po-
tential source investigations that were positive for Legionella spp. was highest (85%) for wellness 
centres. This rate is remarkably high compared to other types of potential sources such as cooling 
towers (55%), hospitals (50%), and private homes (20%). Fifteen wellness centres were identi-
fied as potential sources of infection for a total of 35 Legionnaires’ disease patients, 25 of whom 
were part of different clusters, all positive for Legionella. There was one wellness centre with 
seven clustered patients, two centres with four patients, two centres with three patients, and 
two centres with two patients. After source investigation and environmental sampling twelve 
of these centres were positive for Legionella spp. The L. pneumophila strains found in these sam-
ples were genotypically compared [33,34,46]. For two centres, the L. pneumophila strains in the 
collected samples had a genotype that was indistinguishable from the available patient isolates. 
It should be kept in mind that the investigated wellness centres were not a random selection of 
all available centres in the Netherlands. The circumstances in wellness centres can contribute 
to a Legionella-friendly environment. The abundant presence of showers, whirlpools, swimming 
pools and even air-perfused footbaths can clearly form a Legionella-friendly habitat. Additionally, 
the complexity of water piping systems can create a micro-environment for growth of Legionella. 
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Based on the results of our studies described in Chapter 3 and 4, we concluded that the 
genotype distribution in Legionella isolates from Legionnaires’ disease patients differs from the 
genotype distributions in Legionella isolates found in the environment. The same conclusion 
was reached by French and British researchers [41-43]. The AFLP-types found most frequently 
in cases in the Netherlands are 004 Lyon (ST47), 010 London (ST62) and 006 Copenhagen 
(ST23), accounting for 43% of all culture positive LD patients. However, these genotypes are 
rarely isolated from environmental sources. 
A possible explanation for these findings is that the source investigations may not identify 
the true sources of Legionnaires’ disease. It is possible that the most frequently found virulent 
strains should not be sought in the aquatic environment, but are spread by non-aquatic sourc-
es on days of increased humidity [44,45]. Another possible explanation is that the Legionella 
genotypes are present in the sampled sources but in undetectable concentrations. The recent 
availability of Whole Genome Sequencing (WGS) data offers the possibility of designing strain 
specific PCRs. This may help to find the environmental source of the three most commonly 
found STs (ST23, ST47 and ST62) in environmental sources. 
In 2009 the number of reported cases of Legionnaires’ disease dropped to the lowest level 
in the previous years of surveillance (Chapter 5). Our hypothesis was that this decrease in 
reported Legionella-pneumonia patients could be due to a decrease in patients for whom a di-
agnostic test was performed. Diagnostic tests for Legionella should be requested to identify this 
causative agent in community acquired as well as nosocomial pneumonia. If less diagnostic 
tests for  Legionella had been requested, this could have lead to under-diagnosis and subsequent 
underreporting of Legionnaires’ disease.
We analyzed the number of tests performed between 2007-2009 in three large microbiologi-
cal laboratories, in different geographical regions of the Netherlands. In these three laboratories 
with a great adherence, each laboratory performed different diagnostic tests on the available 
patient material. Several patients were diagnosed by more than one diagnostic method. Serology 
and urinary antigen tests were performed the most, followed by culture, with PCR as third. As 
a diagnostic tool for testing urine samples, all three laboratories used a commercial urinary 
antigen test (Binax NOW). We found an overall decrease in the proportion of patients with a 
positive diagnostic test for Legionella for these 3 laboratories, even though no decrease was found 
in the number of patients for whom a diagnostic test for Legionella was performed. Therefore we 
concluded that it is more likely that other factors, such as whether conditions, might explain 
the the drop in reported Legionella-pneumonia patients in 2009 compared to the previous years. 
 
There are several commercial available tests for detecting L. pneumophila antigen in urine. In 
our evaluations (Chapter 6-9) of different new immuno-chromatographic assays (ICTs), we 
also tested the influence of a prolonged incubation time of the sample on the sensitivity and 
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specificity. The advantages of urinary antigen detection are obvious: specimens are easy to obtain 
and can rapidly be investigated. Therefore the detection of L. pneumophila urinary antigen is a 
valuable tool in the majority of community-acquired cases if L. pneumophila SG1 is the causative 
agent. In our evaluations the results were compared with those obtained with the Binax NOW 
urinary antigen test, the worldwide most used ICT. All new ICTs we evaluated, (Xpect (Ox-
oid), V-test (Coris BioConcept), SD-Bioline (SD-Bioline), TRU-Legionella test (Meridian Bio-
science)), showed a high degree of sensitivity and specificity, comparable with the Binax NOW 
urinary antigen test. All the tested assays demonstrated an increased sensitivity after prolonged 
incubation. Prolonged incubation time, longer than it is recommended by the manufacturer, did 
not effect the specificity of the tests and is in line with earlier investigations [46,47]. Therefore 
we recommended that a longer incubation time than recommended by the manufacturer is used 
routinely. All the assays for the detection of L. pneumophila urinary antigens show sufficient 
recognition of the antigens to L. pneumophila SG1. The disadvantage all these assays is that they 
are not able to detect others than L. pneumophila SG1. In case of a negative antigen test, other 
diagnostic tests should therefore be used to rule out Legionnaires’ disease. 
In an eight-month period in 2009-2010 four cases of Legionnaires’ disease were notified in 
the United Kingdom by the Thames Valley Health Protection Unit (Chapter 10). All the cases 
from this cluster were L. pneumophila urinary antigen positive, and a source investigation was 
started. Further testing, using an L. pneumophila SG1 MAb2 specific urinary antigen assay [48], 
enabled us to exclude a common source in one of the four cases. The absence of an adequate 
respiratory sample in one case necessitated detailed epidemiological investigations to exclude a 
continuous source of this outbreak. One of the patients had spent part of his incubation time 
in South East Asia. DNA-sequence based typing (SBT) of a respiratory isolate was identified as L. 
pneumophila SG1 ST481. The EWGLI SBT typing database, comprising more than 6000 isolates 
from more than 50 countries, showed that there were only two other ST481 isolates. Those iso-
lates were from Dutch travellers, who had been in the same country in South East Asia in 2003 
and 2006. This case demonstrates that using sequence-based typing can prevent high financial 
costs of investigation and management and human costs in unwarranted investigations. Cultur-
ing of respiratory materials allows diagnosis of Legionnaires’ disease as well as sequence-based 
typing and thus probably valuable epidemiological information for public health workers. 
Since Legionella spp. are facultative intracellular bacteria that can survive and multiply in 
human macrophages, the intracellular location of this pathogen is relevant for the efficacy of 
any antimicrobial agent in the treatment of the disease. Antimicrobials that achieve intracellular 
concentrations higher than the minimal inhibitory concentration (MIC) are regarded as more 
effective than antibiotics with poor intracellular penetration [16]. The antimicrobial agents 
most commonly used for treatment are fluoroquinolones, macrolides and rifampicin [49-52]. 
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However, the activity of these antibiotics against a large collection of strains had not been well 
described, and MIC and wild type (WT) distributions were not available. In addition, it is un-
known whether emergence of resistance is a problem, because epidemiological cut- off values 
(ECOFF) to detect resistance have not been described for L. pneumophila. Therefore, in vitro 
tested activity of the antimicrobial agents is difficult to interpret. 
We determined the MIC50, MIC90, the wild-type distribution (WT) and the epidemiological 
cut-off (ECOFF) values for ten different antimicrobials in clinical L. pneumophila SG1 isolates 
(Chapter 11). All isolates were inhibited by low concentrations of the fluoroquinolones and 
macrolides tested, with somewhat higher MICs for the fluoroquinolones. Rifampicin was found 
to be the most active against L. pneumophila isolates in vitro. We found one isolate that showed 
a MIC outside the WT distribution for ciprofloxacin and also for azithromycin and therefore a 
possible resistant strain. This study showed that E-tests can be used on BCYE-α agar for suscep-
tibility testing and can be used to detect resistance. 
We evaluated and described the correlation of MIC value and disk inhibition zone diame-
ters in the 183 clinical L. pneumophila isolates used (Chapter 12). Susceptibility testing was 
performed for ten antimicrobials using disk diffusion tests (antimicrobial susceptibility test 
discs Becton, Dickinson and Company, USA). The inhibition zone diameters of those clinical L. 
pneumophila SG1 strains were evaluated in relation with the MIC and ECOFF values described 
before (Chapter 11). Overall, good correlations between MIC value and disk inhibition zone 
were found for the fluoroquinolones, macrolides and cefotaxim. The study results described 
in chapter 11 and 12 can be used as a reference for the detection of resistance in clinical L. 
pneumophila isolates and for setting of clinical breakpoints. In these studies, looking at suscep-
tibility patterns of commonly used antibiotics for treatment. We detected one possible resistant 
strain that showed a MIC value for ciprofloxacin (MIC 2mg/L) outside the WT distribution 
(ECOFF= 1mg/L). For this strain a point mutation in the quinolone resistance-determining 
region (QRDR) of gyrA was detected (Chapter 13). This mutation, an exchange in the amino 
acid, led to a change in ciprofloxacin susceptibility. The strain was isolated from a patient with 
a severe double-sided pneumonia treated with ciprofloxacin. This finding emphasizes the im-
portance of culturing of clinical samples for Legionella and of susceptibility testing of Legionella 
strains especially in case of delayed clinical response, since reduced susceptibility might have 
been the cause of reduced response to therapy.
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Summary, conclusions and recommendations
Legionella spp. are consistently recognized as an important cause of community- and hospi-
tal-acquired pneumonia and cannot be distinguished from pneumonia due to other pathogens 
on clinical grounds, therefore special laboratory tests are necessary. 
In chapter 1, we discussed the history, the taxonomy, the clinical manifestations, the labo-
ratory diagnosis and antimicrobial susceptibility in Legionella species. 
In part I, (Epidemiology) we described the results of investigations of potential sources of in-
fection with Legionnaires’ disease in the Netherlands. Some of the potential sources were more 
frequently associated with Legionella findings than others. We found (chapter 2) that the pro-
portion of potential source investigations for Legionella spp. was highest for wellness centres 
(85%). Fifteen wellness centres were identified as potential sources of infection for 35 Legion-
naires’ disease patients. Twelve of these centres were positive for Legionella spp. These results 
show that wellness centres are an important source of Legionnaires’ disease. In chapter 3 and 
4, we described the genotyping results of the patient- and environmental- related isolates, and 
concluded that the genotype distribution of the patient isolates differs from the genotype dis-
tribution of Legionella isolates in the environment. With the methods that are now in use, the 
most prevalent clinical STs (ST23, ST47 and ST62) are very rarely recovered from the investigated 
environmental sources. To find those most prevalent STs, there is a clear need to improve the na-
tional and international standards for sampling and detection of Legionella species. Studies using 
coculturing with amoeba should also be considered for investigation of environmental samples. 
Coculturing offers the opportunity to culture Legionella spp. from samples with an extremely 
high contamination level of interfering organisms. Detection Legionella spp. with coculturing 
may provide the opportunity to find the niches were the three most prevalent clinical strains in 
the environment are hiding. Typing methods for discriminating Legionella isolates are essential 
tools in infection prevention and control. Traditional typing methods based on phenotypes and 
genotypes have been used for many years. Sequence Based Typing (SBT) was developed to over-
come the poor reproducibility of molecular typing schemes between laboratories. The principle 
behind this typing method is to identify internal nucleotide sequences in multiple housekeep-
ing genes. This procedure is time consuming and therefore also costly. Using next generation 
sequencing (NGS) technology makes bacterial whole genome mapping (WGM) feasible for 
clinical laboratories. WGM is a well validated molecular technique that may have a high po-
tential for strain typing. WGM have the potential to be used in place of PCR-based sequencing 
or other molecular typing methods and provides a cost effective way to discover genome-wide 
variations. Re-analyzing with well documented genotypically Legionella matches with the WGM 
technique may confirm or reject previous assumption on the genotypical comparison. Also, the 
whole genome sequencings (WGS) technique can offer the opportunity to design strain specific 
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PCRs, which will help to the find environmental sources for the most prevalent clinical STs. It is 
recommended to develop those strain-specific PCRs. International collaboration would enhance 
to explore the environment to find the most prevalent clinical strains.
Part II (Diagnostics) chapter 5 described the investigation of a decrease in reported cases in 
2009. We investigated if this decrease could be explained by the number of performed  Legionella 
tests. We analyzed the number of diagnostic tests performed in three large microbiological 
laboratories in the Netherlands. We concluded that the decrease of the number of reported 
 Legionella-pneumonia patients was not due to a decrease of the performed diagnostic tests. In all 
three laboratories, a commercial urinary antigen test (Binax NOW) was used. There are several 
commercially available tests for detecting of L. pneumophila antigen in urine. The detection of 
L. pneumophila urinary antigen is a valuable tool in the majority of community-acquired cases 
if L. pneumophila SG1 is the causative agent. In our evaluations (Chapter 6-9) of newly avail-
able urinary antigen tests, the results were compared with those obtained with the Binax NOW 
urinary antigen test, the immuno-chromatografische test used the most worldwide. The major 
disadvantage of this test is their inability to detect Legionellaceae other then L. pneumophila SG1. 
In regions where other Legionella than L. pneumophila SG1 are the prominent pathogens, this 
test, if used as a sole diagnostic tool, can result in under-diagnosis of cases. The manufacturers, 
together with researchers in the Legionella-field, should put more effort to designing a urinary 
antigen test that covers more than just L. pneumophila SG1. 
It is recommended that an incubation time longer than recommended by the manufacturer 
is used routinely. Researchers have to keep in mind that a negative urinary antigen result does 
not exclude a Legionella infection. Therefore, it is recommended to also use other diagnostic tools 
as well, e.g. culture or molecular techniques. 
In chapter 10 we described the results of an investigation of four Legionella cases over an 
eight-month period. The use of a specific urinary antigen assay enabled us to exclude a common 
source in one of the four cases. Molecular techniques enabled us to conclude that three of the 
four cases had distinct infections. This case demonstrates the value of molecular diagnostics and 
therefore the importance of obtaining adequate clinical specimens. If no isolates are available, 
a direct SBT-based subtyping technique can also be performed directly on clinical samples. This, 
so-called Nested-PCR Sequence-Based typing method (NPSBT), provides rapid and robust dis-
criminatory epidemiological data. 
Part III (Antimicrobial susceptibility) describes the results of susceptibility testing of clinical 
L. pneumophila SG1 for ten antimicrobials. Our results of susceptibility testing (chapter 11 and 
12) can be used as a reference for the detection of resistance in clinical L. pneumophila isolates 
and as a setting of clinical breakpoints. We only tested one collection of L. pneumophila SG1, 
Summary, conclusions and recommendations
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therefore we recommend setting up a large European project to determine the MIC50, MIC90, 
the wild-type distribution (WT) and the epidemiological cut-off (ECOFF) values for different 
antimicrobials of all Legionella species. The results of this new study can be used as a setting of 
clinical breakpoints for Legionella for different antimicrobials. The finding of a L. pneumophila 
SG1 resistant to ciprofloxacin (chapter 13) highlights the importance for culture and suscep-
tibility testing. A point mutation was detected in the quinolone resistance-determining region 
(QRDR) of gyrA. This mutation, an exchange in the amino acid, led to a change in ciprofloxacin 
susceptibility. The strain was isolated from a patient with a severe double-sided pneumonia 
treated with ciprofloxacin.
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Nederlandse samenvatting, conclusies en aanbevelingen
Legionella species worden algemeen erkend als een belangrijke veroorzaker van een community- of 
hospital acquired pneumonie en kan op klinische gronden niet worden onderscheiden van een 
longontsteking veroorzaakt door andere pathogenen, hiervoor zijn speciale laboratorium testen 
nodig.
In hoofdstuk 1 is de geschiedenis, de taxonomie, de klinische verschijnselen, de laboratorium 
diagnostiek en de antimicrobiële gevoeligheid van Legionella species beschreven.
In deel I (Epidemiologie) beschrijven wij de onderzoeksresultaten van mogelijke bronnen als 
verwekker van Legionella pneumonie in Nederland. Sommige potentiële bronnen werden vaker in 
relatie gebracht met Legionella bevindingen dan andere. Wij hebben gevonden (hoofdstuk 2) dat 
het aandeel positieve Legionella bevindingen bij potentiële bron onderzoek voor Legionella species 
het hoogste was voor de wellness centra (85%). Vijftien wellness centra werden geïdentificeerd als 
potentiële bron voor 35 patiënten. Twaalf van deze centra zijn positief bevonden voor Legionella 
species. Deze bevindingen geven aan dat wellness centra belangrijke bronnen zijn voor het krijgen 
van een Legionella pneumonie. In hoofdstuk 3 en 4 wordt de genotypering beschreven van de 
patiënt- en omgeving gerelateerde Legionella isolaten. De bevinding is dat de verdeling van de 
genotypes van isolaten bij patiënten anders is dan bij de isolaten uit de omgeving. Met de thans 
in gebruik zijnde methodes worden de meest voorkomende klinische Sequence Types (STs), zijnde 
ST23, ST47 en ST62, zeer zelden in de onderzochte environmental bronnen gevonden. Om deze 
meest voorkomende klinische STs te vinden is er een duidelijke noodzaak om de nationale en 
internationale standaards voor bemonstering en detectie van Legionella species te verbeteren. Studies 
waarbij gebruik gemaakt wordt van co-culture techniek met amoeben moet voor de environmental 
monsters worden overwogen. De amoeben co-culture techniek geeft de mogelijkheid om Legionella 
species te kweken uit monsters met een extreem hoog niveau van storende micro-organismen. 
Het detecteren van Legionella species met amoeben co-culture techniek biedt de mogelijkheid om 
de niches te vinden waar de drie meest voorkomende klinische stammen zich in de omgeving 
bevinden. Voor het onderscheiden van Legionella isolaten bij infectiepreventie en bestrijding 
zijn typeringsmethoden essentiële instrumenten. Traditionele typeringsmethoden op basis van 
fenotypen en genotypen zijn al vele jaren in gebruik. Sequence Based Typing (SBT) is ontwikkeld 
om de slechte reproduceerbaarheid van moleculaire typerings schema’s tussen laboratoria te 
overwinnen. Het principe achter deze typeringsmethode is om interne nucleotide secquenties 
in verschillende “houskeeping genes” te identificeren. Deze procedure is tijdrovend en daarmee 
ook kostbaar. Met behulp van “next generation sequencing” (NGS) technologie is het in kaart 
brengen van het gehele bacteriële genoom in klinische laboratoria haalbaar. Whole Genoom 
Mapping (WGM) is een goed gevalideerde moleculaire techniek die voor stam typering van grote 
waarde kan zijn. WGM heeft de potentie om gebruikt te worden in plaats van PCR-gebaseerde 
sequentiebepaling of andere moleculaire typeringen en biedt een kosteneffectieve manier om 
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genoom brede variaties te ontdekken. Het opnieuw analyseren met goed gedocumenteerde 
genotypische Legionella matches met de WGM methode kan op basis van genotypische vergelijking 
een eerdere aanname bevestigen of afwijzen. Ook Whole Genome Sequencing (WGS) kan de 
mogelijkheid bieden om stam specifieke PCRs te ontwikkelen, waarmee het mogelijk kan zijn om 
de bronnen met de meest voorkomende klinische ST’s te vinden. Het is aan te bevelen om deze 
stam specifieke PCRs te ontwikkelen. Internationale samenwerking kan bijdragen om deze meest 
voorkomende klinische stammen in het milieu te vinden. 
Deel II (Diagnostiek) hoofdstuk 5 beschrijft het onderzoek naar de afname van de gemelde 
Legionella cases in 2009. Er is onderzocht of deze daling verklaart kon worden uit een lager aantal 
uitgevoerde testen. Wij hebben het aantal verrichtte diagnostische tests in drie grote microbiologische 
laboratoria in Nederland geanalyseerd. Wij zijn tot de conclusie gekomen dat het lagere aantal 
gemelde Legionella patiënten niet veroorzaakt is door een lager aantal uitgevoerde diagnostische 
bepalingen. In al de drie laboratoria werd een commerciële urine antigeen test (Binax NOW) 
gebruikt. Er zijn diverse commerciële tests verkrijgbaar voor het aantonen van L. pneumophila 
antigeen in urine. De aantonen van L. pneumophila urine antigeen is een waardevol hulpmiddel 
bij het vaststellen als L. pneumophila SG1 de verwekker is. In onze evaluaties (hoofdstuk 6-9) 
van nieuw beschikbare urine antigeen testen zijn de resultaten vergeleken met de resultaten 
verkregen met de Binax NOW urine antigeen test, de wereldwijd meest gebruikte Immuno-
Chromatografische-Test (ICT). Het belangrijkste nadeel van deze testen is het  onvermogen om 
andere Legionellaceae aan te tonen dan L. pneumophila SG1. In gebieden waar L. pneumophila SG1 
niet de meest voorkomende verwekker van LD is, kan de test, indien gebruikt als enige diagnostische 
test, resulteren in onder diagnose van het aantal Legionella pneumonie gevallen. De producenten, 
gezamenlijk met de Legionella onderzoekers, moeten meer energie steken in het vervaardigen van 
een urine antigeen test die niet alleen L. pneumophila SG1 kan aantonen. 
Het is aan te bevelen om, in de routine, een langere incubatie tijd te gebruiken dan  aanbevolen 
door de producent van de test. Onderzoekers moeten er bewust van zijn dat een negatieve 
urine antigeen test een Legionella infectie niet uitsluit. Daarom is het aan te bevelen ook andere 
diagnostische middelen zoals kweek en moleculaire technieken te gebruiken.
In hoofdstuk 10 beschrijven wij de resultaten van een onderzoek van vier Legionella besmettingen 
gedurende een periode van acht maanden. Het gebruik van een specifieke urine antigeen test 
stelde ons in staat om één van de vier gevallen uit te sluiten van een gemeenschappelijke bron. 
Moleculaire technieken maakten het mogelijk om te concluderen dat drie van de vier gevallen een 
afwijkende veroorzaker van de infectie hadden. Dit onderzoek toont de waarde van moleculaire 
diagnostiek en daarmee de belangrijkheid van het verkrijgen van geschikte klinische monsters. Als 
er geen isolaten beschikbaar zijn kan op een klinisch monster een directe SBT-based sub-typerings 
techniek uitgevoerd worden. Deze zo genoemde Nested-PCR Sequence Based typing methode 
(NPSBT), kan snel robuuste epidemiologische gegevens verstrekken.
Nederlandse samenvatting, conclusies en aanbevelingen
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Deel III (Antimicrobiële gevoeligheid) beschrijft de resultaten van gevoeligheidsbepaling van 
klinische L. pneumophila isolaten ten op zichtte van tien antimicrobiële middelen. Onze resultaten 
van de gevoeligheidsbepalingen (hoofdstuk 11 en 12) kunnen gebruikt worden als een referentie 
voor het bepalen van resistentie in klinische L. pneumophila isolaten en als vaststelling van 
klinische breekpunten. Wij hebben slechts één verzameling van L. pneumophila SG1 getest, het 
is aan te bevelen om een groter, Europees project, op te zetten om de MIC50, MIC90, de  wild-
type distributie (WT) en de epidemiologische breekpunten voor de verschillende  antimicrobiële 
middelen ten opzichte van alle Legionella species vast te stellen. Het vinden van een L. pneumophila 
SG1 isolaat resistent voor ciprofloxacin (hoofdstuk 13) onderschrijft het belang van kweek en 
het bepalen van de antimicrobiële gevoeligheid. De stam werd geïsoleerd uit een patiënt met een 
ernstige dubbelzijdige pneumonie en werd behandeld met ciprofloxacin. Een punt mutatie werd 
aangetoond in de quinolone resistentie bepalende regio (QRDR) van gyrA. Deze bevinding toont 
de noodzaak aan van het inzetten van een kweek op Legionella en het testen van de gevoeligheid 
van Legionella isolaten.
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Dit proefschrift is tot stand gekomen dankzij inspanningen van zeer velen. Zonder de stimulering 
en enthousiasme van allen met wie ik heb kunnen en mogen samenwerken was dit proefschrift 
niet tot stand gekomen. Ik voel mij bevoorrecht dat ik naast het vele praktische laboratoriumwerk 
mee heb mogen denken en werken aan de diverse studies en onderzoeksprojecten die ook voor 
anderen hebben geleid tot promotie. Het samenwerken met diverse onderzoeksgroepen en het 
publiceren van wetenschappelijke artikelen heeft mij inzicht gegeven en verder enthousiast 
gemaakt voor het wetenschappelijk onderzoek. Ik wil dan ook een ieder, die op enigerlei wijze 
heeft bijgedragen aan het feit dat dit proefschrift er nu ligt, bedanken.
Een aantal mensen wil ik, zonder anderen tekort willen doen, in het bijzonder bedanken.
Prof. dr. J.W. Mouton, promotor, beste Johan. Bedankt voor de gelegenheid die jij mij enige 
jaren geleden bood om onder jouw supervisie te kunnen promoveren. Het feit dat met al je 
deskundigheid mij hebt kunnen en willen begeleiden kwam voor mij als een geschenk. Dank 
voor de ruimte, de vrijheid en de mogelijkheden die je mij boodt om mijn eigen weg te volgen. Ik 
heb geleerd geduldig te zijn, de tijd gaat zo snel, en heb bewondering voor de wijze waarop je mij 
verder met enthousiasme en kennis begeleid heb tot waar ik nu sta. 
Dr. B.M.W. Diederen, co-promotor, beste Bram. Ik bewaar zeer goede herinneringen aan één 
van onze eerste ontmoetingen, het geven van een vijftal lessen Legionella in het land. Bij de 
voorbereiding van die lessen gaf je mij meteen alle ruimte en vertrouwen om op mijn eigen wijze 
de lessen in te delen. Na afloop was het steeds prettig om in de nazit nog even met elkaar, ook 
over het vak, van gedachten te wisselen. Dat je later tot de maatschap van het Streeklaboratorium 
bent toegetreden heeft onze samenwerking verder verdiept. Zonder jouw stimulering, je snelle en 
bruikbare correcties op de ingeleverde manuscripten was dit proefschrift niet tot stand gekomen. 
Dr. J.W. Den Boer, co-promotor, beste Jeroen. Wij werken al vanaf 1996 samen, eerst was jij nog 
als arts infectieziekten fulltime werkzaam op de GGD en na het gezamenlijke onderzoek van de 
uitbraak in Bovenkarspel (1999) zijn wij, mede door je aanstelling bij het  Streeklaboratorium 
Haarlem, steeds nauwer gaan samenwerken. Veel laboratoriumonderzoek op het gebied van 
 Legionella, verwerkt in databases, heb jij ook kunnen gebruiken voor het publiceren van diverse 
wetenschappelijke publicaties en voor je proefschrift. Ook bij het opzetten van het BEL-project 
hebben wij van elkaars kennis en inzet gebruik gemaakt. Dank voor het vertrouwen dat je in mij 
heb gesteld en de kansen die jij mij geboden hebt en nog steeds biedt. 
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De leden van de manuscriptcommissie: prof. dr. P. W. M. Hermans, prof. dr. E. J. Kuijper en prof. 
dr. J. Schalkwijk wil ik bedanken voor hun bereidheid plaats te nemen in de commissie.
De leden van de promotiecommissie dank ik voor de tijd en aandacht die ze aan dit proefschrift 
besteed hebben.
 
Dr. E.P.F. IJzerman, beste Ed. Jij bent de initiatiefnemer geweest om mij op het pad van wetenschap 
te zetten. Vanaf de uitbraak in Bovenkarspel hebben wij, eerst als “hobby”, het laboratoriumwerk 
voor Legionella uitgebreider opgepakt. Het heeft geresulteerd in je eigen promotie waaraan ik 
met veel plezier heb bijgedragen. Deze bijdrage is voor jou aanleiding geweest om mij, soms 
met dwang, ruimte te geven om zelfstandig onderzoek te doen en tijd vrij te maken om aan dit 
proefschrift te werken. Wat begon als een “hobby” is uitgegroeid naar een afdeling waar veel 
onderzoek op het gebied van Legionella wordt verricht en de “hobby” heeft plaats gemaakt voor 
expertise en professionaliteit. Ik ben je erkentelijk voor de stimulerende wijze waarop je mij 
richting, vertrouwen en kansen hebt gegeven. 
De Maatschap Artsen microbiologie van het Streeklaboratorium, met de maatschapsleden Bram 
Diederen, James Stuart Cohen, Björn Herpes, Eric Ligtvoet, Dick Veenendaal en Ed IJzerman, ben 
ik dank verschuldigd voor de jaren van samenwerking. Dank voor het vertrouwen en geboden 
ruimte om mij te ontwikkelen zowel op het gebied van Laboratoriumwerk en in de wetenschap. 
Zonder jullie aandacht, ruimte en begrip had ik mij niet kunnen ontwikkelen tot dit niveau. 
Ik zie uit naar de voortzetting van deze samenwerking.
Harry Rouwenhoff, vriend en paranimf, voor onze langdurige vriendschap en je luisterend oor en 
ondersteuning ben ik je bijzonder dankbaar. Wij gaan al zo lang met elkaar om, wij hebben onze 
kinderen zien opgroeien, onze gezamenlijke etentjes, de weekenden die wij met elkaar hebben 
doorgebracht wat kan ik dan nog meer zeggen. Dank voor je humor, je opbeurende woorden 
van ondersteuning. Dank ook voor jullie meer dan prettige gezelschap die Coby en ik van jou 
en Rineke tot op heden heb mogen ondervinden. Ik ben erg blij dat jij mij in deze fase van het 
promotietraject hebt willen bijstaan. Ik zie uit naar nog een hele lange tijd van verbondenheid 
en vriendschap. 
Sjoerd Euser, collega en paranimf, wij hebben de jaren dat je aan onze organisatie verbonden 
bent al zeer intensief met elkaar samengewerkt. Vanaf het moment dat het voor mij duidelijk 
werd dat er gewerkt kon worden aan dit proefschrift heb ik dankbaar van jou epidemiologische 
en statistische kennis gebruik kunnen en mogen maken, dank daarvoor. Dank ook voor de steun 
ondervonden bij het tot stand komen van de verschillende manuscripten in dit proefschrift. 
Ik hoop dat wij nog vele publicaties samen tot stand kunnen brengen. 
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Jacqueline Brouwer en Wim Houtenbos dank ik in het bijzonder voor de toewijding voor het 
administreren van de resultaten, het plannen van de bemonsteringen en het uitvoeren daarvan. 
Zonder jullie toewijding aan BEL was dit project niet zo goed geworden als dat het nu is.
Medewerkers van de GGDen in Nederland dank ik voor de samenwerking ondervonden bij 
het opzetten en uitrollen van het BEL-project. Zonder jullie medewerking en inzet was het niet 
mogelijk geweest om alle bemonsteringen en analyses in het kader van het BEL-project uit te 
kunnen voeren. Jullie informatie en inspanning voor het verzamelen van alle patiëntgegevens is 
nog steeds zeer belangrijk.
Artsen Microbioloog in het land, dank voor het toezenden van de Legionella isolaten die een niet 
vervangbare stammenbank heeft opgeleverd en waar wij ook in de toekomst profijt van zullen 
hebben. Ik ga er vanuit dat er door BEL nog vele taarten het land ingestuurd gaan worden.
Prof. dr. E.A.M. Sanders, beste Lieke, ik had hier in één adem dr. R. Veenhoven willen 
noemen en bedanken voor de meer dan prettige wijze van samenwerken in de verschillende 
onderzoeksprojecten. Reinier is helaas veel te vroeg overleden en rest alleen nog de herinnering 
aan hem en hij heeft een grote leegte achtergelaten. Juist deze samenwerking met jullie beiden en 
de vele contacten met de arts-onderzoekers heeft mij een extra inzicht in wetenschappelijke studies 
en onderzoek bijgebracht. De wijze waarop er is overlegd met de verschillende arts-onderzoekers 
en met vele anderen is samengewerkt is voor mij zeer inspirerend geweest en dit is niet in de 
laatste plaats te danken aan jullie tomeloze inzet en enthousiasme voor de onderzoeksprojecten. 
Lieke, ik zie uit naar de komende projecten en voortzetting van onze samenwerking.
Collegae van het UMCU, Debby Boagaert, Elske van Gils, Gerwin Rodenburg, Annemarie 
van Deursen, Menno van den Bergh, Sabine Prevaes, Anne Wyllie, Judith Spijkerman, Giske 
Biesbroek, Astrid Bosch, Wing Ho Man, Krzysztof Trzcinski, Cassandra Krone en Mei Ling, 
zonder jullie enthousiaste samenwerking, deskundigheid en wetenschappelijke inbreng in en bij 
de besprekingen van de (lopende) onderzoeksprojecten was ik nooit zo enthousiast geworden 
voor het werk en de onderzoeken waar wij mee bezig zijn of zijn geweest. Het is voor mij een zeer 
positieve ervaring (geweest) om met jullie te kunnen en mogen samenwerken. Ik verwacht dat 
er van alle verzamelde data en materialen nog een reeks van publicaties zal volgen. 
Collegae van het RIVM, Marjolein Schalken, Eri van Heinsbergen, Josine van Beek, Alienke 
Wijmenga, Nynke Rots en Renee van Boxtel, dank voor de prettige samenwerking voor de 
verschillende (lopende) onderzoeksprojecten. Daar gaat vast nog heel veel moois van komen.
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Met dank te zeggen aan Marlies van Houten, Greetje van Asselt en Jacqueline Zonneveld wil ik 
alle medewerkers van het Spaarneziekenhuis die bij de onderzoeksprojecten betrokken zijn of 
zijn geweest bedanken voor het verzamelen van de studiematerialen, de prettige contacten en de 
toewijding voor het uitvoeren van de verschillende onderzoeksprojecten. 
Collegae van het wetenschapsbureau, locatie Boerhaavegebouw, mijn dank gaat speciaal uit naar 
Anne Eskes, Adinda Drenth, Richard Brohet, Alex Leuverink, Dennis Souverein, Ron Glandorf 
en Tjeerd van de Ploeg, met jullie op het wetenschapsbureau was er altijd wel iets te beleven 
waarbij humor voorop stond en er ook wetenschappelijk aan kruisbestuiving werd gedaan. Dank 
voor de humorvolle momenten opdat we nog veel samen kunnen sparren en lachen.
Natuurlijk en niet in de laatste plaats gaat ook mijn dank uit naar de medewerkers van het 
Streeklaboratorium met wie ik voor sommigen kort en voor anderen al heel lang heb mogen 
en kunnen samenwerken. Zonder deze medewerking zou er niet zoveel in de afgelopen jaren 
tot stand zijn gekomen. Mijn dank gaat hierbij niet alleen uit naar de analytische medewerkers 
maar ook naar de niet laboratorium medewerkers, zonder inzet van al deze werkers kan het 
lab niet functioneren. Mijn extra dank gaat uit naar de analisten die meegewerkt hebben en 
nog meewerken aan het Legionella onderzoek, de andere onderzoeksprojecten, de studies 
en het analyseren en het verwerken van de verzamelde monsters. Jullie toewijding en inzet 
zijn onontbeerlijk voor het onderhouden van een goede samenwerking met de verschillende 
onderzoeksgroepen. Laten wij het goede vasthouden en voortzetten.
Mijn sportvrienden van Toerclub Excelsior en van de Twijnderslaan wil ik ook bedanken dat ik 
mede door hun toedoen nog redelijk in conditie gebleven ben. Het bedrijven van sport brengt 
altijd ook wat competitie met zich mee, ik heb mij de laatste tijd niet doen laten gelden, maar 
reken er op dat ik mijn neus weer aan het venster zal laten zien. Na de gezonde sportieve 
inspanning is het lichaam moe en de geest ontspannen. De nazit is dan vaak de beloning, ik zie 
uit naar nog vele humorvolle nazit momenten!
Een woord van dank hier ook voor mijn dienstmaten Cavalerie Verkenning lichting 70-2 die 
sinds hun opkomst voor hun nummer zo verbonden aan elkaar zijn dat er nog steeds elk jaar een 
reünie is, echte Legionairs maar dan zonder Legionnaires’ disease! Onze jaarlijkse bijeenkomsten 
zijn altijd gezellig en voor de onderlinge contacten zeer waardevol. Hoop dat wij nog vele jaren 
verhalen over fillers en ouwe stompen kunnen uitwisselen, over de tijd dat het vervullen van 
dienstplicht nog gewoon was.
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Dank ook aan mijn familie en vrienden, ik heb jullie de afgelopen jaren niet de aandacht gegeven 
die jullie verdienen. Toch zijn jullie mij al die jaren blijven volgen en steunen en jullie hebben 
ook soms kunnen zorgen voor de broodnodige afleiding. Bedankt voor jullie aandacht en liefde, 
wij gaan vast vaker weer leuke dingen samen doen. 
Coen en Jelmer, mijn zonen, grote kerels, heerlijk dat wij samen met jullie geliefden deze mijlpaal 
in gezondheid kunnen gaan vieren. Ik ben trots op de wijze zoals jullie je ontwikkeld hebben 
en in het leven staan, ik weet ook dat er door jullie uitgekeken is naar deze dag. Zeker, er zijn 
momenten geweest dat ik niet alle aandacht aan jullie kon geven, maar weet wel jullie zijn elke 
dag in mijn gedachten geweest en ik zal er ook nu nog steeds voor jullie zijn. Ik zie uit naar nog 
vele ontmoetingen met elkaar, waar ter wereld dan ook, jullie hebben daar recht op.
Tot slot Coby mijn lief, zonder jouw liefde, toewijding en opoffering was dit niet gelukt. Aan het 
proefschrift heb je inhoudelijk niets kunnen bijdragen, maar jouw support om dit proefschrift tot 
stand te kunnen brengen was groots. Vele keren heb je je afgevraagd is hij nu met mij  getrouwd 
of met zijn werk. Ik besef ook heel goed hoe belastend het voor je moet zijn geweest als ik weer 
naar school ging, het werk mij opeiste, of zoals de laatste maanden boven op mijn kamer aan dit 
proefschrift zat te werken. Als geen ander heb jij begrepen dat ik geniet van het vak Microbiologie 
en Legionella in het bijzonder. Jij hebt mij de ruimte gegeven om hieraan te werken. Wat heerlijk 
dat jij in 1972 in mijn leven bent gekomen en dat wij het samen al tot hier gebracht hebben. Ik 
ben uitermate trots op je, dank voor je zorgzaamheid en het uiten van bezorgd zijn als ik weer 
eens te veel deed, juist dit zette mij weer met beide benen op de grond. Ik weet het zeker wij gaan 
samen nog meer mooie jaren tegemoet.
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